finance report e roche finance report f hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom finance brief key results sales core operating profit margin cer growth sales pharmaceuticals diagnostics group change sales chf chf chf cer ifrs results sales operating profit net income net income attributable roche shareholders diluted eps chf dividend per share chf core results research development core operating profit core eps chf free cash flow operating free cash flow free cash flow change chf chf chf cer net debt capitalisation debt equity proposed board directors cer constant exchange rates percentage changes constant exchange rates calculated using simulations reconsolidating results constant exchange rates average rates year ended december definition cer see core results core eps earnings per share exclude noncore items global restructuring plans amortisation impairment goodwill intangible assets allows assessment actual results underlying performance business full income statement group operating results divisions shown ifrs core basis core concept fully described pages reconciliations ifrs core results given free cash flow used assess groups ability generate cash required conduct maintain operations also indicates groups ability generate cash finance dividend payments repay debt undertake merger acquisition activities free cash flow concept used internal management business free cash flow concept fully described pages reconciliations ifrs cash flow free cash flow given therefinance report roche group finance brief roche roche group reported strong overall results underlying business showing resilience continuing pandemic environment sales grew constant exchange rates cer ifrs net income increased cer core earnings per share increased cer appreciation swiss franc almost currencies adverse impact results expressed swiss francs sales group sales increased cer chf billion increase chf terms pharmaceuticals sales increased cer driven growing demand new medicines including hemlibra ocrevus tecentriq evrysdi phesgo ronapreve diagnostics sales showed growth cer due sales covidrelated tests notably cobas sarscov pcr test sarscov rapid antigen test recovery routine testing across portfolio operating results core operating profit increased cer chf billion increase chf terms research development expenditure grew cer chf billion core basis growth mostly driven latestage investments oncology ophthalmology personalised healthcare research development costs represented group sales ifrs operating results included noncore expenses pretax chf billion major factors chf billion amortisation impairment charges intangible assets chf billion restructuring costs nonoperating results financing costs ifrs decreased cer chf billion due lower interest expenses following repayment debt march income tax expenses ifrs decreased cer chf billion effective core tax rate decreased mainly due impacts resolution several tax disputes net income ifrs net income chf billion increase cer chf terms driven operating results core earnings per share increased cer chf chf terms cash flows operating free cash flow chf billion increase cer due operating performance significant spending inlicensing alliance arrangements free cash flow increased cer chf terms chf billion driven higher operating free cash flow financial position net working capital increased cer driven increases trade receivables divisions net debt increased chf billion chf billion free cash flow offset repurchase roche shares dividends paid cash payments mergers acquisitions credit ratings remained strong aa standard poors aa moodys aa fitch december repurchase million roche shares novartis completed total consideration chf billion shareholder return proposal made increase dividends chf per share would represent th consecutive year dividend growth would result payout ratio subject agm approval total shareholder return tsr representing combined performance share nonvoting equity security roche group finance report roche group finance brief inside cover finance brief financial review roche group consolidated financial statements notes roche group consolidated financial statements general accounting principles current liabilities operating segment information provisions contingent liabilities revenue debt net financial expense equity attributable roche shareholders income taxes subsidiaries associates mergers acquisitions noncontrolling interests global restructuring plans employee benefits property plant equipment pensions postemployment goodwill benefits intangible assets equity compensation plans inventories leases accounts receivable earnings per share nonvoting marketable securities equity security cash cash equivalents statement cash flows noncurrent assets risk management current assets related parties accounts payable list subsidiaries associates noncurrent liabilities significant accounting policies report roche management internal control financial reporting statutory auditors report general meeting roche holding ltd basel multiyear overview supplementary information roche securities roche holding ltd basel financial statements notes financial statements appropriation available earnings statutory auditors report general meeting roche holding ltd basel finance report financial review roche group financial review roche group results finance brief inside cover sales billions chf core operating profit billions chf cer growth sales net income attributable roche shareholders billions chf core eps chf roche group achieved sales growth constant exchange rates cer core operating profit growth ifrs net income increased cer core eps increased cer appreciation swiss franc currencies adverse net impact results expressed swiss francs compared constant exchange rates percentage point sales percentage points core operating profit percentage points core eps ifrs net income sales growth cer driven diagnostics division continued growth sales covidrelated products coupled recovery routine testing across regions pandemic measures eased pharmaceuticals division sales higher due continuing uptake new medicines compensating biosimilar competition core operating profit growth reflects sales growth offset mix impact increasing proportion diagnostics division sales overall group sales well increase research development costs pharmaceuticals division core eps increased cer increase chf terms driven operating results ifrs net income increased decline chf terms reflecting also increase spending restructuring release litigation provisions first half operating free cash flow chf billion increase due operating results base effect significant spending inlicensing alliance arrangements free cash flow chf billion increase result growth operating free cash flow acquisitions genmark tib molbiol completed chf billion repurchase million roche shares novartis closed december total consideration chf billion roche group financial review finance report divisional operating results pharmaceuticals diagnostics corporate group chf chf chf chf sales core operating profit margin sales operating profit margin sales operating free cash flow margin sales divisional operating results development results compared pharmaceuticals diagnostics corporate group sales change cer core operating profit change cer margin percentage point change operating profit change cer margin percentage point change operating free cash flow change cer margin percentage point change sales pharmaceuticals division chf billion chf billion increase cer driven growing demand new medicines including hemlibra ocrevus tecentriq evrysdi phesgo ronapreve together contributed additional chf billion cer new sales overall covid pandemic continued negative impact divisions sales diagnostics division reported sales chf billion increase cer growth mainly due sales covidrelated products notably cobas sarscov pcr test sarscov rapid antigen test total sales covidrelated tests cer chf billion chf billion routine testing greatly affected pandemic rebounded across regions direct result sales grew regions notably europe middle east africa region asiapacific region pharmaceuticals divisions core operating profit decreased cer despite sales growth mainly due increase research development costs higher cost sales royalty operating income increased chf billion due higher profitshare income higher income disposal products comparative period cost sales increased driven higher manufacturing costs due volume growth incremental production costs arising response covid pandemic marketing distribution costs remained stable increased spending ongoing launches rollouts offset reduced spending due various restructuring initiatives covid pandemic research development costs grew growth mostly driven latestage investments oncology neuroscience personalised healthcare addition covidrelated investments notably codevelopment ronapreve regeneron investments across research development activities notably chinafinance report financial review roche group diagnostics division core operating profit increased cer chf billion ahead sales growth cost sales grew sales growth due unfavourable product mix driven increased sales volumes sarscov rapid antigen tests marketing distribution costs increased due higher spending distribution costs following increased sales volumes research development costs increased due increased spending digital projects covid products development coupled projects blood screening alzheimer disease additionally following acquisitions completed genmark chf billion tib molbiol chf billion paid cash ifrs operating profit decreased cer pharmaceuticals division due higher restructuring expenses base effect release litigation provisions increased cer diagnostics division results include chf billion amortisation impairment intangible assets chf billion expenses global restructuring plans financing costs decreased cer ifrs basis chf billion mainly due lower interest expenses attributable repayment debt groups effective core tax rate decreased compared decrease mainly due impact resolution several tax disputes reduced groups effective core tax rate percentage points compared reduction percentage points higher percentage core profit contribution coming tax jurisdictions lower tax rates average group tax rate net income ifrs basis chf billion increase cer net income core basis increased cer chf billion driven cases operating results amount net income attributable noncontrolling interests increased ifrs basis core basis due performance chugai operating free cash flow chf billion increase cer due operating performance base effect significant spending inlicensing alliance arrangements free cash flow chf billion increase cer result growth operating free cash flow roche group financial review finance report income statement change change chf chf chf cer ifrs results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests eps basic chf eps diluted chf core results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core eps basic chf core eps diluted chf see pages definition core results core epsfinance report financial review roche group impact covid pandemic revenues covid pandemic continued negative impact pharmaceuticals divisions sales partly compensated additional sales actemraroactemra received us fda emergency use authorization treatment covid hospitalised adults children addition ronapreve investigational neutralising antibody combination developed regeneron made available patients countries across many geographies economies diagnostics divisions sales growth due comprehensive portfolio covid related tests global recovery routine diagnostic testing sales various covidrelated diagnostic tests chf billion cer compared chf billion quarterly development sales compared yearonyear growth cer q q half year q q full year pharmaceuticals division diagnostics division roche group manufacturing supply despite supply logistics challenges due covid pandemic roche group able continue deliver medicines diagnostics wherever possible patients across broad range disease areas exceptional conditions date limited disruption group continually monitoring situation research development roche groups planned drug launches filings pivotal phase iii trial readouts pivotal trial starts largely track group continuously monitoring ongoing studies terms missed doses overall data integrity operating results impact operating profit major came mainly abovementioned factors revenues overall operating expenses impacted extent covid pandemic various impacts partly offsetting additional costs incurred areas infrastructure distribution costs less spending marketing activities including lower travel costs reduced attendance congresses core results group made changes core results concept result covid pandemic specific covidrelated impacts referred included ifrs core results noted core results exclude noncore items global restructuring plans amortisation impairment goodwill intangible assets regardless cause roche group financial review finance report competition biosimilar generic medicines groups pharmaceutical products generally protected patent rights intended provide group exclusive marketing rights various countries however patent rights varying scope duration group may required enter costly litigation enforce patent intellectual property rights loss market exclusivity one major products either due patent expiration challenges generic medicines biosimilars non comparable biologics reasons could material adverse effect groups business results operations financial condition introduction generic biosimilar noncomparable biologic version similar medicine usually results significant reduction net sales relevant product manufacturers typically offer versions lower prices patents expiry always integral part groups business model future growth remain driven innovation latest information clinical studies included annual report details groups product development portfolio available download httpwwwrochecomresearchanddevelopmentwhowearehowweworkpipelinehtm mabtherarituxan herceptin avastin groups basic primary patents three products expired worldwide sales including regional breakdowns mabtherarituxan herceptin avastin disclosed pharmaceuticals divisions operating results summarised table yearonyear movements also driven regular price volume changes biosimilar competition one factor overall picture sales three products chf billion lower cer prior period decline total mabtherarituxan herceptin avastin sales change divisional sales divisional sales chf chf cer united states europe japan international total sales first biosimilar versions herceptin avastin launched us mid first biosimilar versions mabtherarituxan late europe first biosimilar versions mabtherarituxan herceptin launched mid mid respectively marketed eu countries first biosimilar versions avastin came market europe mid major factor decrease avastin sales first biosimilar versions mabtherarituxan herceptin launched japan biosimilar versions avastin launched late colorectal cancer indication nonsmall cell lung cancer indication sales three products impacted government price cuts well biosimilar competition international region biosimilar versions three products launched many countries together impacts regular price volume changes led decline sales sales mabtherarituxan lower herceptin sales avastin sales lower lucentis groups basic primary patents expired us based publicly available information competitor companies group currently anticipates first biosimilar versions lucentis could come market us around mid us sales lucentis chf million chf millionfinance report financial review roche group mergers acquisitions genmark april group acquired controlling interest genmark diagnostics inc genmark publicly owned us company based carlsbad california listed nasdaq genmark provides multiplex molecular diagnostic solutions designed detect multiple pathogens single patient sample addition genmarks proprietary multiplex technology complements groups diagnostic offering addressing broad range infectious disease testing needs including respiratory bloodstream infections genmark reported diagnostics division total consideration usd billion equivalent chf billion paid cash tib molbiol december group acquired interest tib molbiol group tib molbiol privately owned group based berlin germany tib molbiol manufacturer custom oligonucleotides collaborating group years acquisition tib molbiol enhance groups broad portfolio molecular diagnostics solutions wide range assays infectious diseases tib molbiol reported diagnostics division total consideration eur billion equivalent chf billion paid cash details given note annual financial statements alliance transactions inlicensing alliance transactions resulted intangible assets chf billion recognised chf billion amount chf billion related payments made based upon achievement performance related milestones transactions completed previous years typically inlicensing alliance transactions additional payments may made based upon achievement performancerelated milestones profitsharing royalty agreements global restructuring plans group expanded implementation various global restructuring plans initiated prior years including organisational transformation diagnostics division various resourcing optimisation initiatives pharmaceuticals division global restructuring plans costs incurred millions chf diagnostics site consolidation plans total global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs roche group financial review finance report diagnostics division strategy plans diagnostics division notably diabetes care incurred costs chf million employeerelated matters site consolidation initiatives strategic sustainable site development basel kaiseraugst incurred costs chf million global restructuring plans employeerelated costs mainly came business transformation initiatives pharmaceuticals division outsourcing functions shared service centres external providers total global restructuring costs chf billion details given note annual financial statements impairment goodwill intangible assets pharmaceuticals division pharmaceuticals division recorded impairment charges intangible assets chf billion major items charge chf billion full impairment intangible asset following planned return rights licenses atea pharmaceuticals announcement termination strategic collaboration chf billion related partial impairment two separate assets following reduced sales expectations diagnostics division impairments goodwill intangible assets impairment charges chf billion pharmaceuticals division chf billion diagnostics division details given notes annual financial statements legal environmental cases significant developments details given note annual financial statements share repurchase december roche group repurchased million roche shares held novartis total consideration chf billion repurchased shares reported treasury shares december scheduled cancelled early necessary legal procedures completed transaction financed credit facility banks total repurchase price partly refinanced bond issue usd billion chf billion december december chf billion credit facility outstanding refinancing bond market planned repurchase shares consequent additional financing costs accretive effect eps approximately transaction taken place january fullyear accretive effect including estimated additional financing costs would approximately details given notes annual financial statementsfinance report financial review roche group net income earnings per share ifrs net income increased cer decreased chf terms core eps increased cer chf core basis excludes noncore items global restructuring costs amortisation impairment goodwill intangible assets mergers acquisitions alliance transactions amount net income attributable non controlling interests increased ifrs basis core basis due increased contribution chugai overall group results net income change change chf chf chf cer ifrs net income reconciling items net tax global restructuring plans intangible asset amortisation goodwill intangible asset impairment mergers acquisitions alliance transactions legal environmental cases pension plan settlements normalisation equity compensation plan tax benefit core net income supplementary net income eps information given pages includes calculations core eps reconciles core results groups published ifrs results financial position financial position change change chf chf chf cer pharmaceuticals net working capital longterm net operating assets diagnostics net working capital longterm net operating assets corporate net working capital longterm net operating assets net operating asset net debt lease liabilities pensions income taxes nonoperating assets net total net assets compared start year swiss franc appreciated japanese yen euro significant effect groups net operating assets negative translation effect partially compensated depreciation swiss franc us dollar net effect natural hedge groups us dollardenominated debt exchange rates used given roche group financial review finance report net working capital increased significantly divisions pharmaceuticals division trade receivables increased due underlying sales growth partially offset high collections around end increase inventories driven rampup new products ensuring supply resilience trade payables increased due part outstanding usd million upfront payment diagnostics division inventories increased due ongoing rollout covidrelated products recovery base business trade receivables increased result sales growth increase net debt due repurchase roche shares chf billion dividend payments chf billion merger acquisition payments chf billion partly offset free cash flow chf billion net pension liability lower cer following increases fair value plan assets increases discount rates regions net tax assets increased mainly due taxes paid exceeding income tax expenses partially offset deferred tax effects pension plans lease liabilities increased chf billion due new office leases genentech chugai foundation medicine spark therapeutics free cash flow free cash flow change change chf chf chf cer pharmaceuticals diagnostics corporate operating free cash flow treasury activities taxes paid free cash flow see pages definition free cash flow detailed breakdown groups operating free cash flow chf billion increase cer due operating performance base effect significant spending inlicensing alliance arrangements notably payments sarepta therapeutics chf billion blueprint medicines chf billion free cash flow chf billion increase cer result growth operating free cash flow cash outflow treasury activities lower due higher cash received sale longterm financial investments taxes paid increased due higher payments japanfinance report financial review roche group pharmaceuticals division operating results pharmaceuticals division operating results change change chf chf chf cer ifrs results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income revenue cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow b operating free cash flow margin sales see pages definition core results b see pages definition free cash flow sales overview pharmaceuticals division sales therapeutic area change sales sales chf chf cer oncology immunology neuroscience haemophilia infectious diseases ophthalmology therapeutic areas total sales roche group financial review finance report sales pharmaceuticals division chf billion chf billion increase cer new product sales compensated biosimilar competition mabtherarituxan herceptin avastin sales growth driven growing demand new medicines including hemlibra ocrevus tecentriq evrysdi phesgo ronapreve together contributed additional chf billion cer new sales second half year biosimilar impact slowing expected overall covid pandemic continued negative impact divisions sales actemraroactemra sales increased driven adoption treatment guidelines patients severe covid pneumonia hemlibra sales showed continued strong uptake across us major eu markets sales reaching chf billion increase ocrevus continued growth development sales increase chf billion tecentriq sales grew chf billion mostly due higher demand japan us evrysdi showed high uptake mainly us russia germany since launch phesgo sales showed strong uptake since launch mainly europe us sales reaching chf billion sales ronapreve chf billion total notably japan germany uk india france impact biosimilar competition reduced continued negative impact erosion sales mabtherarituxan herceptin avastin mostly us global sales three products fell chf billion cer chf billion decrease biosimilar competition mabtherarituxan herceptin avastin negative impact chf billion cer sales us sales avastin mabtherarituxan china also affected biosimilar competition herceptin sales china increased europe sales mabtherarituxan herceptin avastin declined chf billion cer first biosimilar versions avastin launched europe mid sales oncology therapeutic area decreased due biosimilar competition mabtherarituxan herceptin avastin described partially compensated growth new products tecentriq phesgo kadcyla tecentriq sales grew regions mostly due continued rollout japan higher demand us international region phesgo showed strong uptake mainly europe us kadcyla showed continuing postlaunch growth across regions europe key driver sales immunology increased mainly driven increase sales actemraroactemra due adoption medicine many countries guidelines treat patients severe covid pneumonia partially offset lower sales mabtherarituxan us due biosimilar entry lucentis sales declined us driven continuing competition infectious diseases sales increased chf billion due sales ronapreve therapeutic areas sales activasetnkase higher usfinance report financial review roche group product sales pharmaceuticals division sales change sales sales chf chf cer oncology perjeta tecentriq avastin herceptin mabtherarituxan kadcyla alecensa gazyvagazyvaro phesgo erivedge polivy xeloda others total oncology immunology actemraroactemra xolair esbriet cellcept mabtherarituxan pulmozyme others total immunology neuroscience ocrevus evrysdi madopar others total neuroscience haemophilia hemlibra total haemophilia infectious diseases ronapreve rocephin tamiflu others total infectious diseases ophthalmology lucentis others total ophthalmology roche group financial review finance report pharmaceuticals division sales continued change sales sales chf chf cer therapeutic areas activasetnkase mircera others total therapeutic areas total sales total mabtherarituxan sales chf million chf million split oncology immunology therapeutic areas ocrevus relapsing forms multiple sclerosis rms primary progressive multiple sclerosis ppms ocrevus regional sales change sales sales chf chf cer united states europe international total sales despite negative impact covid continuously growing demand indications us growth driven new returning patients higher proportion sales coming returning patients europe international region ocrevus continues show high uptake launched notably germany france italy spain franchise perjeta herceptin kadcyla phesgo herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin perjeta regional sales change sales sales chf chf cer united states europe japan international total sales herceptin regional sales change sales sales chf chf cer united states europe japan international total sales finance report financial review roche group kadcyla regional sales change sales sales chf chf cer united states europe japan international total sales phesgo regional sales change sales sales chf chf cer united states europe international total sales sales franchise decreased chf billion herceptin sales lower due biosimilar launches started second half us mid europe increasingly many countries international region sales perjeta grew increases mostly driven china early breast cancer metastatic breast cancer settings us sales perjeta declined due patients residual disease switched kadcyla due launch phesgo kadcyla sales increased across regions us notably early breast cancer setting kadcyla sales benefited positive readout katherine study patients switching new standard treatment tecentriq advanced bladder cancer advanced lung cancer initial therapy nonsquamous nonsmall cell lung cancer nsclc extensivestage small cell lung cancer sclc pdlpositive triplenegative breast cancer unresectable metastatic hepatocellular carcinoma hcc tecentriq regional sales change sales sales chf chf cer united states europe japan international total sales sales increased growth regions notably japan primarily due growth treatment hcc us sales higher driven new indications hcc firstline nsclc international region growth mainly driven china sclc hcc indications europe sales growth mainly driven sclc pdlpositive triplenegative breast cancer indications roche group financial review finance report hemlibra haemophilia hemlibra regional sales change sales sales chf chf cer united states europe japan international total sales sales continued show strong uptake especially us europe strong demand noninhibitor segment avastin advanced colorectal breast lung kidney cervical ovarian cancer relapsed glioblastoma liver cancer combination tecentriq avastin regional sales change sales sales chf chf cer united states europe japan international total sales us sales decreased due continuing impact biosimilars first came market us mid europe sales declined due first fullyear impact launch biosimilars second half international region main driver sales decline biosimilar competition china mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukaemia cll follicular lymphoma fl pemphigus vulgaris pv rheumatoid arthritis ra well certain types antineutrophil cytoplasmic antibody anca associated vasculitis mabtherarituxan regional sales change sales sales chf chf cer united states europe japan international total sales sales lower due biosimilar erosion us sales decreased decline oncology immunology segments sales international region lower decline canada decline china due biosimilar erosionfinance report financial review roche group actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis giant cell arteritis actemraroactemra regional sales change sales sales chf chf cer united states europe japan international total sales sales increased growth driven adoption actemraroactemra many countries treatment guidelines treat patients severe covid pneumonia us main driver sales along europe various clinical studies initiated evaluate safety efficacy actemraroactemra patients severe covid pneumonia results made available healthcare authorities actemraroactemra received us fda emergency use authorization treatment covid hospitalised adults children european commission extended marketing authorisation actemraroactemra include treatment covid adults receiving systemic corticosteroids require supplemental oxygen mechanical ventilation xolair moderate severe persistent allergic asthma aa chronic spontaneous urticaria csu xolair regional sales change sales sales chf chf cer united states total sales sales increased growth chronic spontaneous urticaria indication offset additional competition allergic asthma indication xolair remains market leader allergic asthma indication ronapreve treatment recently diagnosed highrisk patients mild moderate covid ronapreve regional sales change sales sales chf chf cer united states europe japan international total sales roche collaborating regeneron pharmaceuticals inc regeneron develop manufacture distribute ronapreve investigational neutralising antibody combination terms agreement regeneron responsible distribution us roche group responsible distribution outside us orders multiple countries notably japan germany uk india france italy lucentis neovascular wet agerelated macular degeneration namd macular oedema following retinal vein occlusion rvo diabetic macular oedema dme diabetic retinopathy dr lucentis regional sales change sales sales chf chf cer united states total sales us sales decreased due continuing competition roche group financial review finance report activasetnkase acute ischaemic stroke ais acute myocardial infarction ami activasetnkase regional sales change sales sales chf chf cer united states international total sales sales higher mainly driven higher volume us due temporary stockpiling distributors end customers alecensa alkpositive nonsmall cell lung cancer nsclc alecensa regional sales change sales sales chf chf cer united states europe japan international total sales global uptake continued led international region us international region growth mainly due increased sales china growth us mainly driven increased demand first line treatment continuing patients esbriet idiopathic pulmonary fibrosis ipf esbriet regional sales change sales sales chf chf cer united states europe international total sales sales declined driven reduced share prescriptions new patients pharmaceuticals division sales region change sales sales chf chf cer united states europe japan international china total sales finance report financial review roche group united states sales decreased driven impact biosimilar erosion partly offset sales growth new medicines decline total mabtherarituxan herceptin avastin sales due launches biosimilars offsetting growth hemlibra ocrevus evrysdi tecentriq hemlibra continued show strong postlaunch uptake continued market share gains noninhibitor segment ocrevus sales increased driven new returning patient demand evrysdi treatment spinal muscular atrophy showed high uptake since launch third quarter sales chf billion tecentriq sales increased due growth new indications actemra roactemra sales increased mostly due use hospitalised patients severe covid pneumonia sales franchise decreased mostly driven lower herceptin sales partially offset sales phesgo sales increase kadcyla notably early breast cancer setting lucentis sales decreased due continuing competition europe sales grew new product sales compensating biosimilar competition key driver new products growth ronapreve orders germany uk france italy ocrevus hemlibra also reported growth particular france germany kadcyla sales increased mainly driven continued growth france phesgo evrysdi sales showed strong uptake since launch mainly uk germany respectively tecentriq sales continued grow increased driven uptake across europe actemraroactemra sales increased mostly due use hospitalised patients severe covid pneumonia biosimilar competition led combined sales mabtherarituxan herceptin avastin falling japan sales increased mainly driven ronapreve sales second half year sales also increased enspryng tecentriq hemlibra combined fall sales mabtherarituxan herceptin avastin arising biosimilar competition government price cuts international sales increased sales china stable uptake perjeta alecensa tecentriq volume growth herceptin offset biosimilar erosion avastin mabtherarituxan excluding china sales international region increased mainly driven orders ronapreve india sales growth ocrevus hemlibra evrysdi partially offset biosimilar erosion notably canada brazil operating results pharmaceuticals division royalties operating income change chf chf cer royalty income income outlicensing agreements income disposal products profitsharing agreements total ifrs core basis royalty income increased cer mainly driven higher royalty income venclextavenclyxto lucentis sales outside us partially compensated base effect settlement gain chf million income licensing agreements lower due base effect upfront milestone income mostly japan income profitsharing agreements chf million came mainly collaboration agreement regeneron income chf million income sales venclextavenclyxto us chf million addition income sale global rights rivotril chf million sale global rights pegasys excluding china japan chf million roche group financial review finance report pharmaceuticals division cost sales change chf chf cer manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer percentage sales cost sales increased percentage points manufacturing cost sales increased ahead sales increase due two main factors firstly volume growth various product mix factors across portfolio secondly incremental production costs chf million arising response covid pandemic arose atrisk manufacturing rampup rollout ronapreve termination partnership atea pharmaceuticals announced royalty expenses higher driven increased sales certain royaltybearing products notably ocrevus evrysdi partly offset decrease royalty expenses related expired cabilly patent collaboration profitsharing expenses increased driven launch ronapreve partly offset lower us sales mabtherarituxan idleplant impairment reversed first half resulting income chf million partially offset impairments property plant equipment including related assets chf million decrease amortisation charges intangible assets primarily attributable esbriet intangible asset becoming fully amortised late pharmaceuticals division marketing distribution change chf chf cer marketing distribution core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs remained stable cer percentage sales decreased comparative period continuing general slowdown marketing activities including reduction field force various restructuring initiatives lower expenses travel congresses due covid restrictions major marketing distribution activities included supporting ongoing launches rollouts ocrevus tecentriq also prelaunch activities restructuring costs related transformation initiatives sales affiliatesfinance report financial review roche group pharmaceuticals division research development change chf chf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer percentage sales increased percentage points oncology remained primary area research development cancer immunotherapy portfolio key driver neuroscience immunology ophthalmology represent significant areas spending growth spending mostly driven latestage investments oncology neuroscience personalised healthcare higher spend oncology includes first pivotal study giredestrant nextgeneration selective oestrogen receptor degrader people hormone receptorpositive hernegative breast cancer investments tiragolumab lung cancer neuroscience higher spend driven investments gantenerumab investigational antiamyloid beta antibody phase iii development treatment alzheimers disease well pivotal studies fenebrutinib multiple sclerosis significant spending covidrelated projects notably codevelopment regeneron partnership atea pharmaceuticals investments made advanced computation data analytics increased research development activities china additionally inlicensing transactions business combinations asset acquisitions resulted intangible assets chf billion chf billion recognised mainly payments made based upon achievement performancerelated milestones transactions completed previous years see sections mergers acquisitions alliance transactions details intangible asset impairment charges chf million pharmaceuticals division major item related charge chf million fully write intangible asset following announcement termination partnership atea pharmaceuticals pharmaceuticals division general administration change chf chf cer administration pensions past service costs gains losses disposal property plant equipment rightofuse assets business taxes capital taxes general items general administration core basis global restructuring plans mergers acquisitions alliance transactions legal environmental cases pensions plan settlements total ifrs basis core costs decreased cer percentage sales decreased administration costs lower mainly due decreases general management expenses lower legal expenses business taxes capital taxes decreased primarily due lower excise tax expense us ifrs basis increased costs restructuring notably baselkaiseraugst site switzerland change legal environmental cases driven release accutane us litigation provision roche group financial review finance report roche pharmaceuticals chugai subdivisional operating results pharmaceuticals subdivisional operating results millions chf roche pharmaceuticals chugai pharmaceuticals division sales external customers within division core operating profit margin sales external customers operating profit margin sales external customers operating free cash flow margin sales external customers pharmaceuticals division total core operating profit operating profit include elimination chf minus million unrealised intercompany gains roche pharmaceuticals chugai chf minus million increase exchange rate japanese yen adverse impact approximately percentage points chugai core results expressed swiss francs groups consolidated results cer reported japanese yen sales chugai external customers increased sales within division increased chugai core operating profit increased due higher gross profit sales within division higher gross profit sales external customers partially offset higher research development costs operating free cash flow chugai increased mainly result strong operating performance partially offset increase net working capital financial position pharmaceuticals division net operating assets movement movement change change transactions cta chf chf chf cer chf chf trade receivables inventories trade payables net trade working capital receivables payables net working capital property plant equipment rightofuse assets goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given annual financial statements reconciliation balance sheet information given pages currency translation effects balance sheet amounts compared start year swiss franc depreciated us dollar significant effect net operating assets pharmaceuticals division partially compensated appreciation swiss franc japanese yen resulted net positive translation impact exchange rates used given finance report financial review roche group net working capital net working capital increased cer due higher net liability receivablespayables well higher net trade working capital trade receivables increase due underlying sales growth partially offset favourable collections towards end increase inventories driven rampup new products need ensure supply resilience trade payables increased due part outstanding usd million upfront payment net liability position receivablespayables increased due higher accruals rebates chargebacks well higher accrued royalties longterm net operating assets overall longterm net operating assets decreased cer due lower intangible assets partly offset increased property plant equipment intangible assets decreased amortisation impairment charges offset additions capital expenditure includes manufacturing investments us switzerland japan germany site developments switzerland south san francisco chugais research facilities yokohama japan rightofuse assets increased due new office leases genentech chugai foundation medicine spark therapeutics provisions increased due various factors including related atrisk manufacturing rampup rollout ronapreve well site development plans baselkaiseraugst site long term assets increased included accrued income future milestone payments free cash flow pharmaceuticals division operating free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment principal portion lease liabilities paid investments intangible assets operating free cash flow sales see pages definition free cash flow detailed breakdown pharmaceuticals divisions operating free cash flow increased cer chf billion cash generation business measured operating profit net operating cash adjustments increased core operating profit decreased difference mainly due increased provisions atrisk manufacturing rampup rollout ronapreve net working capital absorbed additional chf billion cash largely driven higher trade receivables inventories partially offset higher payables reasons described financial position section increase net working capital significantly lower prior period due settlement payables accrual positions recorded end capital expenditure major items also described financial position section higher investments intangible assets significantly lower mainly due payments sarepta therapeutics chf billion blueprint medicines chf billion roche group financial review finance report diagnostics division operating results diagnostics division operating results change change chf chf chf cer ifrs results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income revenue cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow b operating free cash flow margin sales see pages definition core results b see pages definition free cash flow sales diagnostics division reported overall sales growth cer chf billion sales various covid related tests cer chf billion chf billion sarscov rapid antigen test launched september accounting approximately covidrelated sales part ongoing transformation initiative diagnostics division replaced previous business area structure new customer areas sales presented customer area comparative information restated sales point care molecular lab customer areas grew due covidrelated sales rebound routine testing main contributor growth core lab pathology lab customer areas diabetes care sales growth driven increase blood glucose monitoring resolution dispute rebates applied distributor usfinance report financial review roche group diagnostics division sales customer area change sales sales chf chf cer core lab molecular lab point care diabetes care pathology lab total sales core lab customer area focuses central labs provides diagnostics solutions areas immunoassays clinical chemistry custom biotech sales increased due recovery routine testing across portfolio main growth coming immunoassays higher sales clinical chemistry increase routine testing recovered regions largest contribution coming asiapacific emea grew respectively notably china germany sales growth molecular lab customer area focuses molecular labs provides diagnostics solutions detection monitoring pathogens donor screening sexual health genomics sales grew led covidrelated sales sarscov assays cobas range liat business results included sales chf million genmark acquired effective april sales sequencing sample preparation cervical cancer businesses grew respectively due recovery routine testing sales higher regions led north america asiapacific regions point care customer area provides diagnostics solutions immediately point care emergency rooms general practitioners practices directly patients includes sarscov rapid tests blood gas electrolyte bge tests sales sarscov rapid antigen test reported customer area main driver high growth sales tests concentrated emea region diabetes care customer area provides diagnostics solutions people diabetes healthcare professionals enabling integrated personalised diabetes management sales increased driven increase blood glucose monitoring resolution dispute rebate north america region sales growth driven increased sales emerging markets temporary offsetting continued overall decline blood glucose monitoring market pathology lab customer area focuses pathology labs provides diagnostics solutions tissue biopsies companion diagnostics targeted diagnostics aid choice specific therapies patient sales increased mainly due growth advanced staining business due recovery routine testing growth sales companion diagnostics business diagnostics division sales region change sales sales chf chf cer europe middle east africa emea north america us asiapacific china latin america total sales sales emea region grew mainly due sales sarscov rapid antigen test rebound routine testing asiapacific sales higher due baseline effect pandemic restrictions specifically china sales grew north america sales growth driven growth molecular lab customer area mainly cobas sarscov tests growth core lab customer area due recovery routine testing roche group financial review finance report operating results diagnostics division royalties operating income change chf chf cer royalty income income outlicensing agreements income disposal products total ifrs core basis royalties operating income increased due income outlicensing agreement chf million diabetes care diagnostics division cost sales change chf chf cer manufacturing cost goods sold period costs royalty expenses impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets mergers acquisitions alliance transactions total ifrs basis core costs increased cer due higher covidrelated sales volumes instruments reagents increase sales growth due unfavourable product mix driven increased sales volumes sarscov rapid antigen tests addition impairments property plant equipment incurred connection atrisk manufacturing rampup rollout covidrelated products core cost sales ratio increased percentage points global restructuring costs increased due activities strategy plans diabetes care diagnostics division marketing distribution change chf chf cer marketing distribution core basis global restructuring plans amortisation intangible assets total ifrs basis core costs increased cer due higher spending distribution costs following increased sales volumes well higher personnel expenses core basis marketing distribution costs percentage sales decreased compared due sales growth diagnostics division research development change chf chf cer research development core basis global restructuring plans amortisation intangible assets total ifrs basis core costs increased cer due increased spending digital projects covid products development coupled projects blood screening alzheimers disease percentage sales research development core costs decreased finance report financial review roche group diagnostics division general administration change chf chf cer administration pensions past service costs gains losses disposal property plant equipment rightofuse assets gains losses divestment subsidiaries business taxes capital taxes general items general administration core basis global restructuring plans impairment goodwill intangible assets mergers acquisitions alliance transactions legal environmental cases total ifrs basis core costs increased cer percentage sales core costs decreased administration costs higher due shift reporting lines certain support functions gain general items partly due sales tax refund compensates overpayments made past several years impairment charges chf million due goodwill impairment related avl medical instruments geneweave acquisitions financial position diagnostics division net operating assets movement movement change change transactions cta chf chf chf cer chf chf trade receivables inventories trade payables net trade working capital receivables payables net working capital property plant equipment rightofuse assets goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given annual financial statements reconciliation balance sheet information given pages currency translation effects balance sheet amounts compared start year swiss franc appreciated euro negative effect net operating assets diagnostics division partially offset depreciation swiss franc us dollar resulted negative net translation impact exchange rates used given roche group financial review finance report net working capital net working capital increased due higher accounts receivable inventories increase trade receivables due higher sales compared inventories increased due ongoing rollout covidrelated products recovery underlying business trade payables increased due higher manufacturing purchases support higher sales increase net liability receivablespayables came higher employeerelated accruals customer incentives accruals longterm net operating assets overall longterm net operating assets increased cer mainly attributable increase goodwill intangible assets resulting acquisition controlling interest genmark tib molbiol property plant equipment increased due site investments germany us free cash flow diagnostics division operating free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment principal portion lease liabilities paid investments intangible assets operating free cash flow sales definition free cash flow detailed breakdown see pages operating free cash flow diagnostics division chf billion increase cer compared sales growth positive impact operating free cash flow cash generation business measured operating profit net operating cash adjustments increased chf billion line core operating profit increased chf billion net working capital increased absorbed chf billion cash attributable increase trade receivables inventories described financial position section capital expenditure increased due site investments germany usfinance report financial review roche group corporate operating results corporate operating results summary change chf chf cer administration business taxes capital taxes general items general administration costs core basis global restructuring plans legal environmental cases total costs ifrs basis financial position net working capital longterm net operating assets net operating assets free cash flow b operating free cash flow see pages definition core results b see pages definition free cash flow detailed breakdown general administration costs increased cer core basis administration costs higher increase due buildup shared service centre network provides services divisions general items decreased due higher project costs within overall net amount change net working capital due higher payables change longterm net operating assets due lower provisions due higher assets result shared service centre buildup corporate operating free cash flow lower cer roche group financial review finance report foreign exchange impact operating results groups exposure movements foreign currencies affecting operating results expressed swiss francs summarised following key figures comments growth reported cer chf change cer change chf pharmaceuticals division sales core operating profit diagnostics division sales core operating profit group sales core operating profit exchange rates swiss franc december average december average usd eur jpy results expressed swiss francs negatively impacted appreciation swiss franc many currencies net impact expressed swiss francs compared constant exchange rates percentage point sales percentage points core operating profit percentage points core eps sensitivity group sales core operating profit change average foreign currency exchange rates swiss franc shown table currency sensitivities impact increase average exchange rate sales core operating profit versus swiss franc chf chf us dollar euro japanese yen currencies groups revenues primarily generated sales products customers revenues mainly received local currency customers home market although certain emerging markets invoicing made major international currencies us dollar euro cost sales marketing administration costs follow currency pattern sales majority research development activities incurred groups global research facilities therefore costs mainly concentrated us dollars swiss francs euros general administration costs tend incurred mainly central locations us switzerland germany chugais revenues costs denominated japanese yenfinance report financial review roche group treasury taxation results treasury taxation results change change chf chf chf cer ifrs results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests financial position net debt lease liabilities pensions income taxes equity investments derivatives net collateral net interest payable associated companies net total net assets liabilities free cash flow b treasury activities taxes paid total see pages definition core results b see pages definition free cash flow financing costs core financing costs chf million decrease cer compared interest expenses debt decreased cer chf million mainly due repayment debt net interest cost defined benefit pension plans decreased cer due lower discount rates germany us end full analysis financing costs given note annual financial statements roche group financial review finance report financial income expense core financial income expense net expense chf million increase chf million compared income equity securities reflects fair value changes roche venture fund investments reported net loss chf million net gain chf million mainly due fall value allakos investment december net foreign exchange results reflect hedging costs losses unhedged positions losses chf million net losses chf million full analysis financial income expense given note annual financial statements income taxes groups effective core tax rate decreased percentage points decrease mainly due impact resolution several tax disputes reduced groups effective core tax rate percentage points compared reduction percentage points higher percentage core profit contribution coming tax jurisdictions lower tax rates average group tax rate ifrs results saw effective tax rate decrease percentage points mainly due higher effect resolution several tax disputes compared mentioned details groups income tax expenses related balance sheet positions given note annual financial statements analysis groups effective tax rate profit income profit income tax taxes tax rate tax taxes tax rate chf chf chf chf groups effective tax rate core basis global restructuring plans goodwill intangible assets mergers acquisitions alliance transactions legal environmental cases pension plan settlements normalisation equity compensation plan tax benefit groups effective tax rate ifrs basis financial position increase net debt end due issuance bonds chf billion bridging facility chf billion financed repurchase december roche shares held novartis addition dividend payments chf billion payments mergers acquisitions notably acquisitions genmark chf billion tib molbiol chf billion offset free cash flow chf billion net pension liability lower following increases fair value plan assets increases discount rates regions net tax assets increased mainly due taxes paid exceeding income tax expenses partially offset deferred tax effects pension plans december group held equity investments market value chf billion consist mostly holdings biotechnology pharmaceuticals companies acquired part licensing transactions scientific collaborations investments roche venture fund december group made investment equivalent chf billion freenome holdings inc freenome accounted investment associated company free cash flow net cash outflow treasury activities chf billion compared outflow chf billion due higher cash received sale longterm financial investments separate chf billion equity investments paid freenome sarepta therapeutics total taxes paid chf billion higher cer higher payments japan partly offset lower payments us driven respective business resultsfinance report financial review roche group cash flows net debt operating free cash flow billions chf free cash flow billions chf free cash flow millions chf pharmaceuticals diagnostics corporate group operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment principal portion lease liabilities paid investments intangible assets operating free cash flow treasury activities taxes paid free cash flow operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment principal portion lease liabilities paid investments intangible assets operating free cash flow treasury activities taxes paid free cash flow definition free cash flow detailed breakdown see pages operating free cash flow increased cer chf billion due operating performance base effect significant spending inlicensing alliance arrangements notably payments sarepta therapeutics chf billion blueprint medicines chf billion increase net working capital prior period driven settlement payables accrual positions recorded end free cash flow chf billion increase cer following growth operating free cash flow appreciation swiss franc significant negative impact free cash flows measures expressed chf terms roche group financial review finance report net debt millions chf january cash cash equivalents marketable securities longterm debt shortterm debt net debt beginning period change net debt free cash flow dividend payments share repurchase transactions equity instruments mergers acquisitions net divestments subsidiaries hedging collateral arrangements currency translation fair value movements change net debt december cash cash equivalents marketable securities longterm debt shortterm debt net debt end period definition net debt see net debt currency profile millions chf cash marketable securities debt us dollar euro swiss franc japanese yen total net debt position group december chf billion increase chf billion december increase due financing repurchase roche shares held novartis excluding free cash flow chf billion exceeded payment chf billion dividends chf billion cash payments mergers acquisitions mergers acquisitions net divestments subsidiaries included acquisitions genmark tib molbiol described section mergers acquisitions transactions equity instruments relate purchases connection groups equity compensation plansfinance report financial review roche group contractual obligations commitments group obligations commitments set table carrying values shown consolidated balance sheet potential obligations shown discounted riskadjusted unless otherwise noted amounts denominated foreign currencies translated swiss francs december exchange rates provisions legal environmental matters included timing amount cash outflow uncertain contingent development matters question contractual obligations commitments december millions chf potential obligation undiscounted less carrying year years years years total value onbalance sheet debt bonds notes debt contingent consideration accounts payable noncurrent liabilities lease liabilities current liabilities lease liabilities unfunded defined benefit plans total onbalance sheet commitments offbalance sheet capital commitments property plant equipment leasing commitments contract manufacturing commitments alliance collaboration commitments total offbalance sheet commitments total contractual commitments references notes annual financial statements debt consists mainly bonds notes includes principal interest groups debt instruments debt mainly commercial paper carrying values discounted based interest rates inherent instruments contingent consideration potential payments arising mergers acquisitions carrying values riskadjusted discounted lease liabilities future obligations noncancellable lease contracts unfunded defined benefit plans mainly pension plans groups german affiliates fully reserved pension obligations used selffinancing local affiliates operations carrying values discounted future company contributions groups funded plans shown table capital commitments property plant equipment noncancellable commitments purchase construction mainly roche sites basel switzerland south san francisco us mannheim germany also chugai research development site yokohama japan leasing commitments major noncancellable commitments signed lease agreements lease term yet started mainly relate foundation medicines site boston us genentechs site south san francisco us roche group financial review finance report contract manufacturing commitments future minimum takeorpay commitments purchase inventories arising groups major longterm agreements external contract manufacturing organisations cmos alliance collaboration commitments potential upfront milestone payments may become due groups inlicensing alliance arrangements intangible asset purchase agreements including asset acquisitions potential payments alliance partners asset purchase agreements within next three years included assuming projects currently development successful potential payments beyond three years included asset purchase agreements pensions postemployment benefits postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions expenses groups defined contribution plans chf million chf million plans classified defined benefit plans even groups potential obligation minor relatively remote possibility arising plans usually established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources expenses groups defined benefit plans chf million chf million defined benefit plans funding status balance sheet position chf chf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability overall funding status ifrs basis groups funded defined benefit plans increased compared start year came increase fair value plan assets switzerland increase discount rates regions compared end funding status pension funds monitored local pension fund governance bodies well closely reviewed group level unfunded plans mainly groups german affiliates fully reserved pension obligations invested local affiliates operations unfunded liabilities plans decreased swiss franc terms due movements exchange rates full details groups pensions postemployment benefits given note annual financial statementsfinance report financial review roche group roche shares share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billions chf roche ranked number among peer group consisting roche healthcare companiesa total shareholder return tsr defined share price growth plus dividends measured swiss francs actual exchange rates constant exchange rates cer roche ranked number yearend return roche shares roche nonvoting equity securities combined performance share nonvoting equity security compared weighted average return peer group chf terms cer december roche repurchased million roche shares held novartis total consideration chf billion repurchased shares reported treasury shares december scheduled cancelled early necessary legal procedures completed strong growth pushed world equity markets including healthcare sector record highs growth swiss market index smi slightly trailed major us indices roche outperformed smi strong sales growth diagnostics launches new products peer group abbott abbvie amgen astrazeneca bristolmyers squibb danaher glaxosmithkline johnson johnson lilly medtronic merck co novartis novo nordisk pfizer roche sanofi total shareholder return development dec mar june sept dec roche share roche nonvoting equity security peer set index source refinitiv eikon data roche peer index rebased january peer index converted swiss francs daily actual exchange rates currency fluctuations influence representation relative performance roche versus peer index roche group financial review finance report proposed dividend board directors proposing increase dividend chf per share nonvoting equity security chf approval annual general meeting would th consecutive increase dividend dividend proposal approved shareholders dividend payments total shares nonvoting equity securities amount chf billion chf billion taking account dividend distributions made repurchased shares scheduled cancelled early dividend proposal would result payout ratio based core net income based prices end dividend yield roche share yield nonvoting equity security information roche securities given pages repurchase shares december consequent additional financing costs accretive effect earnings per share numbers approximately transaction taken place january fullyear accretive effect including estimated additional financing costs would approximately information per share nonvoting equity security change chf chf chf eps basic eps diluted core eps basic core eps diluted equity attributable roche shareholders per share dividend per share details please refer notes annual financial statements payout ratio calculated dividend per share divided core earnings per share debt march group completed offering usd million usd million fixed rate notes coupon respectively notes mature march march respectively group received chf million aggregate net proceeds issuance sale fixed rate notes march group completed offering usd million floating rate notes rate equal secured overnight financing rate sofr plus margin notes mature march group received chf million aggregate net proceeds issuance sale floating rate notes due date march group redeemed notes outstanding amount eur million effective interest rate notes cash outflow chf million gain loss recorded redemption july group resolved exercise option call early redemption fixed rate notes outstanding amount usd million par two months scheduled due date september cash outflow chf million plus accrued interest gain loss recorded redemption effective interest rate notes finance report financial review roche group december group completed offering usd million fixed rate notes coupon usd million fixed rate notes coupon usd million fixed rate notes coupon notes mature december december december respectively group received chf million aggregate net proceeds issuance sale fixed rate notes december group resolved exercise option call early redemption fixed rate notes outstanding amount usd million par one month scheduled due date january cash outflow chf million plus accrued interest gain loss recorded redemption effective interest rate notes maturity schedule groups bonds notes outstanding december shown table bonds notes nominal amounts december contractual maturity us dollar euro pound sterling swiss franc total total usd eur gbp chf usd chf beyond total total translated december exchange rates group plans meet debt obligations using existing liquid funds well cash generated business operations free cash flow chf billion chf billion included cash generated operations well payment interest tax shortterm financing requirements group commercial paper program us issue usd billion unsecured commercial paper notes committed credit lines usd billion available backstop lines commercial paper notes totalling usd billion outstanding december usd billion longerterm financing group maintains high longterm investmentgrade credit ratings aa standard poors aa moodys aa fitch facilitate efficient access international capital markets repurchase million roche shares held novartis total consideration chf billion financed credit facility banks total repurchase price partly refinanced bond issue december chf billion credit facility outstanding december refinancing bond market planned information groups debt given note annual financial statements roche group financial review finance report financial risks december group net debt position chf billion chf billion financial assets group managed conservative way objective meet groups financial obligations times asset allocation considerable portion cash marketable securities group currently holds used debt repayment liquid funds either held cash invested highquality investmentgrade fixed income securities investment horizon meet liquidity requirements cash marketable securities chf total chf total cash cash equivalents money market instruments debt securities equity securities total cash marketable securities credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group rating profile groups chf billion cash fixed income marketable securities remained high invested aaaa range group signed netting collateral agreements counterparties order mitigate counterparty risk derivative positions group observe significant increase credit risk due covid pandemic bad debt expenses overdue receivables remained relatively low level liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time addition current liquidity position group strong cash generation ability future cash flows used repay debt instruments coming years group observe significant increase liquidity risk due covid pandemic free cash flow chf billion compared chf billion roche group continues enjoy high longterm investmentgrade credit ratings aa standard poors aa moodys aa fitch time roche rated highest available shortterm ratings agencies ratings changed since onset covid pandemic event financing requirements credit ratings roche group permit efficient access international capital markets including commercial paper market group committed credit lines various financial institutions totalling usd billion available backstop lines commercial paper program december debt drawn credit lines market risk market risk arises changing market prices groups financial assets financial liabilities exposures predominantly related changes interest rates foreign exchange rates equity prices group uses valueatrisk var assess impact market risk financial instruments var data indicates value range within given financial instrument fluctuate preset probability result movements market prices groups var increased since december reflecting bond issuances interest rate risk interest rate risk arises movements interest rates could affect groups financial result value group equity group may use interest rate derivatives manage interest raterelated exposure financial result information financial risk management financial risks var methodology included note annual financial statementsfinance report financial review roche group international financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since new revised standards applied group implemented various minor amendments existing standards interpretations material impact groups overall results financial position see note annual financial statements details roche group roche group consolidated financial statements finance report roche group consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf finance report roche group consolidated financial statements roche group roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche group roche group consolidated financial statements finance report roche group consolidated statement comprehensive income millions chf year ended december net income recognised income statement comprehensive income oci remeasurements defined benefit plans fair value changes equity investments fair value oci items never reclassified income statement fair value changes debt securities fair value oci cash flow hedges currency translation foreign operations items may reclassified income statement comprehensive income net tax total comprehensive income attributable roche shareholders noncontrolling interests total finance report roche group consolidated financial statements roche group roche group consolidated balance sheet millions chf december december december noncurrent assets property plant equipment rightofuse assets goodwill intangible assets deferred tax assets defined benefit plan assets noncurrent assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred tax liabilities defined benefit plan liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity roche group roche group consolidated financial statements finance report roche group consolidated statement cash flows millions chf year ended december cash flows operating activities cash generated operations increase decrease net working capital payments made defined benefit plans utilisation provisions disposal products operating cash flows income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets business combinations asset acquisitions divestment subsidiaries interest received paid dividends received marketable securities investments sales equity securities debt securities purchases equity securities debt securities sales purchases money market instruments time accounts three months net investing cash flows total cash flows investing activities cash flows financing activities proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt hedging collateral arrangements interest paid principal portion lease liabilities paid dividends paid share repurchase equitysettled equity compensation plans net transactions equity financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december finance report roche group consolidated financial statements roche group roche group consolidated statement changes equity millions chf non share retained fair value hedging translation controlling total capital earnings reserves reserves reserves total interests equity year ended december january net income recognised income statement net change fair value financial assets fair value oci cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests december year ended december january net income recognised income statement net change fair value financial assets fair value oci cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends share repurchase equity compensation plans net transactions equity changes noncontrolling interests december roche group notes roche group consolidated financial statements finance report notes roche group consolidated financial statements general accounting principles basis preparation consolidated financial statements hereafter annual financial statements roche group prepared accordance international financial reporting standards ifrs comply swiss law prepared using historical cost convention except items required accounted fair value approved issue board directors february subject approval annual general meeting shareholders march financial statements annual financial statements roche holding ltd company registered switzerland subsidiaries group groups significant accounting policies changes accounting policies disclosed note key accounting judgements estimates assumptions preparation annual financial statements requires management make judgements estimates assumptions affect reported amounts revenues expenses assets liabilities contingent amounts actual outcomes could differ management estimates estimates underlying assumptions reviewed ongoing basis based historical experience various factors revisions estimates recognised period estimate revised following considered key accounting judgements estimates assumptions made believed appropriate based upon currently available information revenue nature groups business many sales transactions simple structure may consist various performance obligations satisfied different times contracts entered diagnostics division typically include performance obligations instruments including provided leasing arrangements reagents consumables services instruments may sold cash sales transactions discounted prices instruments provided operating lease arrangements entire lease revenue may variable subject subsequent reagents sales major sources estimation uncertainty related measurement sales net discounts related obligations including standalone selling prices requires judgement determine different obligations satisfied including whether enforceable purchase commitments obligations exist arise outlicensing agreements may entered obligation may include commitments conduct research latestage development regulatory approval comarketing manufacturing may settled combination upfront payments milestone payments licensing fees reimbursements services provided whether consider commitments single performance obligation separate ones even scope ifrs revenues contracts customers straightforward requires judgement depending conclusion may result revenue calculated inception either recognised spread term longer performance obligation major sources estimation uncertainty related measurement sales recorded net allowances estimated rebates chargebacks cash discounts estimates product returns established time sale product sales allowances based estimates amounts earned claimed related sales december group chf million provisions accruals expected sales returns chargebacks rebates including medicaid us similar rebates countries provisions accruals relating us pharmaceuticals business amounted chf million chf million associated expected sales returns estimates take consideration historical experience current contractual statutory requirements specific known market events trends competitive pricing new product introductions estimated inventory levels shelf life products actual future results vary estimates need adjusted effect sales earnings period adjustmentfinance report notes roche group consolidated financial statements roche group business combinations group initially recognises fair value identifiable assets acquired liabilities assumed noncontrolling interest consideration transferred business combination management judgement particularly involved assessment whether net assets acquired constitute business recognition fair value measurement intellectual property inventories contingent liabilities contingent consideration making assessment management applies judgement considering underlying economic substance items concerned addition contractual terms considered appropriate result judgement management also applies optional concentration test set ifrs business combinations aid assessment whether transaction represents business combination simply substance purchase single asset group similar assets impairment property plant equipment rightofuse assets goodwill intangible assets december group chf million property plant equipment see note chf million rightofuse assets see note chf million goodwill see note chf million intangible assets see note goodwill intangible assets yet available use reviewed annually impairment property plant equipment rightofuse assets intangible assets use assessed impairment triggering event provides evidence asset may impaired assess whether impairment exists estimates expected future cash flows used actual outcomes could vary significantly estimates estimates relate factors changes discount rates planned use buildings machinery equipment closure facilities presence competition technical obsolescence lowerthananticipated product sales could lead shorter useful lives impairment impairment financial assets december group chf million allowance doubtful accounts trade lease receivables see note key estimates allowance doubtful accounts mainly related risk default expected loss rates making estimates inputs selected calculate allowance doubtful accounts based companys past experience existing market conditions well forwardlooking estimates end reporting period pensions postemployment benefits group operates number defined benefit plans fair values recognised plan assets liabilities based upon statistical actuarial calculations key estimates required measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions december present value groups defined benefit obligation chf million see note actuarial assumptions used estimates may differ materially actual results due changes market economic conditions longer shorter lifespans participants changes factors assessed differences could impact defined benefit plan assets liabilities recognised balance sheet future periods legal provisions group provides anticipated legal settlement costs probable outflow resources reliably estimated reliable estimate made provision recorded contingent liabilities disclosed material december group chf million legal provisions status significant legal cases disclosed note estimates consider specific circumstances legal case relevant legal advice inherently uncertain due highly complex nature legal cases estimates could change substantially time new facts emerge legal case progresses environmental provisions group provides anticipated environmental remediation costs probable outflow resources reasonably estimated december group chf million environmental provisions see note environmental provisions consist primarily costs fully clean refurbish contaminated sites including landfills treat contain contamination certain sites estimates inherently uncertain assumptions required related detection previously unknown contamination method extent remediation percentage problematic materials attributable group remediation sites financial capabilities potentially responsible parties estimates could change substantially time new facts emerge environmental remediation progresses contingent consideration provisions group makes provision estimated fair value contingent consideration arrangements arising business combinations december group chf million contingent consideration provisions see note total potential payments contingent consideration arrangements business combinations could chf million see note key estimates required determine amounts expected payments provided considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario discounted net present value estimates could change substantially time new facts emerge scenario develops roche group notes roche group consolidated financial statements finance report income taxes december group current income tax net liability chf million deferred tax net asset chf million see note major sources estimation uncertainty related calculation current deferred tax assets liabilities estimates based interpretations existing tax laws regulations tax positions uncertain accruals recorded within income tax liabilities managements best estimate ultimate liability expected arise based specific circumstances groups historical experience factors may impact estimates current deferred tax balances include changes tax laws regulations rates changing interpretations existing tax laws regulations future levels research development spending changes pretax earnings leases group lessee key judgements include assessing whether arrangements contain lease determining lease term assess whether contract contains lease requires judgement whether depends specified asset whether group obtains substantially economic benefits use asset whether group right direct use asset order determine lease term judgement required extension termination options assessed along facts circumstances may create economic incentive exercise extension option exercise termination option estimates include calculating discount rate based incremental borrowing rate december group chf million rightofuse assets chf million lease liabilities see note group lessor treatment leasing transactions mainly determined whether lease considered operating finance lease requires judgement making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred arrangements take legal form lease nevertheless convey right use asset also covered judgemental assessments consolidation group periodically undertakes transactions may involve obtaining control significant influence companies transactions include equity acquisitions asset purchases alliance agreements cases requires judgement management make assessment whether group control significant influence company whether consolidated subsidiary accounted associated company making judgemental assessment management considers underlying economic substance transaction addition contractual terms impact covid pandemic group assessed certain accounting matters generally require consideration forecast financial information taking account potential future impacts covid pandemic accounting matters assessed included limited groups provisions product returns allowances doubtful accounts trade lease receivables inventory allowances carrying value goodwill intangible assets property plant equipment defined benefit pension plan assets liabilities continued negative impacts pandemic may impact matters impairment issues related covid pandemic noted goodwill intangible assets intangible asset impairment charges chf million incurred result delay clinical trials partly impacted covid pandemic see note significant impact areas assessed groups annual financial statements group continue monitor areas increased judgements risk material changesfinance report notes roche group consolidated financial statements roche group operating segment information group two divisions pharmaceuticals diagnostics revenues primarily generated sale prescription pharmaceutical products diagnostic instruments reagents consumables respectively divisions also derive revenues sale licensing products technology third parties residual operating activities divested businesses certain global activities reported corporate include corporate executive committee global group functions communications human resources finance including treasury taxes legal safety environmental services subdivisional information also presented roche pharmaceuticals chugai operating segments within pharmaceuticals division divisional information millions chf pharmaceuticals diagnostics corporate group revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination interdivisional revenue total segment results operating profit capital expenditure business combinations asset acquisitions additions property plant equipment additions rightofuse assets additions intangible assets total research development research development costs segment information depreciation property plant equipment depreciation rightofuse assets amortisation intangible assets impairment reversal property plant equipment impairment reversal rightofuse assets impairment goodwill impairment intangible assets inventory fair value adjustments equity compensation plan expenses roche group notes roche group consolidated financial statements finance report pharmaceuticals subdivisional information millions chf roche pharmaceuticals chugai pharmaceuticals division revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination income within division total segment results operating profit elimination results within division operating profit capital expenditure business combinations asset acquisitions additions property plant equipment additions rightofuse assets additions intangible assets total research development research development costs elimination costs within division total segment information depreciation property plant equipment depreciation rightofuse assets amortisation intangible assets impairment reversal property plant equipment impairment reversal rightofuse assets impairment goodwill impairment intangible assets inventory fair value adjustments equity compensation plan expenses finance report notes roche group consolidated financial statements roche group net assets millions chf assets liabilities net assets december net operating assets pharmaceuticals diagnostics corporate total current income tax net assets liabilities deferred tax net assets liabilities defined benefit plan net assets liabilities lease liabilities marketable securities cash cash equivalents debt net assets liabilities total net assets net operating assets pharmaceuticals subdivisional information millions chf assets liabilities net assets december roche pharmaceuticals chugai elimination within division pharmaceuticals division roche group notes roche group consolidated financial statements finance report information geographical area millions chf revenues external customers noncurrent assets royalties property plant goodwill sales operating income equipment rightofuse assets ntangible assets switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total sales allocated geographical areas destination according location customer royalties operating income allocated according location group company receives revenue major customers total three us national wholesale distributors represent approximately third groups revenues three us national wholesale distributors mckesson corp chf billion chf billion amerisourcebergen corp chf billion chf billion cardinal health inc chf billion chf billion approximately revenues roche pharmaceuticals operating segment residual diagnostics operating segmentfinance report notes roche group consolidated financial statements roche group revenue disaggregated revenue information disaggregation revenue millions chf revenue revenue contracts revenue contracts revenue customers sources total customers sources total pharmaceuticals division sales therapeutic area oncology immunology neuroscience haemophilia infectious diseases ophthalmology therapeutic areas sales royalty income income outlicensing agreements income disposal products profitsharing agreements royalties operating income diagnostics division sales customer area core lab molecular lab point care diabetes care pathology lab sales royalty income income outlicensing agreements income disposal products royalties operating income total comparative information restated align new customer areas part ongoing transformation initiative diagnostics division replaced previous business area structure new customer areas follows core lab customer area focuses central labs provides diagnostics solutions areas immunoassays clinical chemistry custom biotech molecular lab customer area focuses molecular labs provides diagnostics solutions detection monitoring pathogens donor screening sexual health genomics point care customer area provides diagnostics solutions immediately point care emergency rooms general practitioners practices directly patients includes sarscov rapid tests blood gas electrolyte bge tests roche group notes roche group consolidated financial statements finance report diabetes care customer area provides diagnostics solutions people diabetes healthcare professionals enabling integrated personalised diabetes management pathology lab customer area focuses pathology labs provides diagnostics solutions tissue biopsies companion diagnostics targeted diagnostics aid choice specific therapies patient revenue sources primarily relates lease revenue collaboration income counterparty considered customer income profitsharing agreements grosstonet sales reconciliation pharmaceuticals division grosstonet sales reconciliation pharmaceuticals division shown table companies diagnostics division similar reconciling items much lower amounts pharmaceuticals division sales grosstonet reconciliation millions chf gross sales government regulatory mandatory price reductions contractual price reductions cash discounts customer returns reserves others net sales government regulatory mandatory price reductions consist mandatory price reductions major elements b drug discount program medicaid plans us totalled usd billion equivalent chf billion usd billion equivalent chf billion contractual price reductions include rebates chargebacks result contractual agreements primarily volume based performance based cash discounts include credits offered wholesalers remitting payment purchases within contractually defined incentive periods customer returns reserves allowances established expected product returns sales reductions expected withheld customer upon settlement contractual price reductions cash discounts recorded balance sheet deduction trade receivables see note sales reductions separately payable customers governmental health authorities healthcare regulatory authorities recorded balance sheet accrued liabilities see note provisions sales returns recorded balance sheet provisions see note contract balances receivables millions chf accounts receivable current receivables contracts customers noncurrent receivables contracts customers total receivables current receivables mainly include royalty licensing receivables december total receivables included lease receivables considered receivables contracts customersfinance report notes roche group consolidated financial statements roche group contract assets millions chf accrued income contract costs total contract assets contract liabilities millions chf deferred income noncurrent deferred income current total contract liabilities movement contract liabilities millions chf january business combinations revenue recognised included contract liability balance beginning year increases due cash received receivable excluding amounts recognised revenue year currency translation effects december revenue recognised relation performance obligations satisfied previous years decrease revenue recognised chf million increase chf million relating performance obligations satisfied previous periods mainly due adjustments sales deduction provisions accruals expected sales returns chargebacks allowances respect previous years remaining performance obligations partially unsatisfied longterm contracts remaining performance obligations partially unsatisfied longterm contracts either included deferred income related amounts group expects receive goods services yet transferred customers existing noncancellable otherwise enforceable contracts mainly associated contracts diagnostics division minimum purchase commitments related reagents consumables previously sold instruments well monitoring maintenance services contracts original duration one year less group elected practical expedient disclose transaction price remaining performance obligations end reporting period point time group expects recognise sales transaction price allocated contracts partially unsatisfied performance obligations millions chf contract liability held contract liability held total thereof expected recognised revenue within one year one five years five years total roche group notes roche group consolidated financial statements finance report net financial expense financing costs millions chf interest expense amortisation debt discount net gains losses redemption repurchase bonds notes discount unwind net interest cost defined benefit plans interest expense lease liabilities total financing costs financial income expense millions chf net gains losses equity investments securities fair value profit loss dividend income equity investments securities fair value profit loss dividend income equity investments securities fair value oci net income expense equity investments securities interest income expense debt securities fair value oci amortised cost net gains losses sale debt securities fair value oci net gains losses debt securities fair value profit loss net interest income expense income debt securities net foreign exchange gains losses net gains losses foreign currency derivatives foreign exchange gains losses gains losses net monetary position hyperinflationary economies net financial income expense associates total financial income expense finance report notes roche group consolidated financial statements roche group net financial expense millions chf financing costs financial income expense net financial expense financial result treasury management financial result pension management associates net financial expense hyperinflationary economies since july group considered argentina hyperinflationary economy context ias financial reporting hyperinflationary economies cumulative inflation index last three years exceeds measured national wholesaler price index sistema de ndices de precios mayoristas accordingly group reviewed reporting affiliates argentina necessary restated line ias potential adjustments resulting application ias significant impact groups operating results balance sheet adjustment recorded gains losses net monetary position loss chf million resulting loss purchasing power positive net monetary position groups argentinian affiliates loss chf million roche group notes roche group consolidated financial statements finance report income taxes income tax expenses millions chf current income taxes deferred taxes total income tax expense since group operates internationally subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate changes year year due changes mix groups taxable income changes local tax rates groups average expected tax rate stable significant changes local tax rates tax jurisdictions group operates groups effective tax rate decreased mainly due higher effect resolution several tax disputes compared groups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax rate average expected tax rate tax effect nontaxable incomenondeductible expenses equity compensation plans research development tax credits deductions us state tax impacts tax unremitted earnings resolution several tax disputes prioryear differences groups effective tax rate income tax benefit recorded respect equity compensation plans varies according price underlying equity chf million chf million income tax benefits recorded solely basis ifrs expense multiplied applicable tax rate benefit approximately chf million chf million would recorded tax effects comprehensive income millions chf pretax aftertax pretax aftertax amount tax amount amount tax amount remeasurements defined benefit plans equity investments fair value oci debt securities fair value oci cash flow hedges currency translation foreign operations comprehensive income finance report notes roche group consolidated financial statements roche group income tax assets liabilities millions chf current income taxes assets liabilities net current income tax assets liabilities deferred taxes assets liabilities net deferred tax assets liabilities current income tax liabilities include accruals uncertain tax positions current income taxes movements recognised net assets liabilities millions chf net current income tax asset liability january income taxes paid charged credited income statement charged credited equity equity compensation plans transactions shareholders currency translation effects movements net current income tax asset liability december deferred taxes movements recognised net assets liabilities millions chf property plant equipment rightofuse intangible defined temporary assets assets benefit plans ifferences total year ended december january business combinations asset acquisitions charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects movements december year ended december january business combinations asset acquisitions charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects movements december roche group notes roche group consolidated financial statements finance report net deferred tax assets temporary differences mainly relate accrued liabilities including lease liabilities provisions unrealised profit inventory deferred tax assets recognised tax losses carried forward extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances follows unrecognised tax losses expiry amount applicable amount applicable chf tax rate chf tax rate within one year one five years five years total unrecognised tax losses five years category includes losses used us state income tax purposes states permit tax reporting separate entity basis deferred tax liabilities established withholding tax taxes would payable remittance earnings foreign subsidiaries amounts currently regarded permanently reinvested purpose financial statements total unremitted earnings group regarded permanently reinvested purpose financial statements chf billion december chf billionfinance report notes roche group consolidated financial statements roche group mergers acquisitions note includes transactions accounted business combinations asset acquisitions asset acquisitions acquisitions legal entities qualify business combinations ifrs include acquisitions value acquired companies largely consists rights single asset eg product technology group similar assets cash consideration paid asset acquisitions transaction date subsequent additional contingent payments made upon achievement performancerelated development milestones presented line cash flows asset acquisitions disclosed separately subsequent consideration performancerelated development milestones transactions treated asset acquisitions recognised intangible assets specific milestones achieved recognition criteria met business combinations genmark diagnostics inc april group acquired controlling interest genmark diagnostics inc genmark publicly owned us company based carlsbad california listed nasdaq genmark provides multiplex molecular diagnostic solutions designed detect multiple pathogens single patient sample addition genmarks proprietary multiplex technology complements groups diagnostic offering addressing broad range infectious disease testing needs including respiratory bloodstream infections genmark reported diagnostics division total consideration usd million paid cash tib molbiol group december group acquired interest tib molbiol group tib molbiol privately owned group based berlin germany tib molbiol manufacturer custom oligonucleotides collaborating group years acquisition tib molbiol enhance groups broad portfolio molecular diagnostics solutions wide range assays infectious diseases tib molbiol reported diagnostics division total consideration eur million paid cash protocol first inc december group acquired controlling interest protocol first inc protocol first privately owned us company based salt lake city utah acquisition provides group access protocol firsts software solutions enhance clinical research efficiency protocol first reported pharmaceuticals division total consideration usd million paid cash identifiable assets acquired liabilities assumed set table acquisition accounting genmark finalised annual financial statements led increase deferred tax assets decrease goodwill chf million compared corresponding amounts disclosed interim financial statements amounts tib molbiol protocol first based preliminary information valuations assets liabilities therefore provisional subject adjustment roche group notes roche group consolidated financial statements finance report business combinations net assets acquired millions chf genmark tib molbiol protocol first total property plant equipment rightofuse assets intangible assets product intangibles use intangibles deferred tax assets inventories cash cash equivalents marketable securities longterm debt deferred tax liabilities noncurrent liabilities lease liabilities longterm liabilities net assets liabilities net identifiable assets goodwill total consideration cash total consideration genmarks intangible assets mainly related eplex systems designed support broad range molecular diagnostics sampletoanswer tests compact easytouse workstations selfcontained disposable test cartridges fair value intangible assets determined using excess earnings method based management forecasts observable market data discount rates tax rates foreign exchange rates present value product intangible asset genmarks eplex technology calculated using riskadjusted discount rate present value tib molbiols product intangible assets protocol firsts intangibles calculated using riskadjusted discount rate respectively valuations performed independent valuers genmark goodwill represents technological capabilities multiplex molecular diagnostic solutions furthermore represents control premium acquired workforce expected synergies notably areas manufacturing well commercialisation tib molbiol protocol first goodwill represent control premium acquired workforce expected synergies goodwill genmark tib molbiol transactions allocated diagnostics customer areas cashgenerating units goodwill protocol first transaction allocated roche pharmaceuticals cashgenerating unit none goodwill expected deductible income tax purposes accounts receivable comprised gross contractual amounts due chf million genmark acquisition chf million tib molbiol acquisition expected collectable date acquisition directly attributable transaction costs chf million reported diagnostics operating segment chf million roche pharmaceuticals operating segment within general administration expenses eight months ended december genmark contributed revenue chf million net loss tax chf million results reported diagnostics division reported molecular lab customer area group impact tib molbiol acquisition results diagnostics division reported molecular lab customer area group material acquisitions occurred january management estimates genmark tib molbiol would contributed revenue approximately chf million net loss including intangible asset amortisation tax approximately chf million information provided illustrative purposes necessarily indicative results combined group would occurred genmark tib molbiol actually acquired beginning year indicative future results combined group impact protocol first acquisition results pharmaceuticals division group materialfinance report notes roche group consolidated financial statements roche group business combinations group complete business combinations cash flows business combinations business combinations net cash outflow millions chf pharmaceuticals diagnostics total pharmaceuticals diagnostics total cash consideration paid deferred consideration paid contingent consideration paid cash acquired company total net cash outflow asset acquisitions group complete asset acquisitions asset acquisitions promedior inc february group acquired controlling interest promedior inc promedior privately owned us company based lexington massachusetts promedior reported pharmaceuticals division cash consideration paid acquisition date usd million additional contingent payments may made based upon achievement performancerelated milestones stratos genomics inc may group acquired controlling interest stratos genomics inc stratos genomics privately owned us company based seattle washington stratos genomics reported diagnostics division cash consideration paid acquisition date usd million additional contingent payments may made based upon achievement performancerelated milestones lexent bio inc june group acquired controlling interest lexent bio inc lexent bio privately owned us company based san francisco san diego california lexent bio reported pharmaceuticals division cash consideration paid acquisition date usd million additional contingent payment may made based upon achievement performancerelated milestone inflazome ltd september group acquired controlling interest inflazome ltd inflazome privately owned company based dublin ireland inflazome reported pharmaceuticals division cash consideration paid acquisition date eur million additional contingent payments may made based upon achievement performancerelated milestones tmema ltd october group acquired controlling interest tmema ltd tmema privately owned company based brighton united kingdom tmema reported pharmaceuticals division cash consideration paid acquisition date gbp million additional contingent payments may made based upon achievement performancerelated milestones roche group notes roche group consolidated financial statements finance report asset acquisitions net assets acquired millions chf stratos promedior genomics lexent bio inflazome tmema total intangible assets product intangibles available use deferred tax assets cash cash equivalents net assets liabilities net identifiable assets fair value previously held equity interest total consideration cash deferred consideration total cash consideration cash flows asset acquisitions asset acquisitions net cash outflow millions chf pharmaceuticals diagnostics total pharmaceuticals diagnostics total cash consideration paid cash acquired company contingent payments related previous acquisitions total net cash outflow asset acquisitions previously closed group recorded additions product intangible assets related contingent payments achievement performancerelated milestones chf million chf million thereof chf million paid furthermore group made contingent payments chf million related product intangible assets recognised already december finance report notes roche group consolidated financial statements roche group global restructuring plans group expanded implementation various global restructuring plans initiated prior years including organisational transformation diagnostics division various resourcing optimisation initiatives pharmaceuticals division global restructuring plans costs incurred millions chf diagnostics site consolidation plans total year ended december global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs year ended december global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs diagnostics division strategy plans diagnostics division notably diabetes care incurred costs chf million employee related matters site consolidation initiatives strategic sustainable site development basel kaiseraugst incurred costs chf million global restructuring plans employeerelated costs mainly came business transformation initiatives pharmaceuticals division outsourcing functions shared service centres external providers roche group notes roche group consolidated financial statements finance report global restructuring plans summary costs incurred millions chf employeerelated costs termination costs defined benefit plans employeerelated costs total employeerelated costs site closure costs impairment reversal property plant equipment rightofuse assets accelerated depreciation property plant equipment rightofuse assets gains losses disposal property plant equipment rightofuse assets site closure costs total site closure costs divestment products businesses gains losses divestment subsidiaries gains losses divestment products businesses total costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs finance report notes roche group consolidated financial statements roche group global restructuring plans classification costs millions chf depreciation depreciation amortisation amortisation impairment costs total impairment costs total cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics general administration pharmaceuticals diagnostics corporate total total operating segment roche pharmaceuticals chugai diagnostics corporate total roche group notes roche group consolidated financial statements finance report property plant equipment property plant equipment movements carrying value assets millions chf buildings land machinery construction land mprovements equipment progress total january cost accumulated depreciation impairment net book value year ended december january asset acquisitions additions disposals transfers depreciation charge impairment reversal charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january business combinations additions disposals transfers depreciation charge impairment reversal charge currency translation effects december cost accumulated depreciation impairment net book value finance report notes roche group consolidated financial statements roche group classification impairment property plant equipment millions chf cost sales marketing distribution research development general administration total impairment reversal charge pharmaceuticals division reported impairment reversals property plant equipment chf million net idleplant impairment reversed first half resulting income chf million partially offset impairments property plant equipment including related assets chf million impairment charges chf million incurred diagnostics division mainly connection atrisk manufacturing rampup rollout covidrelated products impairment reversals property plant equipment mainly related global restructuring plans see note reimbursements received insurance companies respect impairments property plant equipment none borrowing costs capitalised property plant equipment none december machinery equipment original cost chf billion chf billion net book value chf billion chf billion leased third parties see note capital commitments group noncancellable capital commitments purchase construction property plant equipment totalling chf billion chf billion roche group notes roche group consolidated financial statements finance report goodwill goodwill movements carrying value assets millions chf january cost accumulated impairment net book value year ended december january business combinations impairment charge recorded within general administration currency translation effects december cost accumulated impairment net book value allocated following cashgenerating units roche pharmaceuticals roche pharmaceuticals product transactions chugai total pharmaceuticals division diagnostics customer areas diabetes care customer area divisional goodwill total diagnostics division cashgenerating units used allocating goodwill pharmaceuticals division basis use cashgenerating units allocating goodwill pharmaceuticals division follows within roche pharmaceuticals operating segment goodwill arises three broad types transactions strategic transactions transformative effect across whole division technology transactions acquired technologies range areas applications product transactions acquired products typically limited synergistic benefits outside immediate product therapeutic area cashgenerating unit goodwill arising strategic transactions roche pharmaceuticals operating segment cashgenerating unit goodwill arising technology transactions also roche pharmaceuticals operating segment however acquired technologies permanently cease operate treated disposal business cases goodwill deemed disposed fully impaired cashgenerating unit goodwill arising product transactions smallest identifiable group assets related revenues related costs arise development commercialisation products question synergistic benefits products therapeutic area revenues costs corresponding assets products also taken account acquired products permanently cease generate economic benefits treated disposal business cases goodwill deemed disposed fully impaired chugai separate operating segment groups financial reporting separate cashgenerating unit goodwill allocatedfinance report notes roche group consolidated financial statements roche group group allocated goodwill roche pharmaceuticals operating segment listed strategic transactions consist genentech foundation medicine flatiron health spark therapeutics technology transactions consist therapeutic human polyclonals dutalys santaris product transactions consist glycart tanox diagnostics division basis use cashgenerating units allocating goodwill diagnostics division follows within diagnostics division goodwill arises three broad types transactions strategic transactions transformative effect across whole division technology transactions acquired technologies range areas applications product transactions acquired products either synergistic benefits across wider business limited synergistic benefits outside immediate product therapeutic area cashgenerating unit goodwill arising strategic transactions diagnostics division cashgenerating unit goodwill arising technology transactions either diagnostics customer areas diabetes care customer area however acquired technologies permanently cease operate treated disposal business cases goodwill deemed disposed fully impaired cashgenerating unit goodwill arising product transactions smallest identifiable group assets related revenues related costs arise development commercialisation products question synergistic benefits products business revenues costs corresponding assets products also taken account cashgenerating unit either diagnostics customer areas diabetes care customer area acquired products permanently cease generate economic benefits treated disposal business cases goodwill deemed disposed fully impaired group allocated goodwill roche diagnostics operating segment listed strategic transactions consist corangeboehringer mannheim technology transactions consist viewics diagnostics customer areas mysugr diabetes care customer area product transactions diagnostics customer areas consist igen bioveris ventana pvt iquum genmark tib molbiol product transactions diabetes care customer area consist disetronic medingo impairment charge impairments goodwill impairment charge diagnostics division assessment potential impairment goodwill diagnostics division carried using cashgenerating units set impairment charges totalling chf million recorded diagnostics division avl medical instruments acquisition charge chf million recorded full writeoff goodwill avl medical instruments acquisition made acquired avl medical instruments leading supplier blood gas electrolyte analysers pointofcare testing blood gas business lossmaking expected continue lossmaking according latest business plans diagnostics customer areas developing replacement product planning substantial research development investments area knowledge around blood gas business synergies gained avl medical instruments acquisition reflected current goodwill amount play minor incidental role future diagnostics customer areas strategy development nextgeneration product accordingly goodwill deemed disposed fully impaired intangible assets relating acquisition fully amortised previous years roche group notes roche group consolidated financial statements finance report geneweave biosciences acquisition charge chf million recorded full writeoff goodwill geneweave biosciences acquisition made acquired geneweave biosciences focused advancing clinical microbiology diagnostic solutions supporting healthcare providers fight drugresistant bacteria acquisition date product intangible assets available use totalling chf million recorded impairment charges recorded fully write intangible assets factors leading impairments decrease forecasted cash flows following change timelines future product development pricing penetration rate due updated market size assumptions updated assumptions timelines research development expenses production costs timelines delayed part due reprioritisation resources covidrelated projects unclear whether would future revenues support carrying value goodwill synergistic benefits products business would incidental accordingly goodwill deemed disposed fully impaired value use value use calculated using discounted expected cash flow approach posttax discount rate applied projected riskadjusted posttax cash flows terminal value discount rate groups weighted average cost capital cashgenerating units integrated operations across large parts group derived capital asset pricing model using data capital markets including government twentyyear bonds assessing value use cash flow projections based recent longterm forecasts approved management longterm forecasts include managements latest estimates sales volume pricing well production operating costs assume significant changes organisation key assumptions used calculations period cash flow projections included longterm forecasts terminal value growth rate discount rate key assumptions used valueinuse calculations period terminal period terminal cash flow value discount rate cash flow value discount rate p rojections growth rate tax p rojections growth rate tax pharmaceuticals division years na years na diagnostics division years years goodwill relating roche pharmaceuticals product transactions productspecific periods cash flow projections used cashgenerating units terminal value growth respective rate exceed longterm projected growth rate relevant market fair value less costs disposal goodwill arising chugai acquisition fair value less costs disposal determined reference publicly quoted price chugai shares sensitivity analysis management performed sensitivity analyses roche pharmaceuticals diagnostics division increased discount rate combined decreasing forecast cash flows chugai decreased publicly quoted share prices results sensitivity analyses demonstrated changes key assumptions would cause carrying values goodwill exceed recoverable amounts december finance report notes roche group consolidated financial statements roche group intangible assets intangible assets movements carrying value assets millions chf product product intangibles intangibles use available use intangibles total january cost accumulated amortisation impairment net book value year ended december january business combinations asset acquisitions additions disposals transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocated operating segment roche pharmaceuticals chugai diagnostics total group year ended december january business combinations asset acquisitions additions disposals transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocated operating segment roche pharmaceuticals chugai diagnostics total group roche group notes roche group consolidated financial statements finance report significant intangible assets december millions chf remaining operating segment net book value amortisation period product intangibles use rozlytrek ignyta acquisition roche pharmaceuticals years genmark acquisition diagnostics years gavreto blueprint medicines inlicensing transaction roche pharmaceuticals years xofluza shionogi inlicensing transaction roche pharmaceuticals years flatiron health acquisition roche pharmaceuticals years kapa acquisition diagnostics years brahms inlicensing transaction diagnostics years foundation medicine acquisition roche pharmaceuticals years luxturna spark therapeutics acquisition roche pharmaceuticals years tib molbiol acquisition diagnostics years product intangibles available use spk haemophilia gene therapy spark therapeutics acquisition roche pharmaceuticals na sarepta inlicensing transaction roche pharmaceuticals na inflazome acquisition roche pharmaceuticals na promedior acquisition roche pharmaceuticals na stratos genomics acquisition diagnostics na spk haemophilia b gene therapy spark therapeutics acquisition roche pharmaceuticals na biontech inlicensing transaction roche pharmaceuticals na dicerna inlicensing transaction roche pharmaceuticals na intangibles technology intangibles use adaptive inlicensing transaction roche pharmaceuticals years classification intangible asset amortisation impairment expenses millions chf amortisation impairment cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics total finance report notes roche group consolidated financial statements roche group internally generated intangible assets december internally generated intangible assets relating commercial software amounted chf million chf million included intangibles group internally generated intangible assets development criteria recognition asset met intangible assets indefinite useful lives group currently intangible assets indefinite useful lives intangible assets available use mostly represent inprocess research development assets acquired either inlicensing arrangements business combinations asset acquisitions separate purchases december approximately projects pharmaceuticals division known decision points within next twelve months certain circumstances could lead impairment due inherent uncertainties research development processes intangible assets available use particularly risk impairment project expected result commercialised product intangible asset impairment impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lower thananticipated sales products capitalised rights could result shortened useful lives impairment impairment charges pharmaceuticals division impairment charges totalling chf million recorded major items related charge chf million full impairment intangible asset following planned return rights licences atea pharmaceuticals announcement termination strategic collaboration asset concerned yet amortised fully written charge chf million partial impairment compound developed together alliance partner mainly driven reduced sales expectations asset concerned yet amortised written estimated recoverable amount chf million charge chf million partial impairment product intangible asset luxturna acquired part spark therapeutics acquisition impairment result reduced sales expectations asset concerned written estimated recoverable amount chf million intangible asset continues amortised remaining estimated useful life six years charge chf million partial impairment intangible asset spk acquired part spark therapeutics acquisition impairment result change planned regulatory timelines revised sales expectations asset concerned yet amortised written estimated recoverable amount chf million charge chf million due decision stop development compound alliance partner asset concerned yet amortised fully written charge chf million due decision stop collaboration project alliance partner following data assessment asset concerned yet amortised fully written charge chf million due decision stop collaboration project alliance partner asset concerned amortised fully written previously recorded impairment compound development partially reversed income chf million recorded asset concerned written estimated recoverable value chf million following clinical data assessment asset concerned yet amortised following clinical data assessment first half impairment charge chf million recorded compound development full review clinical data results second half impact programme impairment fully reversed roche group notes roche group consolidated financial statements finance report impairment charges pharmaceuticals division impairment charges totalling chf million recorded major items related charge chf million partial impairment intangible asset spk novel gene therapy treatment haemophilia acquired part spark therapeutics acquisition impairment result delay clinical trials partly impacted covid pandemic leading reduced sales expectations asset concerned yet amortised written estimated recoverable amount chf million charge chf million partial impairment intangible asset luxturna marketed gene therapy treatment patients inherited retinal disease due mutations copies rpe gene acquired part spark therapeutics acquisition impairment result reduced sales expectations asset concerned written estimated recoverable amount chf million intangible asset continues amortised remaining estimated useful life eight years potential commitments alliance collaborations intangible asset purchase agreements within next three years group party inlicensing alliance arrangements intangible asset purchase agreements including asset acquisitions arrangements purchase agreements may require group make certain milestone similar payments dependent upon achievement agreed objectives performance targets defined collaboration purchase agreements groups current estimate future thirdparty commitments potential payments within next three years set table figures undiscounted riskadjusted meaning include potential payments arise assuming projects currently development successful timing based groups current best estimate figures include potential commitments within group may arise roche chugai businesses potential future thirdparty collaboration purchase payments december millions chf pharmaceuticals diagnostics group within one year one two years two three years total inventories inventories millions chf raw materials supplies work process intermediates finished goods provision slowmoving obsolete inventory total inventories inventories expensed cost sales totalled chf billion chf billion inventory writedowns year resulted expense chf million chf millionfinance report notes roche group consolidated financial statements roche group accounts receivable accounts receivable millions chf trade receivables notes receivable receivables allowances doubtful accounts chargebacks allowances withheld upon settlement total accounts receivable allowances doubtful accounts movements recognised allowance millions chf january additional allowances created unused amounts reversed utilised year currency translation effects december bad debt expenses recorded marketing distribution costs totalled chf million expense chf million marketable securities marketable securities millions chf equity securities fair value profit loss debt securities fair value oci debt securities fair value profit loss money market instruments fair value oci time accounts three months amortised costs total marketable securities marketable securities held fund management purposes primarily denominated us dollars euros swiss francs money market instruments contracted mature within one year december debt securities contracted maturity millions chf within one year one five years five years total debt securities roche group notes roche group consolidated financial statements finance report cash cash equivalents cash cash equivalents millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents noncurrent assets noncurrent assets millions chf equity investments fair value oci equity investments fair value profit loss loans receivable restricted cash receivables contracts customers receivables total financial noncurrent assets longterm employee benefits assets total nonfinancial noncurrent assets associates total noncurrent assets equity investments designated fair value oci mainly investments private companies pharmaceutical sector held part groups strategic alliance effortsfinance report notes roche group consolidated financial statements roche group current assets current assets millions chf accrued interest income derivative financial instruments cash collateral receivables receivables contracts customers receivables total financial current assets prepaid expenses accrued income taxes recoverable assets total nonfinancial current assets total current assets accounts payable accounts payable millions chf trade payables taxes payable dividends payable payables total accounts payable roche group notes roche group consolidated financial statements finance report noncurrent liabilities noncurrent liabilities millions chf deferred income lease liabilities longterm liabilities total noncurrent liabilities longterm liabilities mainly related accrued employee benefits current liabilities current liabilities millions chf deferred income lease liabilities accrued payroll related items interest payable derivative financial instruments cash collateral payables accrued chargebacks allowances separately payable accrued royalties commissions accrued liabilities total current liabilities finance report notes roche group consolidated financial statements roche group provisions contingent liabilities provisions movements recognised liabilities millions chf contingent legal environmental restructuring consideration p rovisions provisions provisions provisions p rovisions total year ended december january additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies deferred consideration contingent consideration asset acquisitions currency translation effects december current noncurrent december year ended december january additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies deferred consideration contingent consideration asset acquisitions currency translation effects december current noncurrent december expected outflow resources within one year one two years two three years three years december chf million provisions utilised chf million chf million chf million included cash flows operating activities chf million chf million included cash flows business combinations payments made deferred contingent consideration arrangements see note roche group notes roche group consolidated financial statements finance report legal provisions legal provisions relate number separate legal matters including claims arising trade various group companies nature amounts timings outflows difficult predict part regular review litigation matters management reassessed provisions recorded certain litigation matters based development various litigations net increase legal provisions chf million notably due development accutane case us provisions previously held released resulted income chf million net expenses legal cases included general administration chf million net income chf million details major legal cases outstanding disclosed environmental provisions provisions environmental matters relate various separate environmental issues number countries nature amounts timings outflows difficult predict significant provisions discounted time value money material significant provisions relate us site nutley new jersey divested september estimated remediation costs landfill site near grenzach germany used manufacturing operations closed years ago estimated remediation costs manufacturing site clarecastle ireland shut meantime expected costs environmental remediation clarecastle site matters reassessed accordingly environmental provisions increased chf million net net environmental expenses chf million none groups procedures environmental protection included annual report pages include actions taken group regard climate change notably groups commitment reduce greenhouse gas emissions restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group timings cash outflows reasonably certain provisions discounted time value money material matters pharmaceuticals division significant provisions relate various business transformation initiatives including resourcing flexibility plans site development plans basel kaiseraugst site well redesign strategic realignment manufacturing network diagnostics division significant provisions associated programmes address longterm strategy corporate relate initiatives outsourcing functions shared service centres external providers details given note contingent consideration provisions group party certain contingent consideration arrangements arising business combinations significant provisions discounted using average discount rate time value money material additional details measurement total potential payments arrangements provided note finance report notes roche group consolidated financial statements roche group provisions provisions relate items shown table exception employee provisions timing cash outflows nature uncertain provisions millions chf sales returns employee provisions items total provisions contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group operates also subject risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable group entered inlicensing alliance arrangements intangible asset purchase agreements including asset acquisitions order gain access potential new products utilise companies help develop groups potential new products arrangements purchase agreements may require group make certain milestone similar payments dependent upon achievement agreed objectives performance targets defined collaboration purchase agreements groups current estimate future thirdparty commitments potential payments within next three years given note roche group notes roche group consolidated financial statements finance report legal cases december legal provisions included provisions legal cases chf million chf million mainly related legal cases pharmaceuticals division chf million chf million diagnostics division chf million chf million provisions recorded cases settled mainly relating meso diagnostics legal case pharmaceuticals legal matters listed avastinlucentis investigations february italian antitrust authority agcm announced investigation determine whether roche genentech novartis entered agreement restrict competition italian market drugs reference particular avastin marketed roche lucentis marketed novartis avastin lucentis two different drugs developed approved different therapeutic purposes contain different active pharmaceutical ingredients march agcm issued verdict alleges roche novartis colluded artificially differentiate avastin lucentis order foster sales lucentis italy agcm fined roche eur million novartis eur million roche appealed agcm verdict tribunale amministrativo regionale del lazio tar december tar upheld decision agcm roche appealed verdict tar consiglio di stato july roche paid eur million fine protest avoid additional penalty fees recorded expense within general administration january european court justice rendered decision five questions referred european court justice consiglio di stato july consiglio di stato issued final verdict case upheld verdicts agcm tar roche filed appeal corte suprema di cassazione rejected october addition roche filed motion revocation consiglio di stato still pending italian ministry health italian regions notified group intention seek damages related matter january french competition authority fca issued statement objections roche genentech novartis regarding anticompetitive practices concerning commercialisation avastin lucentis france fca alleges roche genentech novartis abused collective dominant position french market treatment wet agerelated macular degeneration september fca issued decision finding roche genentech novartis infringed competition law imposed fine eur million roche genentech roche genentech appealed decision december liability held amount fine included accounts payable within line item payables see note january fine paid protest avoid additional penalty fees september roche received administrative fine letter turkish competition authority tca investigation tca alleges roche novartis entered cartel aiming preventing offlabel applications avastin order foster onlabel applications lucentis october fine turkish lira million paid protest avoid additional penalty fees roche filed appeal decision addition group challenging policies regulations allowing offlabelunlicensed use reimbursement economic reasons various countries group vigorously defending matters outcome matters determined time average wholesale prices litigation hoffmannla roche inc hlr roche laboratories inc rli along approximately brand generic pharmaceutical companies named defendants several legal actions us relating pricing pharmaceutical drugs state medicaid reimbursement primary allegation litigations pharmaceutical companies misrepresented otherwise reported inaccurate average wholesale prices awp andor wholesale acquisition costs wac drugs prices allegedly relied upon states calculating medicaid reimbursements entities retail pharmacies states respective attorney general seeking repayment amounts claim overreimbursed time period associated cases december hlr rli defending one awp action filed state new jersey hlr rli vigorously defending trial date set outcome matter determined time boniva litigation hoffmannla roche inc hlr genentech various roche affiliates collectively roche named defendants numerous legal actions us one dismissed case canada relating post menopausal osteoporosis medication boniva litigations plaintiffs allege boniva caused either osteonecrosis jaw atypical femoral fractures december roche defending approximately actions involving approximately plaintiffs brought federal state courts throughout us personal injuries allegedly resulting use boniva cases early discovery stages litigation individual trial results depend variety factors including many unique particular case roche vigorously defending matters outcome matters determined timefinance report notes roche group consolidated financial statements roche group meso litigation february roche diagnostics corporation roche filed lawsuit us district court district delaware meso scale diagnostics llc meso patent infringement case involving certain us patents owned bioveris corporation bioveris company acquired group meso holds limited exclusive licence use certain aspects electrochemiluminescence ecl detection technology roche meso disagree scope licence lawsuit seeking declaratory judgment get judicial clarification roche infringing mesos licence november jury found roches use patents infringed scope mesos licence injunction granted jury awarded meso usd million damages posttrial motions filed parties meso moved enhancement prejudgment interest postjudgment royalties court hearing took place may december us district court issued final order judgment jury award confirmed mesos request enhanced damages denied group appealed decision november hearing us court appeals court decision expected addition pharmaceuticals legal cases listed currently provisions recorded potential future obligations confirmed occurrence nonoccurrence uncertain future events obligation measured sufficient reliability hemlibra litigation may baxalta inc baxalta gmbh together baxalta subsidiaries takeda pharmaceutical company limited filed patent infringement declaratory judgment patent infringement suit us district court district delaware alleging genentech chugai pharmaceutical co ltd chugai currently imminently would manufacture use sell offer sale import us hemlibra would infringe baxaltas us patent baxalta seeking judgment infringement injunctive monetary relief attorneys fees costs expenses may genentech served complaint genentechs response counterclaims complaint filed june june chugai waived service september chugai filed motion dismiss complaint lack personal jurisdiction december baxalta filed request preliminary injunction genentech inhibitor patients would subject injunction hearing held us district court district delaware june hearing baxalta withdrew request preliminary injunction inhibitor patients june baxalta submitted new proposed preliminary injunction order genentech would permitted sell hemlibra inhibitor patients noninhibitor patients currently hemlibra whether clinical trials selected noninhibitor patients additional medically diagnosed condition rendered factor viii therapies impracticable august us district court ruled baxalta denying request injunction september chugai dismissed case february us district court issued final judgment favour genentech stating hemlibra infringe baxaltas patent based courts definition key terms related patent february baxalta appealed decision august appeals court reversed claim construction ruling us district court favour genentech remanded case back us district court september genentech filed motion summary judgment multiple grounds november us district court heard genentechs motions summary judgment invalidity noninfringement doctrine equivalence wilful infringement january us district court granted genentechs motion summary judgment enablement means previously scheduled trial cancelled baxalta expected appeal decision group vigorously defending matter outcome matter determined time iraqi ministry health october f hoffmannla roche ltd fhlr hoffmannla roche inc hlr genentech certain pharmaceutical andor medical device companies named defendants complaint filed federal district court district columbia us behalf us service members relatives allege killed injured iraq iraq lawsuit complaint alleges defendants violated us antiterrorism act various state laws providing funding terrorist organisations sales practices pursuant pharmaceutical andor medical device contracts iraqi ministry health addition fhlr received inquiry july us department justice connection anticorruption investigation relating activities iraq including interactions iraqi government certain matters alleged iraq lawsuit october us department justice closed inquiry fhlr july federal district court granted defendants motions dismiss plaintiffs appealed decision january us court appeals district columbia circuit reversed decision federal district court remanded case proceedings group vigorously defending matter outcome matter determined time roche group notes roche group consolidated financial statements finance report tamiflu qui tam litigation roche holding ltd roche holding hoffmannla roche inc hlr genentech inc genentech served lawsuit filed relator us district court district maryland qui tam whistleblower provisions false claims act lawsuit originally filed seal years earlier behalf us government various us state governments lawsuit alleges certain improper conduct group respect sales tamiflu us government various us state governments us department justice declined intervene lawsuit january group filed motion dismiss september plaintiff dismissed complaint roche holding genentech district court denied hlrs motion summary judgment october district court granted parties joint motion stay discovery amend scheduling order staying discovery six months group vigorously defending matter outcome matter determined time novartis litigation related cabilly royalties may novartis vaccines diagnostics inc novartis pharma ag collectively novartis filed lawsuit genentech inc genentech california state court san mateo county novartis alleges mistakenly overpaid entitled return certain cabilly royalties products cosentyx ilaris totalling usd million following expiry cabilly patent genentech novartis discussions regarding cabilly royalties owed cosentyx ilaris manufactured imported us prior patent expiry sold patent expiry june genentech filed notice removal seeking move case state court federal court july genentech filed motion dismiss claims various grounds response genentechs motion novartis filed amended complaint august september genentech filed motion dismiss amended complaint similar grounds hearing scheduled take place february parties agreed engage voluntary private mediation february group vigorously defending matter outcome matter determined timefinance report notes roche group consolidated financial statements roche group debt debt movements carrying value recognised liabilities millions chf january proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt changes financing cash flows net gains losses redemption repurchase bonds notes amortisation debt discount financing costs business combinations asset acquisitions net foreign currency transaction gains losses currency translation effects changes foreign exchange rates changes fair values hedging instruments changes december bonds notes commercial paper amounts due banks financial institutions borrowings total debt longterm debt shortterm debt total debt pledges groups assets connection debt roche group notes roche group consolidated financial statements finance report bonds notes recognised liabilities effective interest rates bonds notes millions chf effective interest rate underlying including instrument hedging us dollar notes fixed rate notes due september principal usd billion isin usbb notes due january principal usd billion isin usbm notes due september principal usd billion outstanding usd billion isin usbn notes due march principal usd billion isin usbq notes due september principal usd billion outstanding usd billion isin usbe na notes due november principal usd billion outstanding usd billion isin usbj na notes due march principal usd billion isin usbs notes due may principal usd billion isin usbk na notes due january principal usd billion isin usbl na notes due september principal usd billion isin usbp na notes due december principal usd billion isin usbw na notes due december principal usd billion isin usbx notes due march principal usd billion outstanding usd billion isin usuan usau notes due november principal usd billion isin usbh na notes due december principal usd billion isin usby us dollar notes floating rate notes due march principal usd billion isin usbr na euro medium term note programme fixed rate notes due march principal eur billion isin xs notes due february principal eur billion isin xs notes due august principal gbp billion outstanding gbp billion isin xs na notes due february principal eur billion isin xs swiss franc bonds fixed rate bonds due september principal chf billion isin ch bonds due september principal chf billion isin ch bonds due september principal chf billion isin ch na bonds due march principal chf billion isin ch na bonds due september principal chf billion isin ch na genentech senior notes senior notes due july principal usd billion outstanding usd billion isin usac na total bonds notes finance report notes roche group consolidated financial statements roche group bonds notes maturity millions chf within one year one two years two three years three four years four five years five years total bonds notes unamortised discount included carrying value bonds notes millions chf us dollar notes euro notes total unamortised discount issuance bonds notes march group completed offering usd billion usd billion fixed rate notes coupon respectively notes mature march march respectively group received chf million aggregate net proceeds issuance sale fixed rate notes march group completed offering usd billion floating rate notes rate equal secured overnight financing rate sofr plus margin notes mature march group received chf million aggregate net proceeds issuance sale floating rate notes december group completed offering usd billion fixed rate notes coupon usd billion fixed rate notes coupon usd billion fixed rate notes coupon notes mature december december december respectively group received chf million aggregate net proceeds issuance sale fixed rate notes issuance bonds notes group issue bonds notes redemption repurchase bonds notes due date march group redeemed notes outstanding amount eur billion effective interest rate notes cash outflow chf million gain loss recorded redemption july group resolved exercise option call early redemption fixed rate notes outstanding amount usd billion par two months scheduled due date september cash outflow chf million plus accrued interest gain loss recorded redemption effective interest rate notes december group resolved exercise option call early redemption fixed rate notes outstanding amount usd billion par one month scheduled due date january cash outflow chf million plus accrued interest gain loss recorded redemption effective interest rate notes roche group notes roche group consolidated financial statements finance report redemption repurchase bonds notes group repay bonds notes cash flows issuance redemption repurchase bonds notes cash inflows issuance bonds notes millions chf us dollar notes total cash inflows issuance bonds notes cash outflows redemption repurchase bonds notes millions chf euro medium term note programme euro notes us dollar notes total cash outflows redemption repurchase bonds notes commercial paper roche holdings inc commercial paper program roche holdings inc established commercial paper program issue usd billion unsecured commercial paper notes guaranteed roche holding ltd committed credit line available backstop supporting commercial paper program usd billion december july previously existing committed credit lines refinanced one new committed credit line initial maturity five years maturity notes program exceed days date issuance december unsecured commercial paper notes principal amount usd billion average interest rate outstanding movements commercial paper obligations millions chf january net cash proceeds payments currency translation effects december amounts due banks financial institutions december amounts outstanding chf million chf million due within one year amounts denominated various currencies average interest rate position notably included credit facility banks used finance share repurchase transaction see note chf billion outstanding december finance report notes roche group consolidated financial statements roche group equity attributable roche shareholders changes equity attributable roche shareholders millions chf share retained fair value hedging translation c apital earnings reserves reserves reserves total year ended december january net income recognised income statement financial assets fair value oci fair value gains losses equity investments fair value oci fair value gains losses taken retained earnings disposal equity investments fair value oci fair value gains losses debt securities fair value oci fair value gains losses transferred income statement debt securities fair value oci income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences accumulated differences transferred income statement divestment subsidiaries noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests december b entire amount transferred income statement reported financial income expense b cost hedging reserve related eurusd crosscurrency swap included hedging reserve amounted chf million net tax roche group notes roche group consolidated financial statements finance report changes equity attributable roche shareholders millions chf share retained fair value hedging translation c apital earnings reserves reserves reserves total year ended december january net income recognised income statement financial assets fair value oci fair value gains losses equity investments fair value oci fair value gains losses taken retained earnings disposal equity investments fair value oci fair value gains losses debt securities fair value oci fair value gains losses transferred income statement debt securities fair value oci income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences accumulated differences transferred income statement divestment subsidiaries noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends share repurchase equity compensation plans net transactions equity changes noncontrolling interests december b entire amount transferred income statement reported financial income expense b remaining crosscurrency swaps expired march see note therefore hedging reserves longer included costs hedging instruments december finance report notes roche group consolidated financial statements roche group share repurchase november roche group novartis announced agreement whereby roche would repurchase million roche shares nominal value chf held novartis total consideration chf billion repurchased shares would subsequently cancelled roche november extraordinary general meeting roche shareholders approved share capital reduction chf million chf million chf million cancellation shares repurchased novartis share repurchase transaction closed december december repurchased shares reported treasury shares repurchase price including transaction costs scheduled cancelled early necessary legal procedures completed transaction financed credit facility banks total repurchase price partly refinanced bonds issue chf billion december see note december chf billion credit facility outstanding refinancing bond market planned share capital december authorised issued share capital roche holding ltd groups parent company consisted million shares nominal value chf preceding year following closing share repurchase transaction described december million shares held group scheduled cancelled early necessary legal procedures completed upon cancellation shares share capital decrease chf million chf million chf million shares bearer shares group maintain register shareholders december based information supplied group shareholder group pooled voting rights owned shares representing issued shares voting power excluding treasury shares held group december scheduled cancelled early figures include shares without pooled voting rights held outside group individual members group december shareholder group announced would continue shareholder pooling agreement existing since modified shareholder composition duration pool extended indefinite period december based information supplied group ms maja oeri formerly member pool held shares independently pool representing issued shares voting power excluding treasury shares held group december scheduled cancelled early described note december based information supplied group shares owned novartis holding ag basel participation nonvoting equity securities genussscheine december nonvoting equity securities authorised issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange shares participation certificates nonvoting equity securities without consent bearers thereof dividends march shareholders approved distribution dividend chf per share nonvoting equity security chf respect business year distribution holders outstanding shares nonvoting equity securities totalled chf million chf million recorded retained earnings board directors proposed dividends business year chf per share nonvoting equity security dividend proposal subject approval annual general meeting march approved would result total distribution shareholders chf million taking account dividend distributions made repurchased shares scheduled cancelled early roche group notes roche group consolidated financial statements finance report equity instruments holdings equity instruments equivalent number nonvoting equity securities millions millions shares nonvoting equity securities total equity instruments recorded within equity original purchase cost december fair value shares chf billion fair value nonvoting equity securities chf billion equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note addition described million repurchased shares reported treasury shares december scheduled cancelled early necessary legal procedures completed reserves fair value reserve december fair value reserve represents cumulative net change fair value financial assets fair value oci asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francsfinance report notes roche group consolidated financial statements roche group subsidiaries associates chugai effective october roche group chugai completed alliance create leading researchdriven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai consolidated subsidiary chugai fully consolidated subsidiary group based groups interest chugai december roche relationship chugai founded basic alliance licensing research collaboration agreements common stock chugai publicly traded listed tokyo stock exchange stock code tse chugai prepares financial statements accordance international financial reporting standards ifrs filed quarterly basis tokyo stock exchange due certain consolidation entries minor differences chugais standalone ifrs results results chugai consolidated roche group accordance ifrs chugai summarised financial information millions chf income statement sales royalties operating income total revenues operating profit balance sheet noncurrent assets current assets noncurrent liabilities current liabilities total net assets cash flows cash flows operating activities cash flows investing activities cash flows financing activities dividends dividends distributed third parties holding chugai shares totalled chf million chf million recorded noncontrolling interests see note dividends paid chugai roche eliminated consolidation intercompany items roches relationship chugai chugai entered certain agreements roche discussed basic alliance agreement part basic alliance agreement signed december roche chugai entered certain arrangements covering future operation governance chugai amongst matters cover following areas structuring alliance roches rights shareholder roches rights nominate members chugais board directors certain limitations roches ability buy sell chugais common stock chugai issues additional shares common stock connection convertible debt equity compensation plans may issue additional shares purposes affects roches percentage ownership interest basic alliance agreement provides amongst matters chugai guarantee roches right maintain shareholding percentage chugai less roche group notes roche group consolidated financial statements finance report licensing agreements japan umbrella rights agreement signed december chugai exclusive rights market roches pharmaceutical products japan chugai right first refusal development marketing japan development compounds advanced roche rest world umbrella rights agreement excluding japan south korea signed may revised amended restated rest world umbrella rights agreement excluding japan south korea taiwan signed august agreement chugai shall offer roche right first refusal development marketing chugais development compounds markets outside japan excluding south korea taiwan agreements roche chugai signed series separate agreements certain specific products depending specific circumstances terms agreement may result payments arms length basis roche chugai following matters upfront payments right first refusal license product exercised milestone payments dependent upon achievement agreed performance targets royalties future product sales specific product agreements may also cover manufacture supply respective products meet partys clinical andor commercial requirements arms length basis research collaboration agreements roche chugai entered research collaboration agreements areas smallmolecule synthetic drug research biotechnologybased drug discovery associates december group acquired interest freenome holdings inc freenome privately owned us company based south san francisco california groups interest freenome december investment assessed treated associate group group accounts freenome using equity method based freenomes financial statements made available group carrying value groups share freenomes net assets december asset chf million included noncurrent assets see note impact group share freenomes results december december included financial income expense see note finance report notes roche group consolidated financial statements roche group noncontrolling interests changes equity attributable noncontrolling interests millions chf january net income recognised income statement chugai noncontrolling interests total net income recognised income statement equity investments fair value oci debt securities fair value oci cash flow hedges currency translation foreign operations remeasurements defined benefit plans comprehensive income net tax total comprehensive income business combinations dividends noncontrolling shareholders chugai noncontrolling interests equity compensation plans net transactions equity changes noncontrolling interests december chugai noncontrolling interests total noncontrolling interests roche group notes roche group consolidated financial statements finance report employee benefits employee remuneration millions chf wages salaries social security costs defined contribution plans operating expenses defined benefit plans equity compensation plans termination costs employee benefits employee remuneration included operating results net interest cost defined benefit plans total employee remuneration employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits pensions postemployment benefits groups objective provide attractive competitive postemployment benefits employees time ensuring various plans appropriately financed managing potential impacts groups longterm financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations fiscal requirements market practice countries employees employed postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions plans classified defined benefit plans defined contribution plans defined contribution plans funded payments employees group funds administered third parties groups expenses plans chf million chf million assets liabilities recognised groups balance sheet respect plans apart regular prepayments accruals contributions withheld employees wages salaries groups contributions groups major defined contribution plan us roche k savings plan defined benefit plans plans usually established trusts independent group funded payments group companies employees cases notably major defined benefit plans germany plans unfunded group pays pensions retired employees directly financial resources plans usually governed senior governing body board trustees typically composed employee employer representatives funding plans determined local regulations using independent actuarial valuations separate independent actuarial valuations prepared accordance requirements ias use groups financial statements groups major pension plans located switzerland us germany total account groups defined benefit obligation finance report notes roche group consolidated financial statements roche group pension plans switzerland current pension arrangements employees switzerland made plans governed swiss federal occupational old age survivors disability pension act bvg groups pension plans administered separate legal foundations funded regular employee company contributions final benefit contribution based certain minimum guarantees due minimum guarantees swiss plans treated defined benefit plans purposes ifrs financial statements although many characteristics defined contribution plans underfunding may remedied various measures increasing employee company contributions lowering interest rate retirement account balances reducing prospective benefits suspension early withdrawal facility pension plans us groups major defined benefit plans us closed new members since new employees us join defined contribution plan largest remaining defined benefit plans funded pension plans together smaller unfunded supplementary retirement plans benefits based highest average annual rate earnings specified period length employment plans noncontributory employees group making periodic contributions plans underfunding would normally remedied additional company contributions contributions made group pension plans germany groups major pension arrangements germany governed occupational pensions act betravg plans unfunded group pays pensions retired employees directly financial resources plans noncontributory employees benefits based final salary length employment plans closed new members since replaced new plan funded regular employee company contributions administered contractual trust agreement final benefit contribution based minimum guarantee due minimum guarantee plan treated defined benefit plan purposes ifrs financial statements although many characteristics defined contribution plan pension plans rest world represent approximately groups defined benefit obligation consist number smaller plans various countries largest pension plans chugai independently managed chugai main pension plan united kingdom chugai made additional voluntary contributions jpy billion pension plans jpy billion chugai plans fully described chugais ifrs financial statements uk pension plan funded regular employee company contributions benefits based final salary length employment plan closed new members since replaced defined contribution plan postemployment benefit opeb plans represent approximately groups defined benefit obligation consist postemployment healthcare life insurance schemes mainly us plans mainly unfunded andor contributory employees group reimbursing retired employees directly financial resources groups major opeb plans us closed new members since part costs plans reimbursable medicare prescription drug improvement modernization act statutory funding requirement plans group funding plans extent tax efficient contributions made group plans december ifrs funding status including reimbursement rights funded opeb plans us defined benefit plans income statement millions chf post post pension employment total pension employment total plans benefit plans expense plans benefit plans expense current service cost past service income cost settlement gain loss total operating expenses net interest cost defined benefit plans total expense recognised income statement roche group notes roche group consolidated financial statements finance report funding status funding groups various defined benefit plans responsibility respective senior governing body board trustees sponsoring employer managed based local statutory valuations follow legislation requirements respective jurisdiction plan established qualified independent actuaries carry statutory actuarial valuations regular basis actuarial assumptions determining funding status statutory basis regularly assessed local senior governing body funding status closely monitored corporate level unfunded plans mainly groups german affiliates fully reserved pension obligations used selffinancing local affiliates operations ifrs funding status funded defined benefit plans increased reimbursement rights linked postemployment medical plans us represent expected reimbursement medical expenditure provided medicare prescription drug improvement modernization act defined benefit plans funding status millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability reported balance sheet defined benefit plan assets defined benefit plan liabilities plan assets responsibility investment strategies funded plans respective senior governance body board trustees assetliability studies performed regularly major pension plans studies examine obligations postemployment benefit plans evaluate various investment strategies respect key financial measures expected returns expected risks expected contributions expected funded status plan interdependent way goal assetliability study select appropriate asset allocation funds held within plan investment strategy developed optimise expected returns manage risks contain fluctuations statutory funded status assetliability studies include strategies match cash flows assets plan obligations group currently use longevity swaps manage longevity risk plan assets managed using internal external asset managers actual performance continually monitored pension fund governance bodies well closely monitored corporate level financial statements difference interest income actual return plan assets remeasurement recorded directly comprehensive income actual return plan assets gain chf million gain chf million excludes actual return reimbursement rights recognition plan assets limited present value economic benefits available refunds plans reductions future contributions plansfinance report notes roche group consolidated financial statements roche group defined benefit plans fair value plan assets reimbursement rights millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january interest income plan assets reimbursement rights remeasurements plan assets reimbursement rights currency translation effects employer contributions employee contributions benefits paid funded plans benefits paid settlements administration costs december defined benefit plans composition plan assets millions chf equity securities debt securities property cash money market instruments investments december assets invested variety different classes order maintain balance risk return follows equity debt securities mainly quoted market prices level fair value hierarchy property primarily private commercial property funds mainly observable inputs level fair value hierarchy cash money market instruments mainly invested financial institutions credit rating lower investments mainly consist alternatives mortgages commodities insurance contracts used risk management purposes mainly observable inputs level fair value hierarchy unobservable inputs level fair value hierarchy included within fair value plan assets groups shares nonvoting securities fair value chf million chf million debt instruments issued group fair value chf million chf million roche group notes roche group consolidated financial statements finance report defined benefit obligation defined benefit obligation calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth mortality rates present value defined benefit obligation determined discounting estimated future cash outflows using interest rates highquality corporate bonds government bonds countries deep market corporate bonds corporate government bonds denominated currency benefits paid maturity terms approximating terms related pension obligation groups final salarybased defined benefit pension plans us germany united kingdom closed new participants active employees members pension plans time closed new participants continue accrue benefits final salarybased defined benefit pension plans new employees us uk join groups defined contribution plans new employees germany join contributionbased plan minimum guarantee result proportion defined benefit obligation relates closed plans expected decrease future defined benefit pension plans switzerland final benefit contribution based minimum guarantee remain open new employees defined benefit plans defined benefit obligation millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january current service cost interest cost remeasurements demographic assumptions financial assumptions experience adjustments currency translation effects employee contributions benefits paid funded plans benefits paid unfunded plans benefits paid settlements past service income cost settlement gain loss december composition plan active members deferred vested members retired members december plans geography switzerland united states germany rest world december duration years finance report notes roche group consolidated financial statements roche group actuarial assumptions actuarial assumptions used financial statements based requirements set ias employee benefits unbiased mutually compatible estimates variables determine ultimate cost providing post employment benefits set annual basis local management based advice actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover financial assumptions matters interest rates salary benefit levels inflation rates costs medical benefits actuarial assumptions vary based upon local economic social conditions actuarial assumptions used various statutory valuations may differ based local legal regulatory requirements demographic assumptions significant demographic assumptions relate mortality rates groups actuaries use mortality tables take account historic patterns expected changes increases longevity rates employee turnover disability early retirement based historical behaviour average life expectancy assumed individual age follows defined benefit plans average life expectancy age major schemes years male female country mortality table switzerland bvg projected cmi model united states pri projected mp germany heubeck tables g projected cmi model mortality assumptions used pension plans switzerland based bvg bvg applying continuous mortality investigation cmi model longterm rate used longevity improvements group used mortality assumptions pension plans germany heubeck tables g applying cmi model longterm rate longevity improvements financial assumptions based market expectations period obligations settled assumptions used actuarial valuations shown defined benefit plans financial actuarial assumptions weighted weighted average range average range discount rates expected rates salary increases expected rates pension increases expected inflation rates immediate medical cost trend rate ultimate medical cost trend rate discount rates determined reference interest rates highquality corporate bonds government bonds countries deep market corporate bonds expected rates salary increases based expected inflation rates adjustment reflect groups latest expectation longterm real salary increases taking account expected inflation rates amongst factors expected rates pension increases generally linked expected inflation rate funding status plan expected inflation rates derived looking level inflation implied financial markets conjunction economists price inflation forecasts historic price inflation well economic variables circumstances medical cost trend rates take account benefits set plan terms expected future changes medical costs since groups major postemployment medical plans us employees rates driven developments us roche group notes roche group consolidated financial statements finance report sensitivity analysis measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions following table summarises impact change assumptions present value defined benefit obligation defined benefit plans sensitivity defined benefit obligation actuarial assumptions millions chf increase decrease defined benefit obligation life expectancy year increase discount rates increase decrease expected inflation rates increase decrease immediate medical cost trend rate increase decrease sensitivity analysis considers change one assumption time leaving assumptions unchanged approach shows isolated effect changing one individual assumption take account assumptions related method used carry sensitivity analysis prior year cash flows group incurred cash flows defined benefit plans shown table defined benefit plans cash flows millions chf employer contributions net reimbursements funded plans benefits paid unfunded plans total cash inflow outflow based recent actuarial valuations group expects employer contributions funded plans approximately chf million includes estimated chf million additional voluntary contributions related chugai benefit plans benefits paid unfunded plans estimated approximately chf million mostly relate german defined benefit plansfinance report notes roche group consolidated financial statements roche group equity compensation plans group operates several equity compensation plans including separate plans chugai ifrs sharebased payment requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expenses equity compensation plans roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan roche connect roche option plan bonus stock awards chugai plans total operating expenses equitysettled cashsettled cash inflow outflow equity compensation plans millions chf roche option plan exercises chugai plans exercises roche connect costs transactions equity total cash inflow outflow equitysettled equity compensation plans net transactions equity net cash outflow transactions equity mainly arises sales purchases equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note roche group notes roche group consolidated financial statements finance report equity compensation plans roche stocksettled stock appreciation rights group issues stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive nonvoting equity securities reflecting value appreciation market price nonvoting equity securities grant date exercise date roche ssar plan million ssars available issuance tenyear period starting rights nontradable equitysettled awards tenyear duration vest phased basis four years rights granted sevenyear duration vested phased basis three years roche ssars movement number rights outstanding weighted average weighted average number rights exercise price number rights exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche ssars terms rights outstanding december rights outstanding rights exercisable weighted average weighted average weighted average number outstanding years remaining exercise price number exercisable exercise price year grant thousands c ontractual life chf thousands chf total roche restricted stock unit plan group issues restricted stock units rsus awards certain directors management employees selected discretion group rsus nontradable represent right receive nonvoting equity securities rsus vest phased basis four years subject performance conditions rsus granted vest threeyear period currently performance conditions outstanding rsus december roche rsu plan million nonvoting equity securities available issuance tenyear period starting roche rsu plan also includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number nonvoting equity securities individual award grantedfinance report notes roche group consolidated financial statements roche group roche rsus movement number awards outstanding number awards number awards thousands thousands outstanding january granted forfeited transferred participants outstanding december vested transferable roche connect programme enables employees worldwide except us certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market december administrator held million nonvoting equity securities million cost plan chf million chf million roche option plan programme used countries ssars used awards plan give employees right purchase nonvoting equity securities exercise price specified grant date options nontradable equitysettled awards tenyear duration vest phased basis four years options granted sevenyear duration vested phased basis three years roche option plan movement number options outstanding weighted average weighted average number options exercise price number options exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche option plan terms options outstanding december options outstanding options exercisable weighted average weighted average weighted average number outstanding years remaining exercise price number exercisable exercise price year grant thousands c ontractual life chf thousands chf total weighted average share price roche nonvoting equity securities year chf chf roche group notes roche group consolidated financial statements finance report bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year subject approval annual general meeting march issued march number awards fair value per award calculated grant date fair value measurement inputs used measurement fair values grant date equity compensation plans follows fair value measurement roche roche stocksettled stock restricted stock roche appreciation rights unit plan option plan progressively progressively progressively vesting period years years years contractual life years na years number granted year thousands weighted average fair value chf model used binomial market pricea binomial inputs option pricing model share price grant date chf exercise price chf expected volatility b na expected dividend yield na early exercise factor c na expected exit rate na fair value roche rsus equivalent share price date grant b volatility determined primarily reference historically observed prices underlying equity riskfree interest rates derived zero coupon swap rates grant date taken datastream c early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviourfinance report notes roche group consolidated financial statements roche group leases group lessee group enters leasing transaction lessee mainly reasons convenience flexibility group good cash generation ability enjoys strong longterm investment grade credit ratings therefore typically enter leasing arrangements financing considerations main areas leases group entered property offices apartments small number leases represent value cars mostly sales representatives office equipment photocopiers similar rightofuse assets reported groups leases shown table rightofuse assets movements carrying value assets millions chf buildings land machinery land improvements equipment total year ended december january business combinations asset acquisitions additions disposals depreciation impairment reversal charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january business combinations additions disposals depreciation impairment reversal charge currency translation effects december cost accumulated depreciation impairment net book value roche group notes roche group consolidated financial statements finance report classification impairment reversal charge rightofuse assets millions chf cost sales marketing distribution research development general administration total impairment reversal charge impairment charges rightofuse assets mainly related global restructuring plans see note also office closures liabilities reported groups leases shown table leases movements carrying value recognised liabilities millions chf january increase new lease arrangements repayment lease liabilities business combinations asset acquisitions disposals interest expense lease liabilities currency translation effects december noncurrent lease liabilities current lease liabilities total lease liabilities maturity analysis lease liabilities given note liquidity risk section shortterm leases leases lowvalue assets accounted using recognition exemption permitted ifrs expenses shortterm leases recognised straightline basis mainly include shortterm property leases employee apartments amount reported chf million chf million expenses leases lowvalue assets recognised straightline basis mainly include certain office equipment amount reported chf million chf million expenses variable lease payments included measurement lease liabilities chf million chf million income subleasing rightofuse assets chf million group enter sale leaseback transactions major cash flows respect leases group lessee shown table leases cash flows millions chf included cash flows operating activities included cash flows financing activities total lease payments cash flows operating activities include cash flows shortterm lease leases lowvalue assets variable lease payments cash flows financing activities include payment interest principal portion lease liabilities well prepayments made lease commencement datefinance report notes roche group consolidated financial statements roche group leases committed yet commenced july foundation medicine inc fmi entered binding lease agreement third party lease laboratory office space building boston us constructed landlord location currently known boston seaport according agreement fmi committed lease building years commencement date lease currently expected first half initial rightofuse asset lease liability related agreement estimated approximately usd million based current assumptions november genentech inc genentech entered binding lease agreement third party lease laboratory office space building south san francisco us constructed landlord location currently known gateway according agreement genentech committed lease building seven years commencement date lease yet defined subject landlord deliveries earlier march initial rightofuse asset lease liability related agreement estimated approximately usd million based current assumptions group lessor diagnostics division group enters certain contracts include placement diagnostics instruments supply reagents consumables servicing arrangements depending upon term agreement instrument placement may result either finance lease operating lease group performs thorough customer assessment new leasing agreements signed usually group also retains rights terminate modify contracts certain conditions met finance leases certain assets mainly diagnostics instruments leased third parties finance lease arrangements assets reported receivables amount equal net investment lease income finance leases recognised revenue amounts represent fair value instrument approximates present value minimum lease payments arrangement finance income finance lease arrangements longer twelve months deferred subsequently recognised based pattern approximates use effective interest method recorded royalty operating income following amounts recorded income respect finance leases finance leases selected items income millions chf selling profit difference sales cost sales finance income net investment lease currently group income variable lease payments finance leases carrying amount net investment finance leases reported receivables chf million chf million finance leases future minimum lease receipts noncancellable leases millions chf present value minimum gross investment lease lease receipts within one year one two years two three years three four years four five years five years total unearned finance income na na unguaranteed residual value na na net investment lease roche group notes roche group consolidated financial statements finance report operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements income operating leases recognised revenue straightline basis lease term lease revenue entirely based variable lease payments subject subsequent reagent sales performance obligations reagents satisfied lease income chf million chf million included sales chf million chf million relates variable lease payments depending upon index rate leased assets reported within property plant equipment shown table machinery equipment subject operating leases movements carrying value assets millions chf leased use total leased use total january cost accumulated depreciation impairment net book value year ended december january business combinations asset acquisitions additions disposals transfers depreciation charge impairment reversal charge currency translation effects december cost accumulated depreciation impairment net book value undiscounted amounts expected received noncancellable operating leases shown table operating leases future minimum lease receipts noncancellable leases millions chf within one year one two years two three years three four years four five years five years total minimum receipts finance report notes roche group consolidated financial statements roche group earnings per share nonvoting equity security basic earnings per share nonvoting equity security net income attributable roche shareholders chf millions number shares millions number nonvoting equity securities millions weighted average number shares nonvoting equity securities held millions weighted average number outstanding shares nonvoting equity securities used calculate basic earnings per share millions basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security net income attributable roche shareholders chf millions increase noncontrolling interests share group net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number outstanding shares nonvoting equity securities used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf roche group notes roche group consolidated financial statements finance report statement cash flows cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics divisions calculated using indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown statement cash flows operating cash flows also include income taxes paid activities cash generated operations millions chf net income add back nonoperating income expense financing costs financial income expense income taxes operating profit depreciation property plant equipment depreciation rightofuse assets amortisation intangible assets impairment goodwill impairment intangible assets impairment reversal property plant equipment impairment reversal rightofuse assets operating income expense defined benefit plans operating expense equitysettled equity compensation plans net income expense provisions bad debt reversal expense inventory writedowns inventory fair value adjustments net gain loss disposal products adjustments cash generated operations cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associates businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects business combinations divestments well cash generated groups investments interest received paid dividends received marketable securities investments millions chf interest received paid dividends received total finance report notes roche group consolidated financial statements roche group cash flows financing activities cash flows financing activities primarily proceeds issue repayment groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing also included cash flows indicate groups transactions providers equity debt financing cash flows lease payments also included within financing activities cash flows shortterm borrowings shown net movement consist large number transactions short maturity dividends paid millions chf dividends roche group shareholders dividends noncontrolling shareholders chugai noncontrolling interests dividend withholding tax total liabilities arising financing activities movements carrying value recognised assets liabilities millions chf cash principal derivative collateral portion financial receivables interest lease instruments payables debt payable liabilities net net total year ended december january cash flows outflow inflow noncash changes financing costs business combinations asset acquisitions fair value foreign exchange rates december year ended december january cash flows outflow inflow noncash changes financing costs business combinations asset acquisitions fair value foreign exchange rates december significant noncash transactions significant noncash transactions none except leasing transactions group lessee see note roche group notes roche group consolidated financial statements finance report risk management group risk management risk management fundamental element groups business practice levels encompasses different types risks group level risk management integral part longterm forecasting controlling processes material risks monitored regularly discussed corporate executive committee audit committee board directors financial risk management group exposed various financial risks arising underlying operations corporate finance activities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency groups counterparties financial risk management within group governed policies reviewed boards directors roche chugai appropriate areas statutory responsibility policies cover credit risk liquidity risk market risk policies provide guidance risk limits types authorised financial instruments monitoring procedures general principle policies prohibit use derivative financial instruments speculative trading purposes policy implementation daytoday risk management carried relevant treasury functions regular reporting risks performed relevant accounting controlling functions within roche chugai credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group objective managing counterparty credit risk prevent losses liquid funds deposited invested counterparties maximum exposure credit risk resulting financial activities without considering netting agreements without taking account collateral held credit enhancements equal carrying value groups financial assets group considers financial asset default counterparty unlikely pay obligations group full assessing whether counterparty default group considers qualitative quantitative indicators eg overdue status based data developed internally certain financial assets also obtained external sources major part groups receivables past due days relate public customers risk default public customers considered low group reasonable supportable information demonstrate lagging default criterion appropriate particular customer segment accounts receivable december group trade receivables chf billion chf billion subject policy active credit risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures objective trade receivables management maximise collection unpaid amounts group uses allowance matrix estimate allowance doubtful accounts trade receivables expected credit loss ecl rate based groups historical experience groups expectation economic conditions period receivables expected paidfinance report notes roche group consolidated financial statements roche group customer credit risk exposure based accounts receivable days overdue millions chf overdue overdue overdue credit total current months months year impaired december gross carrying amount groups expected credit loss rate allowance doubtful accounts december gross carrying amount groups expected credit loss rate allowance doubtful accounts december groups combined trade receivables balance three us national wholesale distributors mckesson corp amerisourcebergen corp cardinal health inc equivalent chf billion representing groups consolidated trade receivables chf billion representing significant concentration counterparty credit risk due groups large number customers wide geographical spread risk limits exposures continuously monitored country nature counterparties group obtains credit insurance similar enhancements appropriate protect collection trade receivables december collateral considered measure expected credit losses trade receivables none nature geographic location counterparties accounts receivable overdue impaired shown table include balances us national wholesalers described accounts receivable overdue net allowances doubtful accounts allowances nature geographical location counterparties millions chf whole whole salers salers regions total public distributors private total public distributors private switzerland europe north america latin america japan asia australia oceania rest world total cash marketable securities excluding equity securities december group cash marketable securities excluding equity securities chf billion chf billion subject policy restricting exposures highquality counterparties setting defined limits individual counterparties limits counterparty credit ratings reviewed regularly cash cash equivalents held banks financial institutions predominantly rated investment grade based moodys standard poors ratings cash shortterm time deposits subject rules limit groups exposure individual financial institutions roche group notes roche group consolidated financial statements finance report impairment cash cash equivalents measured month expected credit losses ecl basis reference external credit ratings counterparties reflects short maturities exposures cash cash equivalents group considers cash cash equivalents low credit risk based external credit ratings investments marketable securities excluding equity securities entered basis guidelines regard liquidity quality maximum amount general rule group invests highquality securities adequate liquidity counterparties credit rating least baa moodys bbb standard poors credit risk counterparties external ratings investment grade rating closely monitored reviewed individual basis rating analysis cash marketable securities excluding equity securities market values millions chf fair value fair value oci amortised costs oci amortised costs total month ecl month ecl total month ecl month ecl aaa range aa range range bbb range total investment grade bbb range investment grade unrated total gross carrying amounts loss allowance loss allowance related fair value oci affect carrying amount marketable securities excluding equity securities booked corresponding oci reserve instead debt securities amortised cost fair value oci investment grade therefore considered low risk thus impairment allowance determined month expected credit losses ecl reference external credit ratings counterparties debt securities group observed significant increase credit risk would require application lifetime expected credit losses impairment model addition material movements loss allowance respectively master netting agreements group enters derivative transactions collateral agreements international swaps derivatives association isda master netting agreements respective counterparties order mitigate counterparty risk agreements amounts owed counterparty single day respect transactions outstanding currency aggregated single net amount payable one party isda agreements meet criteria offsetting balance sheet group currently enforceable right offset recognised amounts right offset enforceable occurrence future events default credit events contract terms december significant financial assets whose terms renegotiated none impairment losses financial assets excluding equity investmentssecurities impairment losses nonefinance report notes roche group consolidated financial statements roche group liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time roche chugai enjoy strong credit quality rated least one major credit rating agency ratings permit efficient access international capital markets event major financing requirements december group unused committed credit line various financial institutions totalling chf billion chf billion chf billion chf billion serve backstop line commercial paper program july previously existing committed credit lines refinanced one new committed credit line initial maturity five years remaining undiscounted cash flow contractual maturities financial liabilities including estimated interest payments shown table contractual maturities financial liabilities millions chf less carrying value total year years years years december debt bonds notes debt contingent consideration accounts payable noncurrent liabilities lease liabilities current liabilities lease liabilities derivative financial instruments total financial liabilities december debt bonds notes debt contingent consideration accounts payable noncurrent liabilities lease liabilities current liabilities lease liabilities derivative financial instruments total financial liabilities takeorpay commitments group entered contract manufacturing agreements various companies develop manufacturing capacity flexibility mainly pharmaceuticals division future minimum takeorpay commitments within agreements total potential commitment group chf billion december chf billion roche group notes roche group consolidated financial statements finance report market risk market risk arises changing market prices mainly foreign exchange rates interest rates groups financial assets financial liabilities affect groups financial result equity valueatrisk group uses valueatrisk var measure impact market risk financial instruments var indicates value range within given financial instrument fluctuate preset probability result movements market prices var calculated using historical simulation approach scenario financial instruments fully valued total change value earnings determined var calculations based confidence level holding period trading days past ten years holding period reflects time required change corresponding risk exposure deemed appropriate actual future gains losses associated treasury activities may differ materially var analyses due inherent limitations associated predicting timing amount changes interest rates foreign exchange rates equity investment prices particularly periods high market volatilities furthermore var include effect changes credit spreads market risk financial instruments millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component increased due bond issuances december foreign exchange component increased due unfavourable exposure mix price component decreased mainly due lower prices equity investments equity securities foreign exchange risk group uses swiss franc reporting currency result exposed movements foreign currencies mainly us dollar japanese yen euro groups foreign exchange risk management strategy preserve economic value current future assets minimise volatility groups financial result primary focus groups foreign exchange risk management activities hedging transaction exposures arising foreign currency flows monetary positions held foreign currencies group uses forward contracts foreign exchange options crosscurrency swaps hedge transaction exposures application instruments intends continuously immunise unfavourable developments foreign exchange rates interest rate risk group mainly raises debt fixed rate basis bonds notes group exposed movements interest rates mainly us dollar swiss franc euro floating rate financial instruments shortterm debt groups interest rate risk management strategy optimise net interest result group may use forward contracts options interest rate swaps hedge interest rate exposures depending interest rate environment major currencies group use instruments generate appropriate mix fixed floating rate exposuresfinance report notes roche group consolidated financial statements roche group price risk price risk arises mainly movements prices equity securities group manages price risk placing limits individual total equity investments limits defined percentage total liquid funds absolute number individual equity investments capital management group defines capital manages groups total capitalisation sum debt plus equity including noncontrolling interests groups objectives managing capital safeguard groups ability continue going concern continue provide benefits patients returns investors provide adequate return investors based level risk undertaken available necessary financial resources allow group invest areas may deliver future benefits patients returns investors maintain sufficient financial resources mitigate risks unforeseen events capitalisation reported senior management part groups regular internal management reporting shown table capital millions chf capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity total debt capitalisation groups net equity significantly impacted share repurchase see note group subject regulatory capital adequacy requirements known financial services industry group majority shareholding chugai see note chugai public company objectives policies processes managing capital determined chugai management roche group notes roche group consolidated financial statements finance report financial instrument accounting classifications fair values fair values financial assets liabilities together carrying value shown consolidated balance sheet follows carrying value fair value financial instruments millions chf financial instruments mandatorily financial financial fair value instruments fair value assets total profit fair value hedging amortised financial carrying loss oci instruments cost liabilities value fair value december noncurrent assets equity investments financial noncurrent assets accounts receivable marketable securities equity securities debt securities money market instruments time accounts three months cash cash equivalents current assets derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable noncurrent liabilities current liabilities total financial liabilities finance report notes roche group consolidated financial statements roche group carrying value fair value financial instruments millions chf financial instruments mandatorily financial financial fair value instruments fair value assets total profit fair value hedging amortised financial carrying loss oci instruments cost l iabilities value fair value december noncurrent assets equity investments financial noncurrent assets accounts receivable marketable securities equity securities debt securities money market instruments time accounts three months cash cash equivalents current assets derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable noncurrent liabilities current liabilities total financial liabilities fair value bonds notes level calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods roche group notes roche group consolidated financial statements finance report fair value hierarchy table analyses financial instruments carried fair value valuation method different levels defined follows level quoted prices unadjusted active markets identical assets liabilities level observable inputs quoted prices active markets identical assets liabilities level unobservable inputs fair value hierarchy financial instruments millions chf level level level total december marketable securities equity securities fair value profit loss debt securities fair value oci debt securities fair value profit loss money market instruments fair value oci derivative financial instruments equity investments fair value oci equity investments fair value profit loss financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value december marketable securities equity securities fair value profit loss debt securities fair value oci debt securities fair value profit loss money market instruments fair value oci derivative financial instruments equity investments fair value oci equity investments fair value profit loss financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value level financial assets consist treasury bills bonds quoted shares level financial assets consist primarily commercial paper certificates deposit derivative financial instruments group determines level fair values using following valuation techniques marketable securities derivative financial instruments based valuation models use observable market data interest rates yield curves foreign exchange rates implied volatilities similar instruments measurement date equity investments fair value oci fair value profit loss based valuation model uses recently published observable market data group recognises transfers levels fair value hierarchy end reporting period transfer occurred significant transfers level level vice versa year nonefinance report notes roche group consolidated financial statements roche group level fair values details determination level fair value measurements set contingent consideration arrangements millions chf january arising business combinations utilised settlements total gains losses included income statement unused amounts reversed recorded within general administration additional amount created recorded within general administration discount unwind included financing costs total gains losses included comprehensive income currency translation effects december contingent consideration arrangements group party certain contingent consideration arrangements including business combinations fair values contingent consideration business combinations determined considering expected payments discounted present value using riskadjusted average discount rate expected payments determined considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario significant unobservable inputs forecast sales performance criteria riskadjusted discount rate estimated fair value would increase forecast sales performance criteria rates higher riskadjusted discount rate lower december total potential payments contingent consideration arrangements arising business combinations could chf billion chf billion follows potential payments contingent consideration arrangements millions chf acquisition year acquired operating segment dutalys roche pharmaceuticals santaris roche pharmaceuticals genia diagnostics others various diagnostics december roche group notes roche group consolidated financial statements finance report derivative financial instruments cash collateral agreements place counterparties certain derivative financial instruments mitigate counterparty risk following table sets carrying value derivative financial instruments amounts subject master netting agreements derivative financial instruments millions chf assets liabilities foreign currency derivatives forward exchange contracts crosscurrency swaps interest rate derivatives swaps derivatives carrying value derivative financial instruments derivatives subject master netting agreements collateral arrangements net amount collateral arrangements movements cash collateral receivable accrued liability millions chf january net cash delivered group fair value currency translation effects december finance report notes roche group consolidated financial statements roche group hedge accounting described groups risk management strategy hedge transaction exposures arising foreign currency flows monetary positions held foreign currencies well generate appropriate mix fixed floating rate exposures level hedging depends market conditions business requirements group group designates specific interest rate risk management objective ensure predetermined level interest rate risk exposure floating rate hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessments reporting date ensure economic relationship exists hedged item hedging instrument group performs qualitative assessment hedge effectiveness using critical terms match method critical terms hedged items hedging instruments match group concludes risks hedged hedged items hedging instruments sufficiently aligned inherent mismatch hedging relationship hedge ratio applies actual quantities hedged hedge accounting accounting treatment sources ineffectiveness prospective effectiveness assessment method risk category prospective effectiveness accounting treatment potential sources ineffectiveness assessment method interest rate andor foreign exchange rate cash flow hedge counterparty credit risk critical terms match fluctuations foreign exchange rate fluctuations cash flow hedge lower volume hedged items critical terms match counterparty credit risk interest rate fluctuations fair value hedge counterparty credit risk critical terms match ineffective portion hedge accounting recognised income statement included financial income expense measured using hypothetical derivative method cash flow hedges cumulative dollar offset method fair value hedges december december respectively none potential sources ineffectiveness individually collectively resulted material amounts actual ineffectiveness reported hedge accounting relationships table shows fair values nominal amounts derivative financial instruments including range maturity nominal amount hedging instruments designated hedging instruments cash flow hedge fair value hedge december respectively group following cash flow hedges fair value hedges designated qualifying hedge relationship fair values nominal amounts derivatives used hedge accounting december fair value asset fair value liability nominal amount million chf million chf maturity range cash flow hedges risk hedged interest rate foreign exchange rate fluctuations crosscurrency swaps na risk hedged foreign exchange rate fluctuations forward exchange contracts jpy billion risk hedged interest rate fluctuations treasury locks na total fair value hedges risk hedged interest rate fluctuations interest rate swaps usd million interest rate swaps eur million interest rate swaps chf million total roche group notes roche group consolidated financial statements finance report fair values nominal amounts derivatives used hedge accounting december fair value asset fair value liability nominal amount million chf million chf maturity range cash flow hedges risk hedged interest rate foreign exchange rate fluctuations crosscurrency swaps eur million fixed usd risk hedged foreign exchange rate fluctuations forward exchange contracts jpy billion total fair value hedges risk hedged interest rate fluctuations interest rate swaps usd million interest rate swaps eur million interest rate swaps chf million total fair values derivative financial instruments used hedge accounting included current assets see note current liabilities see note groups approach managing market risk including interest rate risk foreign currency risk discussed market risk section note cash flow hedges group entered crosscurrency swaps hedge foreign exchange interest rate risk bonds notes issued group denominated euro due date march group redeemed remaining notes outstanding amount eur billion see note related remaining crosscurrency swaps expired time december instruments recorded net fair value liability chf million ineffective portion november december group entered treasury locks hedge interest rate risk fixed rate notes issued group december see note date treasury locks settled december relating hedging reserve chf million excluding income taxes held deduction within equity released transferred income statement redemption fixed rate notes ineffective portion chugai entered forward exchange contracts hedge part foreign translation exposure swiss franc us dollar december instruments recorded fair value assets chf million fair value liabilities chf million fair value assets chf million fair value liabilities chf million ineffective portion none hedging instruments currently held applying hedge accounting affected interbank offered rates ibor reformfinance report notes roche group consolidated financial statements roche group carrying amount items designated hedged items cash flow hedging relationship millions chf assets liabilities assets liabilities december bonds notes risk hedged crosscurrency swaps interest rate foreign exchange rate fluctuations bonds notes inventories risk hedged forward exchange contracts foreign exchange rate fluctuations inventories hedging reserve continuing hedging relationships millions chf cross forward cross forward treasury currency exchange currency exchange total locks swaps contracts total swaps contracts january gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation effects december entire amount transferred income statement reported financial income expense due date march group redeemed remaining notes outstanding amount eur billion see note related remaining crosscurrency swaps expired time result remaining hedging reserve crosscurrency swaps december hedging relationships hedge accounting longer applied none changes hedging reserve within equity shown note expected undiscounted cash flows qualifying cash flow hedges including interest payments duration derivative contract final settlement maturity shown table expected cash flows qualifying cash flow hedges millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow undiscounted cash flows table affect profit loss shown include interest payments duration derivative contract include final settlement maturity roche group notes roche group consolidated financial statements finance report expected cash flows qualifying cash flow hedges impact profit loss millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow fair value hedges group entered interest rate swaps hedge exposure changes fair value fixedterm debt instruments respect benchmark interest rate december instruments recorded fair value assets chf million fair value liabilities chf million fair value assets chf million fair value adjustments chf million recorded expense interest rate swaps chf million income interest rate swaps currently held applying hedge accounting referenced benchmark rate london interbank offered rate libor fair value hedge highly effective since inception result interest rate swaps largely offset changes fair value hedged debt instruments groups approach managing market risk including interest rate risk discussed market risk section note carrying amount items designated hedged items fair value hedging relationship millions chf fair value fair value adjustments adjustments liabilities c umulative current year december bonds notes risk hedged interest rate swaps interest rate fluctuations bonds notes december bonds notes risk hedged interest rate swaps interest rate fluctuations bonds notes net investment hedges group net investment hedgesfinance report notes roche group consolidated financial statements roche group related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares following closing share repurchase transaction december see note bearer shares held group scheduled cancelled early necessary legal procedures completed december based information supplied group shareholder group pooled voting rights owned shares representing issued shares voting power excluding treasury shares held group december scheduled cancelled early figures include shares without pooled voting rights held outside group individual members group december shareholder group announced would continue shareholder pooling agreement modified shareholder composition group consists mr andr hoffmann ms marieanne hoffmann ms vera michalski mr alexander hoffmann mr frederic hoffmann ms isabel hoffmann mr lucas hoffmann ms marina hoffmann ms kasia barbotinlarrieu ms tatiana fabre mr andreas oeri ms catherine oeri ms sabine duschmal mr jrg duschmal mr lukas duschmal charitable foundation wolf artuma holding ltd shareholder pooling agreement existed since duration pool extended indefinite period december based information supplied group ms maja oeri formerly member pool held shares independently pool representing issued shares voting power excluding treasury shares held group december scheduled cancelled early mr andr hoffmann dr jrg duschmal members board directors roche holding ltd mr hoffmann received remuneration totalling chf chf dr duschmal received remuneration totalling chf chf dr andreas oeri previously member board directors roche holding ltd received remuneration totalling chf transactions group individual members shareholder group subsidiaries associates listing group subsidiaries associates included note listing excludes chugais subsidiaries well companies material notably companies inactive dormant liquidation transactions parent company subsidiaries subsidiaries eliminated consolidation significant transactions group associates roche group notes roche group consolidated financial statements finance report key management personnel total remuneration key management personnel chf million chf million members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees chairman board directors members corporate executive committee cec roche holding ltd receive remuneration consists annual salary bonus expense allowance group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members cec members cec also participate certain equity compensation plans described terms vesting conditions fair value awards disclosed note new members cec included table full calendar year joined cec similarly members cec retiring partway year included full calendar year left cec remuneration members board directors corporate executive committee millions chf salaries including cashsettled bonus bonus stock awards social security costs pensions postemployment benefits equity compensation plans board fees employee benefits total purposes remuneration disclosures values equity compensation plans including bonus stock awards calculated based fair value used note represent cost group awards grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions detailed disclosures regarding executive remuneration required swiss law included remuneration report disclosed annual report pages disclosures values equity compensation plans including bonus stock awards represent fair value employee receives taking account preliminary assessment completed performance conditions fair values shown table reconciles disclosures required swiss law related party disclosures key management personnel reconciliation executive remuneration disclosures required swiss law millions chf total remuneration members board directors corporate executive committee ifrs basis see table deduct bonus stock awards ifrs basis equity compensation plans ifrs basis add back bonus stock awards swiss legal basis equity compensation plans swiss legal basis total remuneration members board directors corporate executive committee swiss legal basis including social security costs board directors annual report corporate executive committee annual report finance report notes roche group consolidated financial statements roche group bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year subject approval annual general meeting march issued march number awards fair value per award calculated grant date equity compensation plans members corporate executive committee received equity compensation shown following tables number rights options awards granted members corporate executive committee roche stocksettled stock appreciation rights roche restricted stock unit plan contributions paid members corporate executive committee millions chf roche connect defined benefit plans transactions group various defined benefit plans employees group described note roche group notes roche group consolidated financial statements finance report list subsidiaries associates following listing group subsidiaries associates excludes chugais subsidiaries well companies material notably companies inactive dormant liquidation listed companies share capital equity interest location company city millions switzerland roche holding ltd basel chf stock exchange six swiss exchange zurich stock code share ro valor stock code genussschein rog valor isin share ch isin genussschein ch market capitalisation chf million japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo stock code tse isin jp market capitalisation jpy million nonlisted companies share capital equity interest location company city millions algeria roche algrie spa hydra dzd argentina productos roche sa qumica e industrial tigre ars roche diabetes care argentina sa tigre ars australia roche diabetes care australia pty limited north ryde aud roche diagnostics australia pty limited north ryde aud roche products pty limited sydney aud austria mysugr gmbh vienna eur roche austria gmbh vienna eur roche diabetes care austria gmbh vienna eur roche diagnostics gmbh vienna eur bangladesh roche bangladesh limited dhaka bdt belarus fllc roche products limited minsk usd belgium roche diagnostics belgium nv diegem eur roche sanv brussels eur bermuda chemical manufacturing trading company limited hamilton usd hoffmannla roche products limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd sapac corporation ltd hamilton cad bolivia roche bolivia srl santa cruz bob bosnia herzegovina roche doo farmaceutsko drustvo roche ltd pharmaceutical company sarajevo bam brazil produtos roche qumicos e farmacuticos sa paulo brl roche diabetes care brasil ltda paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada hoffmannla roche limited mississauga cad chile roche chile limitada santiago de chile clp finance report notes roche group consolidated financial statements roche group share capital equity interest location company city millions china roche china holding ltd shanghai usd roche shanghai pharmaceuticals consulting co ltd shanghai cny roche shanghai pharmaceuticals trading co ltd shanghai usd roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai ltd shanghai usd roche diagnostics suzhou limited suzhou usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop tib molbiol sas santiago de cali cop congo democratic republic roche drc sarlu kinshasa usd costa rica roche services americas sociedad de responsabilidad limitada san jose crc roche servicios sa heredia usd cte divoire roche cte divoire sarl abidjan xof croatia roche doo zagreb hrk czech republic roche sro prague czk denmark obi aps hadsund dkk roche medicinalvarer og kemikalier hvidovre dkk roche diagnostics hvidovre dkk roche innovation center copenhagen hoersholm dkk dominican republic productos roche dominicana srl santo domingo dop ecuador roche ecuador sa quito usd egypt roche diagnostics egypt trading sae giza egp roche egypt manufacturing trading sae cairo egp roche egypt llc cairo egp el salvador productos roche el salvador sa de cv antiguo cuscatlan usd estonia roche eesti tallinn eur finland roche diagnostics oy espoo eur roche oy espoo eur france institut roche sas boulognebillancourt eur roche diabetes care france sas meylan eur roche diagnostics france sas meylan eur roche sas boulognebillancourt eur timkl sas montbonnotsaintmartin eur trophos sa marseille eur georgia roche georgia llc tbilisi gel germany ascur versicherungsvermittlungs gmbh grenzachwyhlen eur flatiron health gmbh cologne eur foundation medicine gmbh penzberg eur galenus mannheim pharma gmbh mannheim eur roche beteiligungs gmbh grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen eur roche diabetes care deutschland gmbh mannheim eur roche diabetes care gmbh mannheim eur roche diagnostics automation solutions gmbh ludwigsburg eur roche diagnostics deutschland gmbh mannheim eur roche diagnostics gmbh mannheim eur roche mtm laboratories ag mannheim eur roche pharma ag grenzachwyhlen eur roche privacy gmbh grenzachwyhlen eur roche real estate services mannheim gmbh mannheim eur roche registration gmbh grenzachwyhlen eur rox health gmbh berlin eur signature diagnostics gmbh potsdam eur tib molbiol syntheselabor gmbh berlin eur ghana roche products ghana limited accra ghs greece roche hellas sa marousi eur roche diagnostics hellas sa marousi eur guatemala productos roche guatemala sociedad annima guatemala gtq honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf roche group notes roche group consolidated financial statements finance report share capital equity interest location company city millions india roche diabetes care india private limited mumbai inr roche diagnostics india private limited mumbai inr roche information solutions india private limited pune inr roche products india private limited mumbai inr indonesia pt roche indonesia jakarta idr iran roche pars co ltd tehran irr ireland inflazome limited dublin eur roche ireland limited clarecastle eur roche products ireland limited dublin eur spark therapeutics ireland limited dublin eur israel medingo ltd yoqneam illit ils roche pharmaceuticals israel ltd hod hasharon ils italy roche diabetes care italy spa monza eur roche diagnostics spa monza eur roche spa monza eur tib molbiol srl genoa eur japan flatiron health kk tokyo jpy roche dc japan k k tokyo jpy roche diagnostics kk tokyo jpy jordan f hoffmannla roche ltd jordan psc amman jod kazakhstan roche kazakhstan llp almaty kzt kenya roche kenya limited nairobi kes kuwait roche trading medicines equipment devices medical supplies spc salmiya kwd latvia roche latvija sia riga eur lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostics malaysia sdn bhd petaling jaya myr roche services asia pacific sdn bhd kuala lumpur myr mauritius roche products mauritius ltd moka mur mexico productos roche sa de cv mexico city mxn roche dc mxico sa de cv mexico city mxn morocco roche sa casablanca mad myanmar roche myanmar company limited yangon usd netherlands roche diabetes care nederland bv almere eur roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics nz limited mount wellington nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio nigeria roche products limited lagos ngn north macedonia roche makedonija dooel skopje eur norway roche diagnostics norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr panama productos roche panama sa panama city pab productos roche interamericana sa prisa panama city usd paraguay roche diagnostics paraguay sa asuncin pyg peru productos roche qfsa lima pen roche farma peru sa lima pen philippines roche philippines inc taguig city php poland roche diabetes care polska sp z oo warsaw pln roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico genentech pr inc san juan usd roche products inc ponce usd syntex puerto rico inc ponce usd romania roche romania srl bucharest ron russian federation rochemoscow jsc moscow rub limited liability company roche diabetes care rus moscow rub limited liability company roche diagnostics rus moscow rub finance report notes roche group consolidated financial statements roche group share capital equity interest location company city millions saudi arabia roche diagnostics saudi arabia llc riyadh sar roche products saudi arabia llc jeddah sar serbia roche doo beograd belgrade rsd singapore roche diabetes care asia pacific pte ltd singapore sgd roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche farmacevtska druba doo ljubljana eur south africa kapa biosystems pty ltd cape town zar roche diabetes care south africa proprietary limited midrand zar roche diagnostics proprietary limited midrand zar roche products proprietary limited midrand zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain roche diabetes care spain sl sant cugat del valls eur roche diagnostics sl sant cugat del valls eur roche farma sa madrid eur tib molbiol sl madrid eur sweden roche ab solna sek roche diagnostics scandinavia ab solna sek switzerland biopharm ag basel chf f hoffmannla roche ltd basel chf hoffmann la roche ltd basel chf intermune international ag basel chf museum tinguely ag basel chf phaor ag basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche chemische unternehmungen ag basel chf roche diabetes care switzerland ltd rotkreuz chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd basel chf syntex pharm ag rotkreuz chf tavero ag basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie sa tunis tnd turkey infogenetik molekler bilgi hizmetleri anonim irketi istanbul try roche diagnostics turkey anonim irketi istanbul try roche mstahzarlari sanayi anonim irketi istanbul try ukraine roche ukraine llc kiev uah united arab emirates roche diabetes care middle east fzco dubai aed roche diagnostics middle east fzco dubai aed roche pharmaceuticals middle east fzco dubai aed united kingdom flatiron health uk ltd st albans gbp genmark diagnostics uk limited egham gbp inflazome uk limited welwyn garden city gbp intermune holdings limited welwyn garden city gbp roche diabetes care limited burgess hill gbp roche diagnostics limited burgess hill gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp spark therapeutics uk ltd london gbp tmema limited welwyn garden city gbp tusk therapeutics limited welwyn garden city gbp roche group notes roche group consolidated financial statements finance report share capital equity interest location company city millions united states adheron therapeutics inc south san francisco usd anadys pharmaceuticals inc south san francisco usd bina technologies inc pleasanton usd bioveris corporation indianapolis usd flatiron health inc new york usd forsight vision inc south san francisco usd foundation medicine inc cambridge usd freenome holdings inc south san francisco usd genentech usa inc south san francisco usd genentech inc south san francisco usd genmark diagnostics inc carlsbad usd genmark holdings inc carlsbad usd hoffmannla roche inc little falls usd surviving corp south san francisco usd igen international inc pleasanton usd igen ls llc pleasanton usd ignyta inc south san francisco usd intermune inc south san francisco usd iquum inc marlborough usd jecure therapeutics inc south san francisco usd kapa biosystems inc wilmington usd lexent bio inc cambridge usd memory pharmaceuticals corp little falls usd prescient design corp south san francisco usd promedior inc south san francisco usd protocol first inc salt lake city usd roche diabetes care inc indianapolis usd roche diagnostics corporation indianapolis usd roche diagnostics hematology inc westborough usd roche diagnostics operations inc indianapolis usd roche diagnostics seattle inc seattle usd roche holdings inc south san francisco usd roche laboratories inc little falls usd roche molecular systems inc pleasanton usd roche palo alto llc south san francisco usd roche sequencing solutions inc pleasanton usd roche tcrc inc little falls usd seragon pharmaceuticals inc south san francisco usd spark therapeutics international holdings inc philadelphia usd spark therapeutics inc philadelphia usd tanox inc south san francisco usd tensha therapeutics inc south san francisco usd therapeutic human polyclonals inc south san francisco usd ventana medical systems inc tucson usd viewics inc santa clara usd uruguay roche international ltd montevideo branch montevideo uyu venezuela productos roche sa caracas vef vietnam roche pharma vietnam company limited ho chi minh city vnd roche vietnam company limited ho chi minh city usd share capital less local currency unitsfinance report notes roche group consolidated financial statements roche group significant accounting policies consolidation policy subsidiaries companies group control group controls entity group exposed rights variable returns involvement entity ability affect returns power entity companies acquired year consolidated date control transferred group subsidiaries divested included date control passes group intercompany balances transactions resulting unrealised income eliminated full changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control associates companies group exercises power exercise significant influence control accounted using equity method segment reporting purpose segment reporting groups corporate executive committee cec considered groups chief operating decision maker determination groups operating segments based organisation units information reported cec regular basis information provided used basis segment revenue profit disclosures reported note geographic analysis based location customers selected segment balance sheet information also routinely provided cec transfer prices operating segments set arms length basis operating assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories assets liabilities provisions reasonably attributed reported operating segments nonoperating assets liabilities mainly include current deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities cash marketable securities investments debt foreign currency translation annual financial statements presented swiss francs group companies use local currency functional currency certain group companies use currencies us dollar swiss franc euro functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity cases gains losses deferred comprehensive income upon consolidation assets liabilities group companies using functional currencies swiss francs translated swiss francs using yearend rates exchange income statement statement cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly comprehensive income revenue sales revenue sale goods supplied product sales services rendered recorded sales sales recognised promise customer contract performance obligation satisfied transferring control promised goods services customer control promised good service refers ability direct use obtain substantially remaining benefits goods services control usually transferred upon shipment delivery upon receipt goods customer services rendered accordance delivery acceptance terms agreed customers goods subject installation instruments sold diagnostics division sales generally recognised upon completion installation customers site customer acceptance amount sales recognised transaction price based consideration group expects receive exchange goods services excluding amounts collected behalf third parties value added taxes taxes directly linked sales contract contains one performance obligation transaction price allocated performance obligation based relative standalone selling prices roche group notes roche group consolidated financial statements finance report instruments diagnostics division may sold together goods reagents consumables well services single contract several contracts combined revenue recognition purposes sales recognised upon satisfaction performance obligations contract instruments either sold cash instalment sales transactions otherwise made available customers finance lease operating lease transactions finance leases arrangements group transfers substantially risks rewards ownership customer treated finance lease arrangements income finance leases recognised revenue amounts represent fair value instrument approximates present value minimum lease payments arrangement interest rates embedded finance lease arrangements approximately market rates income finance leases comparable revenue outright sales finance income finance lease arrangements longer twelve months deferred subsequently recognised based pattern approximates use effective interest rate method recorded royalty operating income operating leases income operating leases recognised revenue straightline basis lease term lease revenue entirely variable subject subsequent reagent sales performance obligation deliver reagents satisfied sales net discounts based estimates regarding related obligations including standalone selling prices fair values requires judgement determine different obligations satisfied including whether enforceable purchase commitments obligations exist arise contracts distributors sales recognised goods physically transferred distributor consignment arrangement distributor acts agent cases sales recognised control goods transfers endcustomer distributors commissions presented within marketing distribution commissions similar payments distributors acting principals deducted sales unless payments exchange distinct service consideration received group exchange goods services may fixed variable variable consideration recognised considered highly probable significant revenue reversal occur underlying uncertainty related variable consideration subsequently resolved common elements variable consideration pharmaceuticals division listed government regulatory mandatory price reductions consist mandatory price reductions major elements b drug discount program medicaid plans us contractual price reductions include rebates chargebacks result contractual agreements primarily volume based performance based cash discounts include credits offered wholesalers remitting payment purchases within contractually defined incentive periods customer returns reserves allowances established expected product returns revenues product sales recorded net allowances estimated rebates chargebacks cash discounts estimates product returns established time sale product sales allowances based estimates amounts earned claimed related sales estimates take consideration historical experience current contractual statutory requirements specific known market events trends competitive pricing new product introductions estimated inventory levels shelf life products actual future results vary estimates need adjusted effect sales earnings period adjustment sales reductions expected withheld customer upon settlement contractual price reductions cash discounts recorded balance sheet deduction trade receivables sales reductions separately payable customers governmental health authorities healthcare regulatory authorities recorded balance sheet accrued liabilities provisions sales returns recorded balance sheet provisions group recognises deferred income contract liability consideration received become receivable group transfers promised goods services customer deferred income mainly relates remaining performance obligations goods free charge certain patient access similar programmes reagents consumables servicesfinance report notes roche group consolidated financial statements roche group remaining performance obligations partially unsatisfied longterm contracts either included deferred income related amounts group expects receive goods services yet transferred customers existing noncancellable otherwise enforceable contracts mainly associated contracts minimum purchase commitments related reagents consumables previously sold instruments well monitoring maintenance services contracts original duration one year less group elected practical expedient disclose transaction price remaining performance obligations end reporting period point time group expects recognise sales royalty operating income royalty operating income includes royalty income income outlicensing agreements income disposal products items royalty income earned licence recognised underlying sales recorded licensee income outlicensing agreements typically arises receipt upfront milestone similar payments third parties granting licence product technologyrelated intellectual property ip outlicensing agreements may entered obligation may include commitments conduct research latestage development regulatory approval comarketing manufacturing licences granted usually rights use ip generally unique therefore basis allocating revenue performance obligations makes use residual approach upfront payments licensing fees usually recognised upon granting licence unless income shall deferred performance obligations using residual approach deferred income released recognised revenue performance obligations satisfied milestone payments typically received upon reaching specific scientific milestone development milestone upon achieving certain annual sales milestone commercial milestone development milestone income recognised point time highly probable respective milestone event criteria achieved risk revenue reversal considered remote commercial milestone income accrued recognised revenue highly probable annual sales milestone reached period payments received disposal product similar rights recognised revenue upon transfer control rights extent payments relate performance obligations portion deferred using residual approach recognised revenue activities manufacturing services rendered income profitsharing agreements collaboration partners recognised underlying sales cost sales recorded collaboration partners also included income services rendered usually part groups primary business activities extent revenue recorded sales recognised control transfers performance obligations satisfied cost sales cost sales includes corresponding direct production costs related production overheads goods sold services rendered royalties alliance collaboration expenses including collaboration profitsharing agreements also reported part cost sales startup costs validation achievement normal production capacity expensed incurred research development internal research development activities expensed incurred following internal research costs incurred purpose gaining new scientific technical knowledge understanding internal development costs incurred application research findings knowledge plan develop new products commercial production development projects undertaken group subject technical regulatory uncertainties opinion management criteria capitalisation intangible assets met prior obtaining marketing approval regulatory authorities major markets postmarketing studies regulatory approval phase iv costs pharmaceuticals business generally involve safety surveillance ongoing technical support drug receives marketing approval sold may required regulatory authorities may undertaken safety commercial reasons costs postmarketing studies capitalised intangible assets opinion management generate separately identifiable incremental future economic benefits reliably measured roche group notes roche group consolidated financial statements finance report acquired inprocess research development resources obtained inlicensing arrangements business combinations separate asset purchases including asset acquisitions capitalised intangible assets acquired asset must controlled group separately identifiable expected generate future economic benefits even uncertainty exists whether research development ultimately result marketable product consequently upfront milestone payments third parties pharmaceutical products compounds regulatory marketing approval recognised intangible assets assets acquired arrangements measured basis set intangible assets policy subsequent internal research development costs incurred postacquisition treated way internal research development costs research development embedded contracts strategic alliances group carefully assesses whether upfront milestone payments constitute funding research development work acquisition asset employee benefits shortterm employee benefits include wages salaries social security contributions paid annual leave sick leave profit sharing bonuses nonmonetary benefits current employees costs recognised within operating results employee rendered associated service group recognises liability profit sharing bonuses contractually obliged past practice created constructive obligation longterm employee benefits include longservice sabbatical leave longservice benefits longterm disability benefits expected costs benefits accrued period employment changes carrying value longterm employee benefit liabilities recognised within operating results termination benefits payable employment terminated group normal retirement date whenever employee accepts voluntary redundancy exchange benefits termination costs recognised earlier group longer withdraw offer benefits group recognises related restructuring costs pensions postemployment benefits defined contribution plans group contributions recognised within operating results employee rendered associated service prepaid contributions recognised asset extent cash refund reduction future payments available defined benefit plans liability recognised balance sheet present value defined benefit obligation less fair value plan assets changes net defined benefit liability recognised occur follows recognised income statement current service cost charged appropriate income statement heading within operating results past service cost including curtailment gains losses recognised immediately general administration within operating results settlement gains losses recognised general administration within operating results net interest net defined benefit liability recognised financing costs recognised comprehensive income actuarial gains losses arising experience adjustments difference previous assumptions actually occurred changes actuarial assumptions return plan assets excluding amounts included net interest net defined benefit liability change limit recognition plan assets excluding amounts included net interest net defined benefit liability net interest net defined benefit liability comprised interest income plan assets interest cost defined benefit obligation interest effect limit recognition pension assets net interest calculated using discount rate used calculating defined benefit obligation applied net defined liability start period taking account changes contribution benefit payments pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations planfinance report notes roche group consolidated financial statements roche group equity compensation plans fair value equity compensation awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading within operating results equitysettled plans increase equity recorded expense subsequent cash flows exercises vested awards recorded changes equity property plant equipment property plant equipment initially recorded cost purchase construction include costs directly attributable bringing asset location condition necessary capable operating manner intended management include items costs site preparation installation assembly costs professional fees net costs testing whether asset functioning properly including validation costs also included initially recorded cost construction interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets property plant equipment depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate components estimated useful lives assets regularly reviewed necessary future depreciation charges accelerated repairs maintenance costs expensed incurred leases group lessee inception contract group assesses whether contract contains lease contract contains lease contract conveys right control use identified asset period time exchange consideration group recognises rightofuse asset corresponding lease liability contract contains lease lease commencement date except shortterm leases leases lowvalue assets payments shortterm leases leases lowvalue assets recognised expense straightline basis term respective lease lease liability initially measured present value future lease payments paid lease commencement date lease payments discounted using interest rate implicit lease readily determinable groups incremental borrowing rate respective markets lease payments include fixed payments variable payments depend index rate known lease commencement date payments exercising extension purchase options group reasonably certain exercise lease liability subsequently measured amortised costs using effective interest method remeasured corresponding adjustment related rightofuse asset change future lease payments following contract renegotiation change index rate reassessment options rightofuse asset initially measured cost comprises initial amount lease liability adjusted payments made lease commencement date includes initial direct costs incurred expected costs obligations dismantle remove refurbish underlying asset less incentives received rightofuse assets depreciated straightline basis lease commencement date shorter lease term useful life underlying asset rightofuse assets assessed impairment whenever indication impairment group lessor certain assets mainly diagnostics instruments leased thirdparty customers finance operating lease arrangements transactions may entered separate contracts combined contracts including reagents consumables services treatment leasing transactions mainly determined whether lease considered operating finance lease requires judgement making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred case lease finance lease operating lease arrangements take legal form lease nevertheless convey right use asset also covered judgemental assessments roche group notes roche group consolidated financial statements finance report finance leases finance lease assets reported receivables amount equal net investment lease income finance leases recognised revenue amounts represent standalone selling price instrument approximates present value minimum lease payments arrangement minimum lease payments exclude variable lease payments contingent rent finance income finance lease arrangements longer twelve months deferred subsequently recognised based pattern approximates use effective interest method recorded royalty operating income operating leases income operating leases recognised revenue straightline basis lease term amounts represent standalone selling price instrument approximates present value minimum lease payments arrangement minimum lease payments exclude variable lease payments contingent rent lease revenue entirely based variable lease payments subject subsequent reagent sales recognised performance obligations reagents satisfied sales net discounts based estimates regarding related obligations including standalone selling prices requires judgement determine different obligations satisfied including whether enforceable purchase commitments obligations exist arise mergers acquisitions business combinations business combinations accounted using acquisition method accounting date acquisition group initially recognises fair value identifiable assets acquired liabilities assumed noncontrolling interest acquired business consideration transferred measured fair value date acquisition group acquire ownership acquired business noncontrolling interests recorded either fair value proportion fair value acquired net assets attributable noncontrolling interest directly attributable acquisitionrelated costs expensed incurred within general administration expenses asset acquisitions asset acquisitions acquisitions legal entities qualify business combinations date acquisition group initially recognises individual identifiable assets acquired liabilities assumed cost group date acquisition allocated individual identifiable assets liabilities basis relative fair values date acquisition subsequent consideration performancerelated development milestones recognised intangible assets specific milestones achieved recognition criteria met transactions give rise goodwill material directly attributable acquisitionrelated costs included cost acquired assets goodwill goodwill arises business combination excess consideration transferred acquire business underlying fair value net identified assets acquired goodwill amortised tested impairment least annually upon occurrence indication impairment intangible assets purchased patents licences trademarks intangible assets initially recorded cost assets acquired business combination initially recorded fair value commercial software development costs capitalised certain recognition criteria technical feasibility commercial viability met available use intangible assets amortised straightline basis useful lives intangible assets reviewed impairment reporting date estimated useful life lower legal duration economic useful life estimated useful lives intangible assets regularly reviewed estimated useful lives major classes amortisable intangible assets follows product intangibles use years marketing intangibles use years technology intangibles use yearsfinance report notes roche group consolidated financial statements roche group impairment property plant equipment rightofuse assets intangible assets impairment assessment carried evidence asset may impaired addition intangible assets yet available use tested impairment annually recoverable amount asset higher fair value less costs disposal value use less carrying value carrying value reduced recoverable amount reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm interest rate impairment loss arises useful life asset reviewed necessary future depreciationamortisation charge accelerated amount impairment loss subsequently decreases decrease related objectively event occurring impairment recognised previously recognised impairment loss reversed income statement impairment reversal impairment goodwill goodwill assessed impairment reporting date additionally tested annually impairment goodwill allocated cashgenerating units recoverable amount cashgenerating unit higher fair value less costs disposal value use less carrying value carrying value goodwill reduced recoverable amount reduction reported income statement impairment loss acquired business included within cashgenerating unit permanently ceases operate treated disposal business separately identifiable goodwill generated initial acquisition business factors made goodwill entirely unrelated continuing operations cashgenerating unit goodwill deemed disposed fully impaired described note also applies acquired products permanently cease generate economic benefits acquired technologies permanently cease operate impairment testing methodology described note inventories inventories stated lower cost net realisable value cost finished goods work process intermediates includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses receivables including accounts receivable receivables carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances receivable represents right consideration unconditional excludes contract assets allowance doubtful accounts recorded expected credit losses term receivables estimates based specific indicators ageing customer balances specific credit circumstances groups historical loss rates category customers adjusted forwardlooking macroeconomic data expenses doubtful trade receivables recognised within marketing distribution expenses trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience receivables written either partly full reasonable expectation recovery receivables written group continues engage enforcement activities attempt recover receivable due recoveries made recognised profit loss trade lease receivables group applies simplified approach prescribed ifrs requirespermits use lifetime expected loss provision initial recognition receivables group measures allowance doubtful accounts equal credit losses expected lifetime trade lease receivables cash cash equivalents cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash equivalents readily convertible known amounts cash subject insignificant risk changes fair value maturity three months less date acquisition roche group notes roche group consolidated financial statements finance report provisions contingencies provisions recognised legal constructive obligation incurred probably lead outflow resources reliably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise discounted time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date determined reference quoted market prices use established valuation techniques option pricing models discounted cash flow method quoted prices active market available financial instruments group classifies financial instruments following measurement categories disclosed note amortised cost fair value oci fair value oci equity investments fair value profit loss including hedging instruments classification depends groups business model managing financial assets contractual terms cash flows group reclassifies debt securities financial assets amortised cost business model managing assets changes initial recognition group measures financial asset fair value plus case financial asset fair value profit loss transaction costs directly attributable acquisition financial asset transaction costs financial assets carried fair value profit loss expensed profit loss amortised cost assets held collection contractual cash flows cash flows represent solely payments principal interest measured amortised cost less provision impairment gain loss debt security subsequently measured amortised cost part hedging relationship recognised profit loss asset derecognised impaired interest income financial assets included financial income using effective interest rate method assets amortised cost mainly comprised accounts receivable cash cash equivalents time accounts three months fair value comprehensive income fair value oci financial assets held collection contractual cash flows selling financial assets assets cash flows represent solely payments principal interest initially recorded subsequently carried fair value changes fair value recorded comprehensive income except recognition impairment gains losses interest revenue foreign exchange gains losses recognised profit loss financial asset derecognised cumulative gain loss previously recognised oci reclassified equity profit loss interest income financial assets included financial income using effective interest rate method fair value comprehensive income assets mainly comprised money market instruments debt securities equity investments fair value comprehensive income fair value oci equity investments private biotechnology companies kept part groups strategic alliance efforts assets subsequently measured fair value dividends recognised financial income profit loss unless dividend clearly represents recovery part cost investment net gains losses recognised oci included fair value reserve asset derecognised cumulative gain loss previously recognised oci reclassified within equity fair value reserve retained earnings never profit lossfinance report notes roche group consolidated financial statements roche group fair value profit loss financial assets whose performance evaluated fair value basis gain loss financial asset subsequently measured fair value profit loss part hedging relationship recognised profit loss presented within financial income expense period arises fair value profit loss assets mainly comprised equity investmentssecurities contingent consideration liabilities initially recorded subsequently carried fair value changes fair value recorded general administration within operating results income statement fair value profit loss hedging instruments derivative financial instruments used manage exposures foreign currency interest rate equity market credit risks instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments changes fair value recorded financial income expense financial liabilities nonderivative financial liabilities financial liabilities initially recorded fair value less transaction costs subsequently carried amortised cost using effective interest rate method financial liabilities mainly comprised debt trade payables debt debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost discount net proceeds received principal value due redemption amortised duration debt instrument recognised part financing costs using effective interest rate method derecognition financial asset derecognised contractual cash flows asset expire group transfers rights receive contractual cash flows financial assets transaction substantially risks rewards ownership financial asset transferred financial liability derecognised contractual obligations discharged cancelled expire impairment financial assets group recognises loss allowances expected credit losses ecl financial assets measured amortised cost debt securities measured fair value oci trade lease receivables group measures allowance doubtful accounts amount equal lifetime ecl debt securities carried fair value oci debt securities financial assets amortised cost determined low credit risk based external credit ratings counterparties group measures loss allowances amount equal month ecl group considers debt securities low credit risk credit risk rating equivalent globally understood definition investment grade group considers least baa moodys bbb standard poors credit risk debt securities carried fair value oci debt securities financial assets amortised cost increased significantly since initial recognition group measures loss allowances amount equal lifetime ecl group assumes credit risk instruments increased significantly days past due financial assets written either partially full realistic prospect recovery generally case group determines customer assets sources income could generate sufficient cash flows repay amounts subject writeoff however financial assets written still subject enforcement activities order comply groups policy recovery amounts due hedge accounting group uses derivatives manage exposures foreign currency interest rate equity market credit risks instruments used may include interest rate swaps crosscurrency swaps forwards contracts options group generally limits use hedge accounting certain significant transactions qualify hedge accounting hedging relationship must meet several strict conditions eligibility hedging hedged instruments formal designation documentation well hedge effectiveness reliability measurement many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income expense roche group notes roche group consolidated financial statements finance report cash flow hedge hedge exposure variability cash flows attributable particular risk associated recognised asset liability highly probable forecasted transaction could affect profit loss hedging instrument recorded fair value effective portion hedge included comprehensive income ineffective portion reported financial income expense hedging relationship hedge foreign currency risk firm commitment highly probable forecasted transaction results recognition nonfinancial item cumulative changes fair value hedging instrument recorded comprehensive income included initial carrying value nonfinancial item date recognition cash flow hedges cumulative changes fair value hedging instrument recorded comprehensive income included financial income expense forecasted transaction affects net income fair value hedge hedge exposure changes fair value recognised asset liability unrecognised firm commitment identified portion asset liability firm commitment attributable particular risk could affect profit loss hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income expense taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable earnings remitted foreseeable future amount tax liabilities uncertain accruals recorded within income tax liabilities managements best estimate ultimate liability expected arise based specific circumstances groups historical experience deferred tax assets liabilities recognised temporary differences tax bases assets liabilities carrying values deferred tax assets recognised extent probable future taxable profit available unused tax losses utilised current deferred tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred taxes determined based currently enacted tax rates applicable tax jurisdiction group operates equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments held groups potential conversion obligations may arise groups equity compensation plans changes accounting policies group implemented various minor amendments existing standards interpretations material impact groups overall results financial position future new revised standards group currently assessing potential impacts various new revised standards interpretations mandatory january group yet applied based analysis date group anticipate material impact groups overall results financial position group also assessing new revised standards mandatory finance report report roche management internal control financial reporting roche group report roche management internal control financial reporting report roche management internal control financial reporting board directors management roche holding ltd responsible establishing maintaining adequate control financial reporting internal control system designed provide reasonable assurance reliability financial reporting preparation fair presentation consolidated financial statements accordance international financial reporting standards internal control systems matter well designed inherent limitations therefore even systems determined effective may prevent detect misstatements provide reasonable assurance respect financial statement preparation presentation also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate management assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework issued committee sponsoring organizations treadway commission coso based assessment management concluded system internal control financial reporting effective december statutory auditor kpmg ag audited consolidated financial statements roche holding ltd year ended december accordance swiss auditing standards international standards auditing isa christoph franz alan hippe chairman board directors chief financial officer basel february roche group statutory auditors report finance report statutory auditors report general meeting roche holding ltd basel report audit consolidated financial statements opinion audited consolidated financial statements roche holding ltd subsidiaries group comprise consolidated balance sheet december consolidated income statement consolidated statement comprehensive income consolidated statement changes equity consolidated statement cash flows year ended notes consolidated financial statements including summary significant accounting policies opinion consolidated financial statements pages give true fair view consolidated financial position group december consolidated financial performance consolidated cash flows year ended accordance international financial reporting standards ifrs comply swiss law basis opinion conducted audit accordance swiss law international standards auditing isas swiss auditing standards responsibilities provisions standards described auditors responsibilities audit consolidated financial statements section report independent group accordance provisions swiss law requirements swiss audit profession well international ethics standards board accountants international code ethics professional accountants including international independence standards iesba code fulfilled ethical responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis opinion key audit matters chargebacks rebates sales returns us pharmaceuticals business carrying value product intangible assets available use pharmaceuticals division income tax uncertain tax positions key audit matters matters professional judgement significance audit consolidated financial statements current period matters addressed context audit consolidated financial statements whole forming opinion thereon provide separate opinion mattersfinance report statutory auditors report roche group chargebacks rebates sales returns us pharmaceuticals business key audit matter response groups pharmaceuticals business makes sales various audit procedures included amongst others sample customers us fall certain government basis obtaining managements calculations accrued mandated commercial contracts purchasing liabilities provisions accounts receivable deductions reimbursement arrangements significant testing accuracy calculations assessing b drug discount program group also provides appropriateness key inputs assumptions used right return us customers certain products estimates performing assessment referenced return periods cases extend several years internal external sources information including future arrangements result deductions terms applicable contracts us government pricing gross amounts invoiced arriving revenue create information historical rates chargebacks rebates obligations group provide customers credits historical rates sales returns consideration current chargebacks rebate payments estimated amounts trends deducted gross sales recorded accrued liabilities rebates provisions sales returns deduction also evaluated accuracy managements estimates accounts receivable chargebacks estimates based comparing rates used historical estimates rates analyses existing contractual legislatively mandated actual rebate payments chargebacks assessed obligations recent trends historical experience changes accrual rates used within estimates comparing accrual rates current chargeback management determined accrued liabilities rebate payment sales return trends deductions accounts receivable expected chargebacks rebates predominantly contractual price reductions also evaluated appropriateness groups chf million necessary december revenue recognition accounting policies including additionally provisions sales returns mainly relating recognition measurement deductions gross sales products loss exclusivity chf million relating chargebacks rebates sales returns recorded december related disclosures focused area arrangements complex establishing appropriate yearend position requires significant judgement estimation management assumptions required estimating provisions sales returns also made complicated given recent loss exclusivity us groups pharmaceutical products information chargebacks rebates sales returns us pharmaceuticals business refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note revenue note accounts receivable note current liabilities note provisions contingent liabilities roche group statutory auditors report finance report carrying value product intangible assets available use pharmaceuticals division key audit matter response product intangibles available use pharmaceuticals audit procedures included amongst others challenging division chf million mostly represent inprocess robustness key assumptions used determine research development assets acquired recoverable amounts including forecast revenues business combinations asset acquisitions inlicensing discount rate arrangements challenge based understanding due inherent uncertainties research commercial prospects individual products well development processes intangible assets available relevant business areas markets use particularly risk impairment impairment operate used valuation specialists assist us assessment requires management make key assumptions evaluating assumptions methodologies used judgements clinical technical commercial management relation discount rate assessed viability new products accordingly also focused key inputs projected pricing volumes audit work areas risks include inability products projected share therapeutic area achieve successful trial results obtain required clinical andor comparing relevant assumptions industry forecasts regulatory approvals highly competitive business reviewing analyst commentaries compared environment therapeutic areas group managements assumptions external data significant assets research development available performed sensitivity analysis individual intangible asset impairment models assess level sensitivity key assumptions could focus work areas assess managements allowance risk addition assessed reasonableness managements assumptions regarding probability obtaining regulatory approval comparison industry practice past history consideration groups internal governance approval processes information carrying value product intangible assets available use pharmaceuticals division refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note intangible assetsfinance report statutory auditors report roche group income tax uncertain tax positions key audit matter response group operates across wide range different tax audit procedures included amongst others obtaining jurisdictions around world thus tax treatments understanding uncertain tax positions inquiry tax filings subject challenge local tax authorities employees tax department management respect crossborder transfer pricing arrangements affiliates inspected documentation relation tax goods services financing transactionrelated tax exposure items including correspondence tax authorities matters connection integration investments reports issued tax advisors verify whether uncertain divestments licensing contracts tax treatments tax positions considered provided involving uncertainty include agreements transfer pricing necessary arrangements affiliates involved groups global manufacturing supply chains significant items challenged managements judgement regarding eventual resolution probable tax authority accept uncertainties assistance local country treatment tax liability recognised financial tax specialists reperformed calculation statements reflects managements best estimate estimated exposure inspected thirdparty transfer outcome based facts known relevant pricing studies evaluated applicable past jurisdiction group open tax transfer pricing experience managements interactions tax matters various tax authorities range authorities respective jurisdiction additionally possible outcomes broad december used tax specialists expertise assess group recognised current income tax liabilities appropriateness key assumptions made chf million includes accruals uncertain management conclude best estimate tax positions outcome focused area uncertainty regarding audit approach included additional audit procedures estimates amounts tax receivable payable consider uncertain tax positions arising group therefore require significant level expertise particular respect transfer pricing arrangements judgement goods services transactionrelated tax matters information uncertain tax positions refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note income taxes roche group statutory auditors report finance report information annual report board directors responsible information annual report information comprises information included annual report include consolidated financial statements standalone financial statements company remuneration report auditors reports thereon opinion consolidated financial statements cover information annual report express form assurance conclusion thereon connection audit consolidated financial statements responsibility read information annual report consider whether information materially inconsistent consolidated financial statements knowledge obtained audit otherwise appears materially misstated based work performed conclude material misstatement information required report fact nothing report regard responsibility board directors consolidated financial statements board directors responsible preparation consolidated financial statements give true fair view accordance ifrs provisions swiss law internal control board directors determines necessary enable preparation consolidated financial statements free material misstatement whether due fraud error preparing consolidated financial statements board directors responsible assessing groups ability continue going concern disclosing applicable matters related going concern using going concern basis accounting unless board directors either intends liquidate group cease operations realistic alternative auditors responsibilities audit consolidated financial statements objectives obtain reasonable assurance whether consolidated financial statements whole free material misstatement whether due fraud error issue auditors report includes opinion reasonable assurance high level assurance guarantee audit conducted accordance swiss law isas swiss auditing standards always detect material misstatement exists misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis consolidated financial statements part audit accordance swiss law isas swiss auditing standards exercise professional judgement maintain professional scepticism throughout audit also identify assess risks material misstatement consolidated financial statements whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinion risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal control obtain understanding internal control relevant audit order design audit procedures appropriate circumstances purpose expressing opinion effectiveness groups internal control evaluate appropriateness accounting policies used reasonableness accounting estimates related disclosures made conclude appropriateness board directors use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt groups ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures consolidated financial statements disclosures inadequate modify opinion conclusions based audit evidence obtained date auditors report however future events conditions may cause group cease continue going concern evaluate overall presentation structure content consolidated financial statements including disclosures whether consolidated financial statements represent underlying transactions events manner achieves fair presentationfinance report statutory auditors report roche group obtain sufficient appropriate audit evidence regarding financial information entities business activities within group express opinion consolidated financial statements responsible direction supervision performance group audit remain solely responsible audit opinion communicate board directors relevant committee regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit also provide board directors relevant committee statement complied relevant ethical requirements regarding independence communicate relationships matters may reasonably thought bear independence applicable actions taken eliminate threats safeguards applied matters communicated board directors relevant committee determine matters significance audit consolidated financial statements current period therefore key audit matters describe matters auditors report unless law regulation precludes public disclosure matter extremely rare circumstances determine matter communicated report adverse consequences would reasonably expected outweigh public interest benefits communication report legal regulatory requirements accordance article para item co swiss auditing standard confirm internal control system exists designed preparation consolidated financial statements according instructions board directors recommend consolidated financial statements submitted approved kpmg ag mark baillache marc ziegler licensed audit expert licensed audit expert auditor charge basel february kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member firm kpmg global organisation independent member firms affiliated kpmg international limited private english company limited guarantee rights reserved roche group multiyear overview supplementary information finance report multiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied dividend proposed board directors retrospectivelyfinance report multiyear overview supplementary information roche group multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied dividend proposed board directors retrospectively roche group multiyear overview supplementary information finance report sales division millions chf pharmaceuticals diagnostics total sales geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total additions property plant equipment division millions chf pharmaceuticals diagnostics corporate total finance report multiyear overview supplementary information roche group additions property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche group multiyear overview supplementary information finance report alternative performance measures financial information included financial review includes certain alternative performance measures apms accounting measures defined ifrs particular core results net working capital net operating assets free cash flow constant exchange rates apms used instead considered alternatives groups consolidated financial results based ifrs apms may comparable similarly titled measures disclosed companies apms presented financial review relate performance current year comparative periods core results core results allow assessment groups actual results defined ifrs underlying performance business core results concept used internal management business based ifrs results following adjustments global restructuring plans see note excluded amortisation impairment intangible assets see note excluding commercial software intangible assets impairment goodwill see note excluded acquisition accounting impacts accounting mergers acquisitions alliance transactions see financial review excluded discontinued operations currently none excluded legal environmental cases see financial review excluded global issues outside healthcare sector beyond groups control excluded material treasury items major debt restructurings currently none excluded pension plan settlements see note excluded tax benefit recorded ifrs respect equity compensation plans ecps varies according price underlying equity replaced normalised tax benefit ifrs expense multiplied applicable tax rate see note core results concept described october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm groups ifrs results including divisional breakdown reconciled core results tables calculation core eps also given tables additional commentary adjustment items given financial reviewfinance report multiyear overview supplementary information roche group core results reconciliation millions chf intan intan pension normali global gibles gibles alliance legal plan sation restruc amorti impair trans environ settle global ecp tax ifrs turing sation ment actions mental ments issues benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results reconciliation millions chf intan intan pension normali global gibles gibles alliance legal plan sation restruc amorti impair trans environ settle global ecp tax ifrs turing sation ment actions mental ments issues benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests roche group multiyear overview supplementary information finance report divisional core results reconciliation millions chf intan intan pension global gibles gibles alliance legal plan restruc amorti impair trans environ settle ifrs turing sation ment actions mental ments core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit divisional core results reconciliation millions chf intan intan pension global gibles gibles alliance legal plan restruc amorti impair trans environ settle ifrs turing sation ment actions mental ments core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit finance report multiyear overview supplementary information roche group core eps basic core net income attributable roche shareholders chf millions weighted average number outstanding shares nonvoting equity securities used calculate basic earnings per share millions core earnings per share basic chf core eps diluted core net income attributable roche shareholders chf millions increase noncontrolling interests share core net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number outstanding shares nonvoting equity securities used calculate diluted earnings per share millions core earnings per share diluted chf free cash flow free cash flow used assess groups ability generate cash required conduct maintain operations also indicates groups ability generate cash finance dividend payments repay debt undertake merger acquisition activities free cash flow concept used internal management business operating free cash flow calculated based ifrs operating profit adjusted certain noncash items movements net working capital capital expenditures investments property plant equipment intangible assets well principal portion lease liabilities paid leased assets operating free cash flow different cash flows operating activities defined ias includes capital expenditures within responsibility divisional management excludes income taxes paid within responsibility divisional management cash outflows defined benefit plans allocated operating free cash flow based current service cost residual allocated treasury activities free cash flow calculated operating free cash flow adjusted treasury activities taxes paid free cash flow different total cash flows defined ias excludes dividend payments cash inflowsoutflows financing activities issuancerepayment debt purchasesale marketable securities cash inflowsoutflows mergers acquisitions divestments roche group multiyear overview supplementary information finance report operating free cash flow free cash flow calculated shown tables additional commentary adjustment items given financial review operating free cash flow reconciliation millions chf cash flows operating activities ifrs basis accordance ias add back income taxes paid deduct investments property plant equipment principal portion lease liabilities paid investments intangible assets disposal property plant equipment disposal intangible assets pensions postemployment benefits add back total payments defined benefit plans deduct allocation payments operating free cash flow acquisitionrelated items including transaction costs operating items operating free cash flow free cash flow reconciliation millions chf cash flows operating activities ifrs basis accordance ias deduct investments property plant equipment principal portion lease liabilities paid investments intangible assets disposal property plant equipment disposal intangible assets interest paid operating items including acquisitionrelated items treasury items free cash flow finance report multiyear overview supplementary information roche group supplementary information used calculate divisional operating free cash flow shown table divisional operating free cash flow information millions chf pharmaceuticals diagnostics corporate group depreciation amortisation impairment depreciation property plant equipment depreciation rightofuse assets amortisation intangible assets impairment reversal property plant equipment impairment reversal rightofuse assets impairment goodwill impairment intangible assets total adjustments add back expenses equitysettled equity compensation plans net income expense provisions net gain loss disposals noncash working capital items deduct utilisation provisions proceeds disposals total operating profit cash adjustments ebitda group use earnings interest tax depreciation amortisation ebitda either internal management reporting external communications opinion groups management operating free cash flow gives useful consistent measurement cash earnings ebitda includes many noncash items provisions allowances trade receivables inventories certain noncash entries arising acquisition accounting pension accounting operating free cash flow also includes cash used investments property plant equipment leased assets intangible assets whereas ebitda excludes costs cash outflows items convenience readers use ebitda provided table starting point uses core results already exclude amortisation impairment goodwill intangible assets ebitda using core results millions chf pharmaceuticals diagnostics corporate group ebitda core operating profit depreciation impairment property plant equipment core basis depreciation impairment rightofuse assets core basis ebitda margin sales roche group multiyear overview supplementary information finance report net operating assets net operating assets allow assessment groups operating performance business independently financing tax activities net operating assets calculated property plant equipment leased assets rightofuse assets goodwill intangible assets net working capital longterm net operating assets minus provisions calculation net operating assets disclosed note annual financial statements shown tables net operating assets reconciliation millions chf treasury pharmaceuticals diagnostics corporate taxation group property plant equipment rightofuse assets goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities lease liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net assets net operating assets reconciliation millions chf treasury pharmaceuticals diagnostics corporate taxation group property plant equipment rightofuse assets goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities lease liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net assets finance report multiyear overview supplementary information roche group net debt net debt used monitor groups overall short longterm liquidity net debt calculated sum total debt longterm shortterm less marketable securities cash cash equivalents net debt calculations including details movements current year shown table financial review net working capital net working capital used assess groups efficiency utilising assets shortterm liquidity net trade working capital calculated trade receivables inventories minus trade payables net working capital calculated net trade working capital adjusted receivables payables net working capital net trade working capital calculations shown tables pharmaceuticals division diagnostics division corporate financial review constant exchange rates certain percentage changes financial review calculated using constant exchange rates cer allow assessment groups financial performance effects exchange rate fluctuations eliminated percentage changes constant exchange rates calculated using simulations reconsolidating current reported period prior period numbers constant currency exchange rates equalling average exchange rates prior year example cer change line item equivalent calculated using average exchange rate year ended december line item line item subsequently calculating change percent respect two recalculated numbers foreign exchange gains losses excluded calculation cer growth rates earnings per share disclosures countries significant devaluation local currency current year simulations use average exchange rate current year instead prior year avoid cer growth rates artificially inflated roche group roche securities finance report roche securities price development share chf roche share swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr standard poors index rebased eight roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded us overthecounter market since july finance report roche securities roche group number shares nonvoting equity securities number shares nominal value chf number nonvoting equity securities genussscheine nominal value total issued number shares nonvoting equity securities genussscheine held total outstanding following closing share repurchase transaction december see note roche group consolidated financial statements number shares nonvoting equity securities genussscheine held roche group december summarised table include bearer shares scheduled cancelled early necessary legal procedures completed data per share nonvoting equity security chf earnings basic earnings diluted core earnings basic core earnings diluted equity attributable roche shareholders dividend c stock price share b opening high low yearend stock price nonvoting equity security genussschein b opening high low yearend nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed six swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors roche group roche securities finance report market capitalisation millions chf yearend key ratios yearend dividend yield shares dividend yield nonvoting equity securities genussscheine priceearnings shares priceearnings nonvoting equity securities genussscheine stock codes share nonvoting equity security american depositary receipt adr six swiss exchange ro rog bloomberg ro sw rog vx rhhby us reuters ros rogvx rhhbypkfinance report roche holding ltd basel roche holding ltd basel financial statements notes financial statements summary significant accounting policies fulltime equivalent employees hareholders equity board executive shareholdings contingent liabilities equal pay analysis roche companies significant shareholders switzerland appropriation available earnings statutory auditors report general meeting roche holding ltd basel roche holding ltd basel financial statements finance report financial statements balance sheet millions chf december december current assets cash cash equivalents marketable securities accounts receivable group companies shortterm loans group companies accrued dividends receivable subsidiaries shortterm receivables total current assets noncurrent assets longterm loans group companies investments total noncurrent assets total assets shortterm liabilities accounts payable group companies interestbearing liabilities banks interestbearing liabilities group companies shortterm liabilities provisions total shortterm liabilities longterm liabilities provisions total longterm liabilities total liabilities shareholders equity share capital nonvoting equity securities genussscheine pm pm legal retained earnings general legal retained earnings voluntary reserves retained earnings free reserve special reserve available earnings balance brought forward previous year net income year equity instruments total shareholders equity total shareholders equity liabilities pm pro memoria nonvoting equity securities genussscheine nominal valuefinance report financial statements roche holding ltd basel income statement millions chf year ended december income income investments dividend income financial income interest income loans group companies income marketable securities guarantee fee income group companies income total income expenses administration expenses expenses financial expenses direct taxes total expenses net income roche holding ltd basel notes financial statements finance report notes financial statements summary significant accounting policies basis preparation financial statements roche holding ltd basel company prepared accordance provisions swiss law accounting financial reporting nd title swiss code obligations co prescribed law significant accounting principles applied described company prepared consolidated financial statements accordance recognised accounting standard international financial reporting standards accordance co company decided forgo presenting additional information audit fees notes well cash flow statement valuation methods translation foreign currencies marketable securities reported lower cost market value financial assets including investments reported cost less appropriate writedowns equity instruments recognised cost deducted equity time purchase equity instruments sold gain loss recognised income statement assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except investments translated historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred investments direct indirect investments company subsidiaries listed note roche group annual financial statements listing excludes chugais subsidiaries well companies material notably companies inactive dormant liquidation ownership interests equal voting rights equity instruments including treasury shares equity instruments including treasury shares recognised purchase price deducted shareholders equity time purchase case resale gain loss recognised financial income financial expenses upon cancellation bearer shares repurchased shares derecognised corresponding decrease share capital nominal value cancelled shares voluntary reserves retained earnings exceeding amount dividend distributions made equity instruments held company including treasury shares income investments dividend income dividend income distributions subsidiaries accrued financial statements company provided annual general meetings subsidiaries approve distribution dividend prior approval annual financial statements roche holding ltd board directors income investments included dividend income chf billion declared one subsidiary business year approved annual general meeting january accrued december included accrued dividends receivable subsidiaries taxes direct taxes include corporate income capital taxesfinance report notes financial statements roche holding ltd basel shareholders equity share repurchase november company novartis announced agreement whereby company would repurchase bearer shares company nominal value chf held novartis total consideration chf billion repurchased shares would subsequently cancelled company november extraordinary general meeting companys shareholders approved share capital reduction chf million chf million chf million cancellation shares repurchased novartis share repurchase transaction closed december december repurchased shares reported treasury shares repurchase price excluding transaction costs scheduled cancelled early necessary legal procedures completed transaction financed credit facility banks total repurchase price partly redeemed company chf billion credit facility outstanding december share capital previous year share capital amounts chf million share capital consists bearer shares nominal value chf following closing share repurchase transaction described december bearer shares held company scheduled cancelled early necessary legal procedures completed upon cancellation shares share capital decrease chf million chf million chf million included equity nonvoting equity securities genussscheine part share capital confer voting rights however nonvoting equity security confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value share capital participation certificates equity instruments including treasury shares december company held bearer shares treasury shares repurchased repurchase price chf billion repurchase price excluding transaction costs deducted shareholders equity nonvoting equity securities held company sell bearer shares nonvoting equity securities december company hold bearer shares nonvoting equity securities company neither purchased sold bearer shares nonvoting equity securities company subsidiaries meet definitions requirements article b co hold equity instruments within roche group annual financial statements entities mainly foundations included consolidation qualify subsidiaries article b co roche holding ltd basel notes financial statements finance report movement recognised amounts millions chf voluntary reserves retained earnings legal retained special available equity share capital earnings free reserve reserve earnings instruments total equity january net income dividends transactions equity instruments december net income dividends transactions equity instruments december net income dividends transactions equity instruments share repurchase december upon cancellation shares early necessary legal procedures completed share capital decrease chf million chf million chf million available earnings decrease chf billionfinance report notes financial statements roche holding ltd basel contingent liabilities guarantees company issued guarantees certain bonds notes commercial paper notes credit facilities group companies nominal amount outstanding december chf billion chf billion described note roche group annual financial statements significant shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting march information available company controlling shareholders december based information supplied group shareholder group pooled voting rights owned shares representing issued shares voting power excluding treasury shares held company december scheduled cancelled early see note figures include shares without pooled voting rights held outside group individual members group december shareholder group announced would continue shareholder pooling agreement modified shareholder composition group consists mr andr hoffmann ms marieanne hoffmann ms vera michalski mr alexander hoffmann mr frederic hoffmann ms isabel hoffmann mr lucas hoffmann ms marina hoffmann ms kasia barbotinlarrieu ms tatiana fabre mr andreas oeri ms catherine oeri ms sabine duschmal mr jrg duschmal mr lukas duschmal charitable foundation wolf artuma holding ltd shareholder pooling agreement existed since duration pool extended indefinite period december based information supplied group ms maja oeri formerly member pool held shares independently pool representing issued shares voting power excluding treasury shares held company december scheduled cancelled early december based information supplied group shares owned novartis holding ag basel participation fulltime equivalent employees annual average number fulltime equivalent employees exceed ten people roche holding ltd basel notes financial statements finance report board executive shareholdings board directors directors mr andr hoffmann dr jrg duschmal certain members founders families closely associated belong shareholder group pooled voting rights end shareholder group held shares detailed information group given note addition end year members board directors persons closely associated held shares nonvoting equity securities genussscheine shown table shareholdings members board directors nonvoting equity securities shares genussscheine c franz hoffmann j brown p bulcke h clevers j duschmal p frost hauser r p lifton e b poussot schwan b c suessmuth dyckerhoff c c total include shares held shareholder group pooled voting rights b member corporate executive committee dr schwans shareholdings disclosed tables c jointly held close relative close relatives hauser held nonvoting equity securities genussscheine e prof dr r p lifton held roche american depositary receipts adrs eight adrs equivalent one nonvoting equity security genussschein adrs traded us overthecounter market since july corporate executive committee end year members corporate executive committee persons closely associated held shares nonvoting equity securities shown table shareholdings members corporate executive committee nonvoting equity securities shares genussscheine schwan b anderson hippe schinecker c wilbur total equity compensation awards ssars stocksettled stock appreciation rights rsus restricted stock unitsfinance report notes financial statements roche holding ltd basel remuneration equity compensation plans members corporate executive committee composed stocksettled stock appreciation rights ssars restricted stock units rsus december members corporate executive committee held stocksettled stock appreciation rights ssars shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information given remuneration report included annual report pages ssars awards granted members corporate executive committee vest four years awards granted vested three years ssars awards held december year issue total schwan b anderson hippe schinecker c wilbur total strike price chf expiry date mar mar mar mar mar mar mar december members corporate executive committee held restricted stock units rsus shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information given remuneration report included annual report pages rsu awards granted members corporate executive committee vest four years thereafter nonvoting equity securities andor shares may remain blocked ten years rsu awards held december year issue total schwan b anderson hippe schinecker c wilbur total information relating number value rights options awards granted employees roche group members board directors corporate executive committee company disclosed note note roche group annual financial statements roche holding ltd basel notes financial statements finance report equal pay analysis roche companies switzerland per swiss gender equality act july employers switzerland employees required conduct internal equal pay analysis within one year roche companies switzerland subject federal act conducted equal pay analysis accordance gender equality act equal pay analyses confirmed equal pay requirements women men met required federal act equal pay analyses verified either roche employees representation licensed audit firmfinance report appropriation available earnings roche holding ltd basel appropriation available earnings proposals annual general meeting chf available earnings balance brought forward previous year net profit year release free reserve release special reserve reduction per resolution extraordinary general meeting november shares scheduled cancelled early necessary legal procedures completed total available earnings appropriation available earnings distribution ordinary dividend chf gross per share entitled dividend nonvoting equity security genussschein chf last year total appropriation available earnings carried forward account roche holding ltd basel statutory auditors report finance report statutory auditors report general meeting roche holding ltd basel report audit financial statements opinion audited financial statements roche holding ltd comprise balance sheet december income statement year ended notes financial statements including summary significant accounting policies opinion financial statements pages year ended december comply swiss law companys articles incorporation basis opinion conducted audit accordance swiss law swiss auditing standards responsibilities provisions standards described auditors responsibilities audit financial statements section report independent entity accordance provisions swiss law requirements swiss audit profession fulfilled ethical responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis opinion report key audit matters based circular federal audit oversight authority key audit matters matters professional judgement significance audit financial statements current period determined key audit matters communicate report responsibility board directors financial statements board directors responsible preparation financial statements accordance provisions swiss law companys articles incorporation internal control board directors determines necessary enable preparation financial statements free material misstatement whether due fraud error preparing financial statements board directors responsible assessing entitys ability continue going concern disclosing applicable matters related going concern using going concern basis accounting unless board directors either intends liquidate entity cease operations realistic alternative auditors responsibilities audit financial statements objectives obtain reasonable assurance whether financial statements whole free material misstatement whether due fraud error issue auditors report includes opinion reasonable assurance high level assurance guarantee audit conducted accordance swiss law swiss auditing standards always detect material misstatement exists misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis financial statementsfinance report statutory auditors report roche holding ltd basel part audit accordance swiss law swiss auditing standards exercise professional judgement maintain professional scepticism throughout audit also identify assess risks material misstatement financial statements whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinion risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal control obtain understanding internal control relevant audit order design audit procedures appropriate circumstances purpose expressing opinion effectiveness internal control evaluate appropriateness accounting policies used reasonableness accounting estimates related disclosures made conclude appropriateness board directors use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt entitys ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures financial statements disclosures inadequate modify opinion conclusions based audit evidence obtained date auditors report however future events conditions may cause entity cease continue going concern communicate board directors relevant committee regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit also provide board directors relevant committee statement complied relevant ethical requirements regarding independence communicate relationships matters may reasonably thought bear independence applicable actions taken eliminate threats safeguards applied matters communicated board directors relevant committee determine matters significance audit financial statements current period therefore key audit matters describe matters auditors report unless law regulation precludes public disclosure matter extremely rare circumstances determine matter communicated report adverse consequences would reasonably expected outweigh public interest benefits communication report legal regulatory requirements accordance article para item co swiss auditing standard confirm internal control system exists designed preparation financial statements according instructions board directors confirm proposed appropriation available earnings complies swiss law companys articles incorporation recommend financial statements submitted approved kpmg ag mark baillache marc ziegler licensed audit expert licensed audit expert auditor charge basel february kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member firm kpmg global organisation independent member firms affiliated kpmg international limited private english company limited guarantee rights reservedpublished cautionary statement regarding forwardlooking statements f hoffmannla roche ltd finance report contains certain forwardlooking statements group communications forwardlooking statements may identified words basel switzerland believes expects anticipates projects intends tel seeks estimates future similar expressions wwwrochecom discussion among things strategy goals plans intentions various factors may cause actual results differ orderdownload publications materially future reflected forwardlooking internet rochecompublications statements contained annual report among others email baselwarehouseservicesrochecom pricing product initiatives competitors legislative fax regulatory developments economic conditions delay inability obtaining regulatory approvals bringing media relations products market fluctuations currency exchange rates tel general financial market conditions uncertainties email mediarelationsrochecom discovery development marketing new products new uses existing products including without limitation negative results investor relations clinical trials research projects unexpected side effects tel pipeline marketed products increased government pricing email investorrelationsrochecom pressures interruptions production loss inability obtain adequate protection intellectual property rights corporate sustainability committee litigation loss key executives employees tel adverse publicity news coverage email corporatesustainabilityrochecom statement regarding earnings per share growth profit next annual general meeting forecast interpreted mean roches march earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share roche trademarks legally protected links thirdparty pages provided convenience express opinion content thirdparty pages expressly disclaim liability thirdparty information use roche finance report published german english case doubt differences interpretation english version shall prevail german text reporting consists actual annual report finance report contains annual financial statements consolidated financial statements regards content management report per articles incorporation consists aforementioned reports exception remuneration report printed nonchlorine bleached fsccertified paperfinance report e roche finance report f hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom